Document:

<PAGE>

                                                                     Exhibit 4.1
INT
Pharmaceuticals
INCORPORATED UNDER THE LAWS
OF THE STATE OF DELAWARE
SEE REVERSE FOR CERTAIN DEFINITIONS
CUSIP 45885B 10 0
This Certifies that
is the record holder of
FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $.001 PAR VALUE, OF
INTERMUNE PHARMACEUTICALS, INC.
transferable on the books of the Corporation by the holder hereof in person or
by duly authorized attorney upon surrender of this certificate properly
endorsed. This certificate is not valid until countersigned by the Transfer
Agent and registered by the Registrar.
WITNESS the facsimile seal of the Corporation and the facsimile signatures of
its duly authorized officers.
Dated:
SECRETARY
PRESIDENT AND CHIEF EXECUTIVE OFFICER
COUNTERSIGNED AND REGISTERED:
CHASEMELLON SHAREHOLDER SERVICES, L.L.C.
TRANSFER AGENT AND REGISTRAR
BY
AUTHORIZED SIGNATURE

                                       1.
<PAGE>

The Corporation shall furnish without charge to each stockholder who so requests
a statement of the powers, designations, preferences and relative,
participating, optional, or other special rights of each class of stock of the
Corporation or series thereof and the qualifications, limitations or
restrictions of such preferences and/or rights. Such requests shall be made to
the Corporation's Secretary at the principal office of the Corporation.

The following abbreviations, when used in the inscription on the face of this
certificate, shall be construed as though they were written out in full
according to applicable laws or regulations:

TEN COMD
TEN ENTD
JT TEND

as tenants in common
as tenants by the entireties
as joint tenants with right of
survivorship and not as tenants
in common

UNIF GIFT MIN ACTD.................Custodian......................
                                 (Cust)                           (Minor)
                 under Uniform Gifts to Minors
                 Act..........................................
                                                     (State)
UNIF TRF MIN ACTD...............Custodian (until age...........)
                            (Cust)
            ...................under Uniform Transfers
                             (Minor)
            to Minors Act...................................
                                                         (State)

Additional abbreviations may also be used though not in the above list.

For Value Received,                                hereby sell(s), assign(s) and
transfer(s) unto

PLEASE INSERT SOCIAL SECURITY OR OTHER
IDENTIFYING NUMBER OF ASSIGNEE

(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE)
Shares
of the common stock represented by the within Certificate, and do hereby
irrevocably constitute and appoint
Attorney
to transfer the said stock on the books of the within named Corporation with
full power of substitution in the premises.

                                       1.
<PAGE>

Dated
X
X
NOTICE:
THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON
THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR
ENLARGEMENT OR ANY CHANGE WHATEVER.

Signature(s) Guaranteed

THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS,
STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN
AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO S.E.C. RULE
17Ad-15.
By

                                       2.<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                                                   EXHIBIT 10.12

               AMENDED AND RESTATED EXCLUSIVE SUBLICENSE AGREEMENT

                                 BY AND BETWEEN

                         INTERMUNE PHARMACEUTICALS, INC.

                                       AND

                              CONNETICS CORPORATION

                                 APRIL 27, 1999

<PAGE>

               AMENDED AND RESTATED EXCLUSIVE SUBLICENSE AGREEMENT

       THIS AMENDED AND RESTATED EXCLUSIVE SUBLICENSE AGREEMENT (the
"Agreement") is made and entered into as of April 27, 1999 (the "Effective
Date") by and between CONNETICS CORPORATION, a Delaware corporation with a
principal place of business at 3400 West Bayshore Road, Palo Alto, CA 94303
("Connetics"), and INTERMUNE PHARMACEUTICALS, INC., a California corporation
with a principal place of business at 3294 West Bayshore Road, Palo Alto, CA
94303 ("InterMune"). InterMune and Connetics may be referred to herein as a
"Party" or, collectively, as the "Parties."

                                    RECITALS

A.     WHEREAS, InterMune is a corporation formed for the purpose of research
and development of biopharmaceutical products for the treatment of infectious
and autoimmune diseases; and

B.     WHEREAS, Connetics has licensed the rights to certain immunology-based
products and to the technology relating thereto from Genentech, Inc.
("Genentech") pursuant to that certain License Agreement for Interferon Gamma by
and between Connetics and Genentech dated May 5, 1998 (the "Genentech License");
and

C.     WHEREAS, InterMune and Connetics have entered into that certain Exclusive
Sublicense Agreement dated August 21, 1998 (the "Original Agreement") pursuant
to which (a) Connetics granted an exclusive sublicense to InterMune under the
Genentech License to develop, make, have made, import, offer for sale and sell
therapeutic products containing or derived from such immunology-based products
and technology for use for certain specific indications, and (b) InterMune
granted to Connetics the exclusive option to practice such sublicensed rights in
the dermatology field;

D.     WHEREAS, Connetics and Genentech have amended the Genentech License
through Amendment No. 1 to License Agreement effective December 28, 1998,
Amendment No. 2 to License Agreement effective January 15, 1999 and Amendment
No. 3 to the License Agreement effective April 27, 1999, pursuant to which
Connetics acquired from Genentech certain additional rights to the
aforementioned immunology-based products and technology, with the intent of
sublicensing such additional rights to InterMune;

E.     WHEREAS, Connetics is participating in that certain financing transaction
for InterMune Series A Preferred Shares (the "Series A Transaction") and, as
partial consideration to Connetics for its participation in the Series A
Transaction, InterMune has agreed to pay to Connetics, (i) pursuant to that
certain Collaboration Agreement between the Parties effective as of even date
herewith (the "Collaboration Agreement"), five hundred thousand dollars
($500,000) on the effective date of the Collaboration Agreement and five hundred
thousand dollars ($500,000) on March 31, 2001, and (ii) pursuant to this
Agreement, a milestone payment of one million five hundred thousand dollars
($1,500,000) as further described herein;

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       1.

<PAGE>

F.     WHEREAS, as further consideration to Connetics for its participation in
the Series A Transaction, InterMune has agreed to issue to Connetics pursuant to
the Collaboration Agreement, (i) nine hundred sixty thousand (960,000) shares of
Series A-1 Preferred Stock, (ii) shares of Series B Preferred Stock of an
aggregate value of five hundred thousand dollars ($500,000), and (iii) shares of
Series C Preferred Stock of an aggregate value of one million dollars
($1,000,000); and

G.     WHEREAS, InterMune and Connetics now desire to replace and supersede the
Original Agreement with this Agreement;

       NOW, THEREFORE, the Parties agree as follows:

1.     DEFINITIONS

1.1    "AFFILIATE" means any company or entity controlled by, controlling or
       under common control with a Party. As used in this Section, "control"
       means (a) that an entity or company owns, directly or indirectly, fifty
       percent (50%) or more of the voting stock of another entity, or (b) that
       an entity, person or group has the actual ability to control and direct
       the management of the entity, whether by contract or otherwise, but
       excluding, for all purposes of this Agreement, Connetics, as to
       InterMune, and InterMune, as to Connetics.

1.2    "AMENDMENT NO. 3" means that certain Amendment No. Three to License
       Agreement entered into between Connetics and Genentech effective April
       27, 1999. For clarity, the phrase "as amended by Amendment No. 3" as used
       herein is intended only for ease of reference and not as a limitation.

1.3    "BEST EFFORTS" means every necessary and prudent effort of a Party
       applied in a prompt, commercially reasonable manner, to the maximum
       extent reasonably allowed by such Party's available financial resources,
       taking into account all of such Party's business commitments for such
       financial resources.

1.4    "BLA" means a Biologics License Application.

1.5    "CONNETICS KNOW-HOW" means all Know-How in the areas of quality
       assurance/ quality control (QA/QC), pharmaceutical science, process
       development or regulatory affairs that (a) is Controlled by Connetics
       during the term of this Agreement, and (b) is necessary or useful to the
       discovery, development, use or manufacture of Products, but excluding all
       Know-How that is part of the Genentech License Rights.

1.6    "CONTROLLED" means with respect to any material, Know-How or intellectual
       property right, that the Party owns or has a license to such material,
       Know-How or intellectual property right and has the ability to grant
       access, a license, or a sublicense to such material, Know-How or
       intellectual property right to the other Party as provided for herein
       without violating an agreement with a Third Party as of the time the
       Party would be first required hereunder to grant the other Party such
       access, license or sublicense.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       2.

<PAGE>

1.7    "DERMATOLOGY FIELD" means the administration to humans of therapeutic
       products for the treatment, prevention or diagnosis of any dermatological
       disease or condition, including, without limitation, atopic dermatitis,
       keloids/hypertrophic scars, pustular psoriasis and scleroderma, but
       excluding (i) any cancer disease or condition, (ii) any infectious
       disease or condition, and (iii) any indication outside of the IG Field.

1.8    "DERMATOLOGY SUBLICENSEE" means a Third Party to which Connetics has
       granted a sublicense under the sublicense rights granted by InterMune to
       Connetics pursuant to Section 4.1.

1.9    "FDA" means the U.S. Food and Drug Administration, or any successor
       agency.

1.10   "GENE THERAPY" means the therapeutic or prophylactic treatment of a human
       being with: (a) one or more oligonucleotides or nucleotide sequences, in
       native form or chemically modified, which are introduced into the body in
       free form, bound to a carrier molecule, contained in any molecular
       vesicle (e.g. a liposome), incorporated into or attached to a vector of
       any type, contained in any cellular construct and/or contained in any
       mechanical device or (b) cells which have been manipulated EX VIVO using
       one or more oligonucleotides or nucleotide sequences.

1.11   "GENE THERAPY FIELD" means the administration to humans of Licensed Gene
       Product for Gene Therapy for the treatment or prevention of any human
       disease or condition, provided however, that "Gene Therapy Field" shall
       not include any treatment or prevention of any type of cardiac or
       cardiovascular disease or condition.

1.12   "GENENTECH" means Genentech, Inc., a Delaware corporation with its
       principal office at 1 DNA Way, South San Francisco, CA 94080.

1.13   "GENENTECH LICENSE" means the License Agreement for Interferon Gamma
       between Genentech and Connetics dated May 4, 1998, as amended by
       Amendment No. 1 to License Agreement effective December 28, 1998,
       Amendment No. 2 to License Agreement effective January 15, 1999, and
       Amendment No. 3, all of which are attached hereto as Exhibit 1.13.

1.14   "GENENTECH LICENSE RIGHTS" means all rights under Patents, Know-How and
       trademarks granted to Connetics by Genentech under the Genentech License,
       but only to the extent the Genentech License permits the practice of such
       rights for the uses set forth in Article 3 herein. "Genentech License
       Rights" shall not include any Third Party Product Rights.

1.15   "GENENTECH PATENTS" means all the Patent rights which are granted to
       Connetics under the Genentech License.

1.16   "GENENTECH SUPPLY AGREEMENT" means the Supply Agreement entered into
       between Genentech and Connetics dated May 4, 1998, a copy of which is
       attached hereto as Exhibit 1.16.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       3.

<PAGE>

1.17   "IG FIELD" means the administration to humans of Licensed Protein Product
       for the treatment or prevention of any human disease or condition,
       provided however, that "IG Field" shall not include: (i) the
       administration to humans of Licensed Protein Product for the treatment or
       prevention of any type of arthritis or cardiac or cardiovascular disease
       or condition or (ii) use of Licensed Protein Product for Gene Therapy.

1.18   "INTERFERON GAMMA" OR "IG" means the polypeptide described as "Interferon
       Gamma" in Section 1.20 of the Genentech License.

1.19   "INTERMUNE NET SALES" means "Net Sales" of Licensed Protein Products in
       the Territory for use in the IG Field by InterMune and its sublicensees
       hereunder other than Connetics and its Affiliates and Dermatology
       Sublicensees.

1.20   "KNOW-HOW" means all information, data, know-how, trade secrets,
       inventions, developments, results, techniques and materials, whether or
       not patentable.

1.21   "LICENSED PRODUCT," "LICENSED GENE PRODUCT" AND "LICENSED PROTEIN
       PRODUCT" shall each have the same meaning as defined in Section 1.22 of
       the Genentech License (as amended by Amendment No. 3).

1.22   "LICENSED TECHNOLOGY" means the Genentech License Rights and the
       Connetics Know-How.

1.23   "NET SALES" means "Net Sales" (as defined in Section 1.25 of the
       Genentech License) of Licensed Protein Products in the Territory for use
       in the IG Field by InterMune and any of its sublicensees hereunder.

1.24   "PATENTS" means any and all issued or pending patents and patent
       applications, both foreign and domestic, and including without limitation
       (a) all divisionals, continuations and continuations-in-part of any such
       applications, (b) any patents that issue from any of the foregoing, and
       (c) all substitutions, extensions, reissues, renewals, supplementary
       protection certificates and inventors' certificates with respect to any
       of the foregoing issued patents.

1.25   "TERRITORY" means the United States and Japan.

1.26   "THIRD PARTY" means any party besides the Parties and their respective
       Affiliates.

1.27   "THIRD PARTY PRODUCT RIGHTS" shall have the meaning set forth in Section
       1.37 of the Genentech License (as amended by Amendment No. 3).

1.28   "UNITED STATES" means the United States and its territories and
       possessions.

2.     ORIGINAL AGREEMENT SUPERSEDED

       The Parties agree that the Original Agreement is hereby replaced and
superseded in all respects by this Agreement as of the Effective Date.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       4.
<PAGE>

3.     LICENSES AND COVENANTS

3.1    GENENTECH LICENSE RIGHTS.

(a)    Connetics hereby grants to InterMune the exclusive sublicense, even as to
       Connetics, under the Genentech License Rights to develop, use, sell,
       offer for sale, import, make and have made:

(i)    Licensed Protein Products in the IG Field in the Territory, subject to
       any rights Connetics obtains under Section 4.1 below, and

(ii)   Licensed Gene Products in the Gene Therapy Field in the United States.

(b)    InterMune may sublicense any or all the foregoing rights to the extent
       that Connetics is permitted to do so under the Genentech License.

3.2    THIRD PARTY PRODUCT RIGHTS.

(a)    Connetics hereby grants to InterMune the exclusive sublicense, even as to
       Connetics, under any Third Party Product Rights Connetics acquires in
       Japan pursuant to Section 2.1(g)(iii) of the Genentech License (as
       amended by Amendment No. 3), which sublicense may be further sublicensed
       by InterMune to the extent that Connetics is permitted to do so under the
       Genentech License.

(b)    Connetics hereby assigns to InterMune its entire right, title and
       interest to Connetics' rights of negotiation to Third Party Product
       Rights pursuant to Section 2.1(h) of the Genentech License (as amended by
       Amendment No. 3). In the event that Genentech notifies Connetics of the
       availability of any such Third Party Product Rights, Connetics shall
       promptly notify InterMune thereof.

3.3    CONNETICS KNOW-HOW. Connetics hereby grants to InterMune a non-exclusive
       license under the Connetics Know-How to develop, use, make, have made,
       import, offer for sale and sell (a) Licensed Products in the Territory,
       and (b) any products covered by Third Party Patent Rights to which
       Connetics or InterMune acquires rights under the Genentech License in the
       applicable territory.

3.4  GENENTECH SUPPLY AGREEMENT. Connetics hereby assigns to InterMune its
     entire right, title and interest under the Genentech Supply Agreement and
     agrees to notify Genentech of such assignment in accordance with Section
     5.4 thereof. As of the Effective Date, InterMune shall be deemed to be the
     successor in interest of Connetics under the Genentech Supply Agreement and
     shall assume all obligations and be entitled to all rights of Connetics
     under such agreement. InterMune hereby covenants that it shall maintain the
     Genentech Supply Agreement effective and in good standing. To the extent
     Connetics exercises its option pursuant to Section 4.1 below, InterMune
     shall procure for and supply to Connetics (and its Dermatology
     Sublicensees, if any) its requirements for Bulk Product and Finished
     Product (as such terms are defined in the Genentech Supply Agreement) for
     use in the Dermatology

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       5.

<PAGE>

       Field from Genentech pursuant to the Genentech Supply Agreement or from
       any Third Party manufacturer(s) contracted by InterMune to manufacture
       Finished Product and Bulk Product, provided that Connetics shall pay to
       InterMune InterMune's cost, without markup, for procuring and supplying
       such Finished Product and Bulk Product to Connetics.

3.5    TRANSFER OF DATA AND MATERIALS. Promptly following the Effective Date,
       Connetics and InterMune shall work cooperatively together to transfer to
       InterMune all documents or materials in Connetics' possession comprising
       or containing the Licensed Technology, including without limitation,
       biological and chemical materials, regulatory filings, and data, and
       Connetics shall transfer any and all additions or improvements to the
       Licensed Technology to InterMune as soon as is reasonably practicable
       after the creation, development or acquisition of such addition or
       improvements.

3.6    CONNETICS COVENANT. Connetics hereby covenants that it shall maintain the
       Genentech License effective and in good standing subject to InterMune's
       performance under Section 3.7 below.

3.7    INTERMUNE PERFORMANCE UNDER GENENTECH LICENSE.

(a)    InterMune shall perform in lieu and instead of Connetics in carrying out
       the rights and obligations of Connetics under the Genentech License to
       the extent permitted in Section 2.3(c) of the Genentech License
       (including without limitation the insurance obligations set forth in
       Section 10.4 of the License Agreement (as amended by Amendment No. 3)),
       and except as set forth in Article 4 below. Connetics agrees to use
       commercially reasonable diligent efforts to cooperate with InterMune to
       enable it to exercise such rights and to perform such obligations
       thereunder.

(b)    In the event that InterMune reasonably anticipates that it is likely to
       materially default under any obligation under the Genentech License that
       it is obligated to perform pursuant to subsection (a) above, InterMune
       shall notify Connetics as promptly as reasonably practicable of such
       default. At Connetics' request, InterMune shall cooperate fully with
       Connetics in order to prevent, mitigate or cure such default.

4.     OPTION TO DERMATOLOGY RIGHTS

4.1    OPTION GRANT. InterMune hereby grants to Connetics the exclusive option
       to obtain the exclusive sublicense under the Genentech License Rights to
       develop, use, make, have made, import, offer for sale and sell Licensed
       Protein Products for use solely in the Dermatology Field in the United
       States, subject to Genentech's rights under the Genentech License.
       Connetics may exercise such option at any time prior to the [ * ]
       anniversary of the Effective Date by providing InterMune written notice
       of its desire to exercise such option. Upon InterMune's receipt of such
       notice, InterMune shall be deemed to have granted to Connetics the
       exclusive, royalty-free (with respect to InterMune only), sublicense
       under the Genentech License Rights to use, make, have made, import, offer
       for sale and sell Licensed Protein Products in the Dermatology Field in
       the United States for the term of this Agreement, subject to the terms of
       the Genentech License, and Connetics shall undertake all obligations

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       6.

<PAGE>

       under the Genentech License relating to its development and
       commercialization of Licensed Protein Products in the Dermatology Field
       in the United States, including without limitation those obligations
       described in Sections 4.2 and 4.4 below. Such sublicense shall be further
       sublicenseable by Connetics to the extent permitted by the Genentech
       License. If not exercised by the [ * ] anniversary of the Effective Date,
       the option granted in this Section 4.1 shall expire.

4.2    PAYMENTS AND OTHER OBLIGATIONS UNDER GENENTECH LICENSE. If Connetics
       exercises such option as set forth in Section 4.1 above:

(i)    In the event that Connetics or a Dermatology Sublicensee achieves one of
       the milestones set forth in Sections 8.2(a) or (b) of the Genentech
       License with respect to its Licensed Protein Product, Connetics or such
       Dermatology Sublicensee shall inform InterMune thereof and provide such
       milestone payment due under the Genentech License to InterMune, and
       InterMune agrees to render such payment to Genentech on behalf of
       Connetics.

(ii)   In the event that milestone payments to Genentech as set forth in
       Sections 8.1 (c) and (d) of the Genentech License are triggered by the
       sale of Licensed Protein Product by both Connetics and InterMune (and/or
       their sublicensees) in the Territory, the Parties shall promptly meet and
       in good faith determine a fair apportionment between the Parties of the
       payment to be made to Genentech for such milestone based upon the
       relative Net Sales of each Party for such calendar year or other agreed
       upon method of apportionment. Connetics shall then submit to InterMune
       its portion of such milestone payment in accordance with the terms of the
       Genentech License, and InterMune agrees to render such payment to
       Genentech on behalf of Connetics.

(b)    ROYALTIES. Connetics shall be responsible for making all payments due (i)
       to Genentech under Section 8.3 of the Genentech License, and (ii) to
       Genentech or any other Third Party under Section 8.4 of the Genentech
       License, in each case on Net Sales of Licensed Protein Products by
       Connetics, its Affiliates and its Dermatology Sublicensees, in accordance
       with the Genentech License.

(c)    DEFAULT. In the event that Connetics reasonably anticipates that it is
       likely to materially default under any obligation under the Genentech
       License that it is obligated to perform under Section 4.1, including
       without limitation the obligations described in subsections (a) and (b)
       above, Connetics shall notify InterMune as promptly as reasonably
       practicable of the nature of such default. At InterMune's request,
       Connetics shall cooperate fully with InterMune in order to prevent,
       mitigate or cure such default.

4.3    OFF-LABEL SALES. If Connetics exercises the option set forth in Section
       4.1 then:

(a)    Each Party agrees and shall require its sublicensees, if any, to use
       commercially reasonable efforts to formulate all Licensed Protein
       Products developed by such Party or sublicensee thereof in a manner to
       reduce, to the extent reasonably practicable, the possibility that such

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       7.

<PAGE>

       Licensed Protein Product can be used in the other Party's field of use as
       provided hereunder. If a Party cannot so formulate a particular Licensed
       Protein Product, then such Party agrees to use its Best Efforts to
       prevent sales of such Licensed Protein Product for use in the other
       Party's field of use, including without limitation instructing its sales
       forces, and requiring all sublicensees to instruct their sales forces,
       that such Licensed Protein Product is not to be promoted, marketed or
       sold for use in the other Party's field of use.

(b)    In the event that either Party determines that a Licensed Protein Product
       is being used in a field of use other than for which it was intended,
       such Party shall immediately inform the other Party. The Parties shall
       then promptly meet and diligently and in good faith determine a fair and
       reasonable mechanism for equitable allocation of the sales of such
       Licensed Protein Product that are used outside the field of use for which
       they are intended.

4.4    PATENT COSTS. If Connetics exercises the option set forth in Section 4.1,
       then Connetics agrees to reimburse InterMune all costs paid by InterMune
       to Genentech under Section 5.2 of the Genentech License which relate to
       any patent or patent application the claims of which: (a) are
       specifically directed to a Licensed Protein Product for use in the
       Dermatology Field and (b) do not relate to a Licensed Protein Product for
       use in any area of the IG Field other than the Dermatology Field.

4.5    MILESTONE PAYMENTS. If Connetics exercises its options under Section 4.1,
       then Connetics shall make the following cash milestone payments to
       InterMune:

(a)    [ * ] within thirty (30) days following the date on which the first NDA
       or BLA for a Licensed Protein Product is filed with the FDA by Connetics
       for an indication in the Dermatology Field.

(b)    [ * ] within thirty (30) days following the date Connetics receives FDA
       clearance for each new indication in the Dermatology Field of a Licensed
       Protein Product for commercial sale in the United States.

4.6    DERMATOLOGICAL INDICATIONS OUTSIDE OF THE DERMATOLOGY FIELD.

(a)    It is the intention of the Parties that Connetics shall be InterMune's
       preferred marketing partner for sales of Licensed Protein Product to
       dermatologists in the United States during the term of this Agreement.
       Therefore, during the term of this Agreement, if either Party desires to
       sell Licensed Protein Product to dermatologists in the United States for
       use for indications that are outside of the Dermatology Field but within
       the IG Field (an "Outside Indication"), the provisions of this Section
       4.6 shall apply.

(b)    In the event that either Party desires to sell a Licensed Protein Product
       for an Outside Indication to dermatologists in the United States during
       the term of this Agreement, such Party shall give the other Party written
       notice of such interest, which notice shall specify the indication of
       interest. If InterMune notifies Connetics that InterMune itself desires
       to sell such Licensed Protein Product for an Outside Indication directly
       to dermatologists in the United States, then the procedures of subsection
       (d) shall apply. Otherwise, for ninety (90)

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       8.

<PAGE>

       days following receipt of such notice, the Parties shall exclusively
       negotiate in good faith for the reasonable commercial terms under which
       Connetics shall exclusively sell such Licensed Protein Product for such
       Outside Indication to dermatologists in the United States. In the event
       that, at the end of such ninety (90) day period, the Parties have failed
       to enter into a written agreement on such commercially reasonable terms,
       Connetics' rights with respect to the sale of such Licensed Protein
       Product for such Outside Indication shall terminate and InterMune shall
       have no further obligations to Connetics under this Section 4.6 with
       respect to such Licensed Protein Product for such Outside Indication
       except as set forth is subsections (c) and (d) below.

(c)    If the Parties have failed to enter into an agreement by the end of such
       ninety (90) day period, as described in subsection (b) above, InterMune
       shall then have the right during the following one hundred eighty (180)
       day period to enter into an agreement with a Third Party for the sale to
       dermatologists of such Licensed Protein Product for such Outside
       Indication on economic terms that, taken as a whole, are substantially
       the same as, or more favorable to InterMune than, those last offered in
       writing by Connetics for such rights pursuant to subsection (b) above. If
       at the end of such one hundred eighty (180) day period InterMune has not
       entered into an agreement with a Third Party to sell such Licensed
       Protein Product for such Outside Indication to dermatologists in the
       United States, then the procedures set forth in subsection (b) above
       shall again apply, provided that InterMune may proceed alternatively
       under subsection (d) below.

(d)    If InterMune itself desires to sell such Licensed Protein Product to
       dermatologists in the United States for Outside Indications, then upon
       written notice from InterMune, Connetics and InterMune shall enter into
       good faith negotiations, for a period of ninety (90) days from Connetics'
       receipt of such notice, for the reasonable commercial terms upon which
       InterMune shall grant to Connetics the rights to co-promote such Licensed
       Protein Product for such Outside Indication to dermatologists in the
       United States. InterMune agrees that it shall not unreasonably withhold
       its agreement to such commercially reasonable terms. In the event that,
       at the end of such ninety (90) day period, the Parties have failed to
       enter into a written agreement for such co-promotion rights, InterMune
       shall have no further obligations to Connetics under this Section 4.6
       with respect to such Licensed Protein Product for such Outside
       Indication, PROVIDED THAT InterMune may not enter into an agreement with
       a Third Party for the rights to co-promote Licensed Protein Product for
       such Outside Indication to dermatologists in the United States on
       economic terms that, taken as a whole, are less favorable to InterMune
       than those last offered in writing by Connetics for such rights. In the
       event that InterMune does not enter into such a co-promotion agreement
       with a third party and instead solely promotes and sells such Licensed
       Protein Product for such Outside Indication to dermatologists in the
       United States itself, if at any time following such sole promotion and
       sale InterMune determines in its sole discretion that it desires to grant
       a license to the rights to promote and sell the rights to co-promote such
       Licensed Protein Product for such Outside Indication to dermatologists in
       the United States to another party (other than an Affiliate), then the
       procedures set forth in subsection (b) above shall apply.

5.     CONSIDERATION

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       9.
<PAGE>

5.1    ROYALTIES.

(a)    Beginning on January 1, 2002, InterMune shall pay to Connetics a royalty
       of [ * ] of InterMune Net Sales in the United States. InterMune shall
       continue to pay such royalties to Connetics until such time as the
       cumulative InterMune Net Sales in United States, beginning on January 1,
       2000, are equal to [ * ]. Thereafter, InterMune shall pay to Connetics a
       royalty of [ * ] of InterMune Net Sales in the United States for the
       remainder of the term of the Agreement.

(b)    All royalties due under this Section 5.1 shall be due and payable
       quarterly within thirty (30) days following the last day of each quarter
       in which royalties are incurred beginning with first calendar quarter of
       2002.

5.2    MILESTONE PAYMENT. InterMune shall pay to Connetics a milestone payment
       of one million five hundred thousand dollars ($1,500,000), as follows
       (the "Milestone Payment"), payable in a lump sum or in installments based
       on the level of InterMune Net Sales as follows:

(a)    If annualized InterMune Net Sales in the United States for 2001, based on
       InterMune Net Sales in the United States for the third and fourth
       calendar quarters of 2001, ("2001 Net Sales") are equal to or greater
       than [ * ], then on March 31, 2002, InterMune shall, at its election,
       either (i) pay the full Milestone Payment to Connetics, or (ii) pay to
       Connetics [ * ] of the Milestone Payment and furnish to Connetics a
       promissory note for the balance of the Milestone Payment, which
       promissory note shall provide for three (3) principal payments to
       Connetics of [ * ] each due upon June 30, 2002, September 30, 2002 and
       December 31, 2002, respectively.

(b)    If 2001 Net Sales are equal to or greater than [ * ] but less than [ * ],
       then on March 31, 2002, InterMune shall pay to Connetics [ * ] of the
       Milestone Payment, and furnish to Connetics a promissory note for the
       balance of the Milestone Payment (the "Remaining Payment"), which
       promissory note shall provide for full payment of the balance of such
       note to Connetics on the earlier to occur of (i) March 31, 2004, or (ii)
       the last day of the month following the consecutive twelve (12) month
       period that InterMune Net Sales in the United States are equal to or
       greater than [ * ], subject to subsection (d) below.

(c)    If 2001 Net Sales are less than [ * ], then on March 31, 2002, InterMune
       shall pay to Connetics a portion of the Milestone Payment equal to [ * ]
       multiplied by a fraction, the numerator of which is 2001 Net Sales and
       the denominator of which is [ * ]. InterMune shall furnish to Connetics a
       promissory note for the balance of the Milestone Payment (the "Remaining
       Payment"), which promissory note shall provide for full payment of the
       balance of such note to Connetics on the earlier to occur of (i) March
       31, 2004, or (ii) the last day of the month following the consecutive
       twelve (12) month period that InterMune Net Sales in the United States
       are equal to or greater than [ * ], subject to subsection (d) below.

(d)    With respect to the promissory note for the Remaining Payment described
       in subsection (b) or (c) above, if InterMune is to pay the balance of
       such note on March 31, 2004, and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      10.

<PAGE>

       InterMune Net Sales in the United States for the twelve (12) month period
       preceding March 31, 2004 are equal to or greater than [ * ] but less than
       [ * ], then:

(i)    InterMune may, at its election, pay [ * ] of the Remaining Payment either
       in cash or in Preferred Shares of InterMune stock at the fair market
       value of such shares, determined as the average closing price of such
       shares over the previous thirty (30) day period; and

(ii)   With respect to the other [ * ] of the Remaining Payment, Connetics may,
       at its election, receive such fifty percent either in cash or in
       Preferred Shares of InterMune stock at the fair market value of such
       shares, determined as the average closing price of such shares over the
       previous thirty (30) day period, provided that Connetics shall notify
       InterMune of its election in writing at least thirty (30) days prior to
       the date that such payment is due; and

(e)    With respect to the Remaining Payment described in subsection (b) or (c)
       above, if InterMune is to pay the balance of such note on March 31, 2004,
       and InterMune Net Sales in the United States for the twelve (12) month
       period preceding March 31, 2004 are less than [ * ], then InterMune may,
       at its election, either:

(1)    Pay such Remaining Payment in cash or in Preferred Shares of InterMune
       stock at the fair market value of such shares, determined as the average
       closing price of such shares over the previous thirty (30) day period; or

(2)    Grant to Connetics the license to the Accounting and Revenue Rights to
       CGD Units (as defined below), on commercially reasonable terms to be
       agreed upon by the Parties, in which event InterMune shall thereafter
       have no further obligation to Connetics with respect to such Remaining
       Payment. Such license shall be [ * ] with respect to InterMune but not
       with respect to Genentech or any other Third Party, and shall expire upon
       the date of expiration of the last to expire Genentech Patent covering
       the manufacture, use or sale of Licensed Products for the treatment of
       CGD in the United States and its territories and possessions. As used
       herein, "Accounting and Revenue Rights to CGD Units" means the right to
       book net revenues, expenses and net profits for the sales of Licensed
       Product for the treatment of chronic granulomatous disease by InterMune
       and its sublicensees in the United States.

(f)    All promissory notes referred to in this Section 5.2 shall bear interest
       at the rate of the prime rate plus [ * ].

5.3    REPORTS; AUDIT RIGHTS. InterMune shall provide to Connetics a copy of all
       reports submitted to Genentech by InterMune pursuant to Section 8.8 of
       the Genentech License when InterMune submits such report to Genentech.
       Connetics shall furthermore have the same audit rights as Genentech
       pursuant to Section 8.8.

5.4    PAYMENTS UNDER GENENTECH LICENSE. InterMune shall make, on behalf of
       Connetics, all payments owed by Connetics to Genentech under Sections 8.2
       and 8.3 of the Genentech License with respect to InterMune's activities
       hereunder, except as set forth in Section 4.2 above. Each Party shall be
       responsible for paying all royalties due to Third Parties other than

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      11.

<PAGE>

       Genentech under Section 8.4 of the Genentech License with respect to such
       Party's and/or sublicensee thereof activities hereunder.

6.     INTELLECTUAL PROPERTY

6.1    OWNERSHIP OF INVENTIONS. Each Party shall remain the sole owner of its
       respective technology and other intellectual property that it owned as of
       the Effective Date. A Party shall not have or acquire any rights in any
       inventions, Know-How or intellectual property rights of the other Party,
       except as specifically granted herein.

6.2    PATENT PROSECUTION. InterMune shall have all the rights of Connetics
       under the Genentech License to participate in the prosecution of the
       Genentech Patents, and shall pay all patent costs due under the Genentech
       License, except as set forth in Section 4.4 above.

6.3    INFRINGEMENT OF THIRD PARTY PATENTS. In the event that a Third Party
       files an action against a Party alleging that such Party's activities
       under this Agreement infringe such Third Party's patent rights, such
       Party shall give written notice to the other Party, and the Parties will
       consult and cooperate on the best course of action. The Party that was
       sued shall have the right to defend itself against such action, and the
       other Party shall provide all reasonable assistance in such defense.

6.4    INFRINGEMENT OF LICENSED PATENTS. In the event that either Party becomes
       aware that a Third Party is infringing any rights in the Genentech
       Patents, such Party shall promptly notify the other. InterMune shall have
       the right, in Connetics' stead, to enforce the Genentech Patents to the
       full extent Connetics has such rights under the Genentech License, and
       Connetics will reasonably cooperate with InterMune in such enforcement
       actions and take all reasonably necessary steps to facilitate InterMune's
       enforcement of the Genentech Patents.

6.5    COOPERATION. Each Party agrees to cooperate with the other and take all
       reasonable additional actions as may be reasonably required to achieve
       the intent of this Article 5, including, without limitation, the
       execution of all necessary and appropriate instruments and documents.

7.     REPRESENTATIONS AND WARRANTIES

7.1    MUTUAL REPRESENTATIONS AND WARRANTIES. Each Party hereby represents and
       warrants to the other Party as follows:

(a)    Such Party (i) is duly organized, validly existing and in good standing
       under the laws of the state in which it is organized; (ii) has the power
       and authority and the legal right to own and operate its property and
       assets, to lease the property and assets it operates under lease, and to
       carry on its business as it is now being conducted; and (iii) is in
       compliance with all requirements of applicable law, except to the extent
       that any noncompliance would not materially adversely affect such Party's
       ability to perform its obligations under the Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      12.

<PAGE>

(b)    Such Party (i) has the power and authority and the legal right to enter
       into the Agreement and to perform its obligations hereunder, and (ii) has
       taken all necessary action on its part to authorize the execution and
       delivery of the Agreement and the performance of its obligations
       hereunder. The Agreement has been duly executed and delivered on behalf
       of such Party, and constitutes a legal, valid, binding obligation,
       enforceable against such Party in accordance with its terms.

(c)    All necessary consents, approvals and authorizations of all governmental
       authorities and other persons required to be obtained by such Party in
       connection with the Agreement have been obtained.

(d)    The execution and delivery of the Agreement and the performance of such
       Party's obligations hereunder (i) do not conflict with or violate any
       requirement of applicable laws or regulations or any material contractual
       obligation of such Party, and (ii) do not materially conflict with, or
       constitute a material default or require any consent under any material
       contractual obligation of such Party.

7.2    CONNETICS REPRESENTATIONS AND WARRANTIES. Connetics hereby represents and
       warrants that:

(a)    To Connetics' knowledge as of the Effective Date, the Licensed Technology
       practiced as permitted herein does not infringe on any intellectual
       property rights owned by any Third Party.

(b)    Connetics possesses the necessary interest, title and right to the
       Licensed Technology to grant the licenses and to make the assignments to
       InterMune hereunder.

8.     INDEMNIFICATION

8.1    INDEMNIFICATION BY CONNETICS. Connetics agrees to indemnify, hold
       harmless and defend InterMune and InterMune's directors, officers,
       employees and agents, and the directors, officers, employees and agents
       of any InterMune Affiliate from and against any and all claims, suits,
       losses, damages, costs, fees and expenses resulting from or arising out
       of any negligent or wrongful act or omission by Connetics or its
       Affiliates, or any breach by Connetics of its obligations under this
       Agreement or under the Genentech License, except to the extent that such
       claims, suits, losses, damages, costs, fees or expenses arises or results
       from any negligent or wrongful act or omission of InterMune or its
       Affiliates.

8.2    INDEMNIFICATION BY INTERMUNE. InterMune agrees to indemnify, hold
       harmless and defend Connetics and its directors, officers, employees and
       agents, and the directors, officers, employees and agents of any
       Connetics Affiliates from and against any and all claims, suits, losses,
       damages, costs, fees and expenses resulting from or arising out of damage
       or injury caused by a negligent or wrongful act or omission of InterMune
       or its Affiliates, or any breach by InterMune of its obligations under
       this Agreement, except to the extent that such claims, suits, losses,
       damages, costs, fees or expenses arises or results from any negligent or
       wrongful act or omission of Connetics or its Affiliates.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      13.

<PAGE>

8.3    INDEMNIFICATION PROCEDURE. In all cases where one Party seeks
       indemnification by the other under this Article 8, the Party seeking
       indemnification shall promptly notify the indemnifying Party of receipt
       of any claim or lawsuit covered by such indemnification obligation and
       shall cooperate fully with the indemnifying Party in connection with the
       investigation and defense of such claim or lawsuit. The indemnifying
       Party shall have the right to control the defense, with counsel of its
       choice, provided that the non-indemnifying Party shall have the right to
       be represented by advisory counsel at its own expense. The indemnifying
       Party shall not settle or dispose of the matter in any manner which could
       negatively and materially affect the rights or liability of the
       non-indemnifying Party without the non-indemnifying Party's prior written
       consent, which shall not be unreasonably withheld.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      14.
<PAGE>

9.     CONFIDENTIALITY

9.1    CONFIDENTIAL INFORMATION OBLIGATIONS. As used herein, "Confidential
       Information" means all information that a Party discloses to the other
       Party under this Agreement or had disclosed to the other Party under the
       Original Agreement, provided that Confidential Information shall not
       include such information excluded under Section 9.2. Except to the extent
       expressly authorized by this Agreement or otherwise agreed in writing by
       the Parties, each Party agrees that, during the term of this Agreement
       and for five (5) years after the expiration or termination of this
       Agreement, it shall keep confidential and shall not publish or otherwise
       disclose and shall not use for any purpose other than as provided for in
       this Agreement any Confidential Information furnished to it by the other
       Party pursuant to this Agreement.

9.2    EXCEPTIONS. The obligations set forth in Section 9.1 shall not apply to
       any Information that the receiving Party can demonstrate by competent
       evidence:

(a)    was already known to the receiving Party, other than under an obligation
       of confidentiality, at the time of disclosure by the other Party;

(b)    was generally available to the public or otherwise part of the public
       domain at the time of its disclosure to the receiving Party by the other
       Party;

(c)    became generally available to the public or otherwise part of the public
       domain after its disclosure and other than through any act or omission of
       the receiving Party in breach of this Agreement;

(d)    was disclosed to the receiving Party, other than under an obligation of
       confidentiality to a third Party, by a third Party who had no obligation
       to the disclosing Party not to disclose such information to others; or

(e)    is independently developed by the receiving Party without using any of
       the other Party's Confidential Information.

9.3    TERMS OF THE AGREEMENT. The Parties agree that the terms of the Agreement
       will be considered Confidential Information of both Parties.
       Notwithstanding the foregoing, a Party shall have the right to disclose
       the material financial terms of the Agreement to any bona fide potential
       investor, investment banker, acquiror, merger partner or other potential
       financial partner, subject to such Party obtaining the agreement of such
       party receiving such Confidential Information to keep such information
       confidential.

9.4    PERMITTED DISCLOSURE. Notwithstanding the limitations in this Article 9,
       each Party may disclose Confidential Information belonging to the other
       Party (or otherwise subject to this Article 9), to the extent such
       disclosure is reasonably necessary in the following instances, but solely
       for the limited purpose of such necessity:

(a)    filing or prosecuting Patents;

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      15.

<PAGE>

(b)    regulatory and tax filings;

(c)    prosecuting or defending litigation;

(d)    complying with applicable governmental laws or regulations or valid court
       orders;

(e)    conducting preclinical or clinical trials of Licensed Products; and

(f)    disclosure to Affiliates, licensees, sublicensees, employees, consultants
       or agents who agree to be bound by similar terms of confidentiality and
       non-use at least equivalent in scope to those set forth in this Article
       9.

       Notwithstanding the foregoing, in the event a Party is required to make a
disclosure of the other Party's Confidential Information pursuant to Section
9.4, it will give reasonable advance notice to the other Party of such
disclosure and endeavor in good faith to secure confidential treatment of such
information. In any event, the Parties agree to take all reasonable action to
avoid disclosure of Confidential Information hereunder. Further, the Parties
agree to consult with one another on the provisions of this Agreement to be
redacted in any filings made by a Party with the United States Securities and
Exchange Commission or as otherwise required by law.

10.    TERMINATION

10.1   TERM OF AGREEMENT. The term of this Agreement shall expire, unless
       earlier terminated as provided by Section 10.2 below, upon expiration or
       termination of the Genentech License.

10.2   TERMINATION FOR MATERIAL BREACH. If either Party shall default in a
       material manner with respect to any material provision of this Agreement
       and the other Party shall have given the defaulting Party written notice
       of such default, the defaulting Party shall have thirty (30) days to cure
       such default. If such default is not cured within such thirty (30) day
       period, the non-defaulting Party shall have the right, upon notice to the
       defaulting Party and without prejudice to any other rights the
       non-defaulting Party may have, to terminate this Agreement unless the
       defaulting Party is in the process of attempting in good faith to remedy
       such default, in which case, the thirty (30) day cure period shall be
       extended by an additional thirty (30) days. Any material default by
       InterMune in the performance of any material obligation under the
       Genentech License assumed by InterMune pursuant to Section 3.7 of this
       Agreement shall be deemed a material default of this Agreement and shall
       entitle Connetics to terminate this Agreement in accordance with this
       Section 10.2.

10.3   EFFECT OF TERMINATION. Upon termination or expiration of the Agreement,
       (a) all licenses granted by Connetics to InterMune under Article 2 will
       terminate; (b) any and all claims and payment obligations that accrued
       prior to the date of such termination or expiration shall survive such
       termination; (c) each Party shall return all of the other Party's
       Confidential Information; and (d) all right, title and interest of
       InterMune under the Genentech Supply Agreement shall revert to Connetics,
       and Connetics shall be deemed to be the successor in

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      16.

<PAGE>

       interest of InterMune under the Genentech Supply Agreement and shall
       assume all obligations and be entitled to all rights of InterMune under
       such agreement.

10.4   SURVIVING RIGHTS. The obligations and rights of the Parties under Section
       5.3, 6.1, and Articles 8, 9, 10 and 11 shall survive termination or
       expiration of the Agreement.

10.5   ACCRUED RIGHTS AND SURVIVING OBLIGATIONS. The termination or expiration
       of the Agreement for any reason shall be without prejudice to any rights,
       which shall have accrued to the benefit of either Party prior to such
       termination or expiration, including any damages arising from any breach
       hereunder. Such termination or expiration shall not relieve either Party
       from obligations which are expressly indicated to survive termination or
       expiration of the Agreement.

10.6   BANKRUPTCY RIGHTS. In the event that this Agreement is terminated or
       rejected by a Party or its receiver or trustee under applicable
       bankruptcy laws due to such Party's bankruptcy, then all rights and
       licenses granted under or pursuant to this Agreement by such Party to the
       other Party are, and shall otherwise be deemed to be, for purposes of
       Section 365(n) of the Bankruptcy Code and any similar law or regulation
       in any other country, licenses of rights to "intellectual property" as
       defined under Section 101(52) of the Bankruptcy Code. The Parties agree
       that all intellectual property rights licensed hereunder, including
       without limitation any patents or patent applications in any country of a
       Party covered by the license grants under this Agreement, are part of the
       "intellectual property" as defined under Section 101(52) of the
       Bankruptcy Code subject to the protections afforded the non-terminating
       Party under Section 365(n) of the Bankruptcy Code, and any similar law or
       regulation in any other country.

11.    MISCELLANEOUS

11.1   WAIVER. No waiver by either Party hereto of any breach or default of any
       of the covenants or agreements herein set forth shall be deemed a waiver
       as to any subsequent or similar breach or default.

11.2   ASSIGNMENT. This Agreement shall be binding upon and inure to the benefit
       of the Parties hereto and their permitted successors and assigns;
       provided, however, that neither Party shall assign any of its rights and
       obligations hereunder without the prior written consent of the other
       Party, except as incident to the merger, consolidation, reorganization or
       acquisition of stock or assets affecting substantially all of the assets
       or actual voting control of the assigning Party. Any assignment or
       attempted assignment by either Party in violation of the terms of this
       Section 10.2 shall be null and void and of no legal effect.

11.3   NOTICES. Any notice or other communication required or permitted to be
       given to either Party hereto shall be in writing and shall be deemed to
       have been properly given and to be effective on the date of delivery if
       delivered in person or by facsimile or five (5) days after mailing by
       registered or certified mail, postage paid, to the other Party at the
       following address:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      17.

<PAGE>

       In the case of InterMune:             InterMune, Inc.
                                             3294 West Bayshore Road
                                             Palo Alto, CA 94303
                                             Fax: (650) 858-2937
                                             Attention: President

       with a copy to:                       Cooley Godward LLP
                                             Five Palo Alto Square
                                             Palo Alto, CA 94306
                                             Fax: (650) 857-0663
                                             Attention: Barclay James Kamb, Esq.

       In the case of Connetics:             Connetics Corporation
                                             3400 West Bayshore Road
                                             Palo Alto, CA 94303
                                             Fax: (650) 843-2899
                                             Attention: Chief Executive Officer

Either Party may change its address for communications by a notice to the other
Party in accordance with this Section.

11.4   HEADINGS. The headings of the several sections are inserted for
       convenience of reference only and are not intended to be a part of or to
       affect the meaning or interpretation of this Agreement.

11.5   AMENDMENT. No amendment or modification hereof shall be valid or binding
       upon the Parties unless made in writing and signed by both Parties.

11.6   GOVERNING LAW. This Agreement shall be governed exclusively by the laws
       of the State of California, U.S.A., as such law applies to contracts
       entered into between and to be performed by California residents entirely
       in the State of California.

11.7   DISPUTE RESOLUTION.

(a)    In the event of any controversy or claim arising out of, relating to or
       in connection with any provision of this Agreement, or the rights or
       obligations of the Parties hereunder, the Parties shall try to settle
       their differences amicably between themselves by referring the disputed
       matter to the President of InterMune and the Chief Executive Officer of
       Connetics for discussion and resolution. Either Party may initiate such
       informal dispute resolution by sending written notice of the dispute to
       the other Party, and within ten (10) days after such notice such
       representatives of the Parties shall meet for attempted resolution by
       good faith negotiations. If such personnel are unable to resolve such
       dispute within thirty (30) days of initiating such negotiations, either
       Party may seek to have such dispute resolved by binding arbitration under
       this Section 11.7. The arbitration shall be held in Palo Alto, California
       according to the Commercial Arbitration Rules of the American Arbitration
       Association (the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      18.

<PAGE>

       "Rules"). The arbitration will be conducted by a panel of three (3)
       arbitrators who are knowledgeable in the subject matter that is at issue
       in the dispute, are not affiliated directly or indirectly with either
       Party, and are selected by mutual agreement of the Parties. Failing such
       agreement, the arbitrators shall be selected appointed as provided in the
       Rules. During the arbitration, the Parties shall have such discovery
       rights as the arbitrators may allow, consistent with the discovery
       permitted by the Federal Code of Civil Procedure. In conducting the
       arbitration, the arbitrators shall apply the rules of evidence applicable
       in California, and shall be able to decree any and all relief of an
       equitable nature, including but not limited to such relief as a temporary
       restraining order, a preliminary injunction, a permanent injunction, or
       replevin of property, as well as specific performance. The arbitrators
       shall also be able to award direct and indirect damages, but shall not
       award any other form of damage (e.g., punitive or exemplary damages). The
       reasonable fees and expenses, of the arbitrators, along with the
       reasonable legal fees and expenses of the prevailing Party (including all
       expert witness fees and expenses), the fees and expenses of a court
       reporter, and any expenses for a hearing room, shall be paid as follows:
       If the arbitrators rule in favor of one Party on all disputed issues in
       the arbitration, the losing Party shall pay one hundred percent (100%) of
       such fees and expenses; if the arbitrators rule in favor of one Party on
       some issues and the other Party on other issues, the arbitrators shall
       issue with the rulings a written determination as to how such fees and
       expenses shall be allocated between the Parties. The arbitrators shall
       allocate fees and expenses in a way that bears a reasonable relationship
       to the outcome of the arbitration, with the Party prevailing on more
       issues, or on issues of greater value or gravity, recovering a relatively
       larger share of its legal fees and expenses. The decision of the
       arbitrators shall be final and may be entered, sued on or enforced by the
       Party in whose favor it runs in any court of competent jurisdiction at
       the option of such Party. Whether a claim, dispute or other matter in
       question would be barred by the applicable statute of limitations, which
       statute of limitations also shall apply to any claim or disputes subject
       to arbitration under this Section, shall be determined by binding
       arbitration pursuant to this Section.

(b)    Notwithstanding anything to the contrary in this Agreement, either Party
       may seek immediate injunctive or other interim relief without resort to
       arbitration from any court of competent jurisdiction with respect to any
       breach of Article 9 hereof, or as necessary to enforce and prevent
       infringement of the patent rights, copyright rights, trademarks, trade
       secrets, or other intellectual property rights owned or controlled by a
       Party or its Affiliates.

11.8   FORCE MAJEURE. Any delays in performance by any Party under this
       Agreement shall not be considered a breach of this Agreement if and to
       the extent caused by occurrences beyond the reasonable control of the
       Party affected, including but not limited to acts of God, embargoes,
       governmental restrictions, fire, flood, explosion, riots, wars, civil
       disorder, rebellion or sabotage. The Party suffering such occurrence
       shall immediately notify the other Party as soon as practicable, and any
       time for performance hereunder shall be extended by the actual time of
       delay caused by the occurrence.

11.9   INDEPENDENT CONTRACTORS. In making and performing this Agreement,
       InterMune and Connetics act and shall act at all times as independent
       contractors and nothing contained in

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      19.
<PAGE>

       this Agreement shall be construed or implied to create an agency,
       partnership or employer and employee relationship between InterMune and
       Connetics. At no time shall one Party make commitments or incur any
       charges or expenses for or in the name of the other Party.

11.10  SEVERABILITY. If any part of this Agreement is declared invalid by any
       legally governing authority having jurisdiction over either Party, then
       such declaration shall not affect the remainder of the Agreement and the
       Parties shall revise the invalidated part in a manner that will render
       such provision valid without impairing the Parties' original interest.

11.11  CUMULATIVE RIGHTS. The rights, powers and remedies hereunder shall be in
       addition to, and not in limitation of, all rights, powers and remedies
       provided at law or in equity, or under any other agreement between the
       Parties. All of such rights, powers and remedies shall be cumulative, and
       may be exercised successively or cumulatively.

11.12  COUNTERPARTS. This Agreement may be executed in two or more counterparts,
       each of which shall be an original and all of which shall constitute
       together the same document.

11.13  ENTIRE AGREEMENT. This Agreement and any and all Exhibits referred to
       herein, in conjunction with the other "Intercompany Agreements" (as that
       term is described in the Collaboration Agreement), embodies the entire
       understanding of the Parties with respect to the subject matter of the
       Intercompany Agreements, and supersedes and terminates all previous
       communications, representations or understandings, either oral or
       written, between the Parties relating to the subject matter of the
       Intercompany Agreements.

                       THIS SPACE INTENTIONALLY LEFT BLANK

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      20.
<PAGE>

       IN WITNESS WHEREOF, both InterMune and Connetics have executed this
Agreement, as of the day and year first written above.

INTERMUNE PHARMACEUTICALS, INC.            CONNETICS CORPORATION

By:  /s/ W. Scott Harkonen                 By:  /s/ T. Wiggans
    ---------------------------------          ---------------------------------
Name:  W. SCOTT HARKONEN                   Name:  THOMAS WIGGANS
      -------------------------------            -------------------------------
Title:  PRESIDENT                          Title:  PRESIDENT
       ------------------------------             ------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       21.

<PAGE>

<TABLE>
<S>                                                                                       <C>
1..........................................................................Definitions    2
     1.1..................................................................."Affiliate"    2
     1.2............................................................."Amendment No. 3"    2
     1.3................................................................"Best Efforts"    2
     1.4........................................................................."BLA"    2
     1.5.........................................................."Connetics Know-How"    2
     1.6.................................................................."Controlled"    2
     1.7..........................................................."Dermatology Field"    2
     1.9........................................................................."FDA"    3
     1.10..............................................................."Gene Therapy"    3
     1.11........................................................."Gene Therapy Field"    3
     1.12.................................................................."Genentech"    3
     1.13.........................................................."Genentech License"    3
     1.14..................................................."Genentech License Rights"    3
     1.15.........................................................."Genentech Patents"    3
     1.16................................................."Genentech Supply Agreement"    3
     1.17..................................................................."IG Field"    3
     1.18..................................................."Interferon Gamma" or "IG"    3
     1.19........................................................"InterMune Net Sales"    4
     1.20..................................................................."Know-How"    4
     1.21..."Licensed Product," "Licensed Gene Product" and "Licensed Protein Product"    4
     1.22........................................................"Licensed Technology"    4
     1.23.................................................................."Net Sales"    4
     1.24...................................................................."Patents"    4
     1.25.................................................................."Territory"    4
     1.26................................................................"Third Party"    4
     1.27................................................."Third Party Product Rights"    4
     1.28.............................................................."United States"    4
2........................................................Original Agreement Superseded    4
3...............................................................Licenses and Covenants    4
     3.1......................................................Genentech License Rights    4
     3.2....................................................Third Party Product Rights    5
     3.3............................................................Connetics Know-How    5
     3.4....................................................Genentech Supply Agreement    5
     3.5................................................Transfer of Data and Materials    5
     3.6............................................................Connetics Covenant    6
     3.7.................................InterMune Performance under Genentech License    6
4.........................................................Option to Dermatology Rights    6
     4.1..................................................................Option Grant    6
     4.2........................Payments and Other Obligations under Genentech License    6
     4.3...............................................................Off-Label Sales    7
     4.4..................................................................Patent Costs    7
     4.5............................................................Milestone Payments    8
     4.6...................Dermatological Indications Outside of the Dermatology Field    8
5........................................................................Consideration    9

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        1.
<PAGE>

     5.1.....................................................................Royalties    9
     5.2.............................................................Milestone Payment    9
     5.3.........................................................Reports; Audit Rights    11
     5.4..............................................Payments under Genentech License    11
6................................................................Intellectual Property    11
     6.1.......................................................Ownership of Inventions    11
     6.2............................................................Patent Prosecution    12
     6.3...........................................Infringement of Third Party Patents    12
     6.4..............................................Infringement of Licensed Patents    12
     6.5...................................................................Cooperation    12
7.......................................................Representations and Warranties    12
     7.1.........................................Mutual Representations and Warranties    12
     7.2......................................Connetics Representations and Warranties    13
8......................................................................Indemnification    13
     8.1..................................................Indemnification by Connetics    13
     8.2..................................................Indemnification by InterMune    13
     8.3.....................................................Indemnification Procedure    13
9......................................................................Confidentiality    14
     9.1..........................................Confidential Information Obligations    14
     9.2....................................................................Exceptions    14
     9.3........................................................Terms of the Agreement    14
     9.4..........................................................Permitted Disclosure    14
10.........................................................................Termination    15
     10.1............................................................Term of Agreement    15
     10.2..............................................Termination for Material Breach    15
     10.3........................................................Effect of Termination    15
     10.4.............................................................Surviving Rights    16
     10.5.....................................Accrued Rights and Surviving Obligations    16
     10.6............................................................Bankruptcy Rights    16
11.......................................................................Miscellaneous    16
     11.1.......................................................................Waiver    16
     11.2...................................................................Assignment    16
     11.3......................................................................Notices    16
     11.4.....................................................................Headings    17
     11.5....................................................................Amendment    17
     11.6................................................................Governing Law    17
     11.7...........................................................Dispute Resolution    17
     11.8................................................................Force Majeure    18
     11.9......................................................Independent Contractors    18
     11.10................................................................Severability    18
     11.11...........................................................Cumulative Rights    19
     11.12................................................................Counterparts    19
     11.13............................................................Entire Agreement    19
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        2.
<PAGE>

                                  EXHIBIT 1.13

                         GENENTECH LICENSE (AS AMENDED)

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        iii
<PAGE>

                              LICENSE AGREEMENT FOR

                                INTERFERON GAMMA

                                     BETWEEN

                              CONNETICS CORPORATION

                                       AND

                                 GENENTECH, INC.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       iv
<PAGE>

                                TABLE OF CONTENTS
<TABLE>
<CAPTION>
                                                                                        PAGE
<S>                                                                                     <C>
1.0      Definitions.......................................................................2
         1.1      Best Efforts.............................................................2
         1.2      Biogen License...........................................................2
         1.3      Biogen License Rights....................................................2
         1.4      BLA......................................................................2
         1.5      Bulk Product.............................................................2
         1.6      C.F.R....................................................................2
         1.7      CGD......................................................................2
         1.8      Connetics Knowhow........................................................2
         1.9      Connetics Patent Rights..................................................3
         1.10     ELA......................................................................3
         1.11     FDA......................................................................3
         1.12     Field of Use.............................................................3
         1.13     Finished Product.........................................................4
         1.14     Fully Burdened Manufacturing Cost........................................4
         1.15     Gene Therapy.............................................................4
         1.16     Genentech Knowhow........................................................5
         1.17     Genentech Manufacturing Knowhow..........................................5
         1.18     Genentech Patent Rights..................................................5
         1.19     IND......................................................................6
         1.20     Interferon Gamma.........................................................6
         1.21     Interferon Gamma-1B......................................................6
         1.22     Licensed Product.........................................................6
         1.23     NDA......................................................................7
         1.24     NDC......................................................................7
         1.25     Net Sales................................................................7
         1.26     Party....................................................................8
         1.27     PLA......................................................................8
         1.28     Territory................................................................8
         1.29     Transfer Date............................................................8

2.0      License Grant.....................................................................8
         2.1      Patent and Knowhow License Grant.........................................8
         2.2      Trademark License Grant.................................................10

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        v
<PAGE>

         2.3      Sublicenses.............................................................11
         2.4      Grant Back License.  ...................................................14
         2.5      Data Transfer and Cooperation...........................................14

3.0      Product Development and Milestones...............................................19
         3.1      Commercialization Milestones............................................19
         3.2      Diligence...............................................................22
         3.3      Review of Clinical Development Plan and Marketing Programs..............24
         3.4      New Delivery Forms......................................................25
         3.5      Costs of Development....................................................25
         3.6      Joint Development and Marketing Activities..............................25
         3.7      Compliance with Law and Safety and Adverse Event Reporting..............26
         3.8      Clinical Development Reports ...........................................26
         3.9      Technology Outside the Field of Use.....................................26

4.0      Supply of Interferon Gamma-1B....................................................29
         4.1      Bulk Product and Finished Product.......................................29
         4.2      Supply of Non-human Interferon Gamma....................................29

5.0      Intellectual Property Rights.....................................................29
         5.1      Ownership...............................................................29
         5.2      Patent Prosecution and License Fees.....................................30
         5.3      Patent Infringement.....................................................31
         5.4      Third Party Rights......................................................32
         5.5      Trademark Infringement..................................................32
         5.6      CMCC License ...........................................................32

6.0      Product Promotion................................................................33
         6.1      Promotion...............................................................33
         6.2      Encroachment............................................................33

7.0      Confidentiality..................................................................33

8.0      Up-front Payment, Milestone Payments and Royalties...............................35
         8.1      Up-front Payment........................................................35
         8.2      Milestone Payments for Licensed Products ...............................37
         8.3      Royalties...............................................................38
         8.4      Third-Party Royalties...................................................38
         8.5      Royalty Payments........................................................39
         8.6      Taxes...................................................................39

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        vi
<PAGE>

         8.7      Termination.............................................................39
         8.8      Records and Reporting...................................................40

9.0      Representations and Warranties...................................................41
         9.1      Disclaimer..............................................................41
         9.2      Representations and Warranties..........................................41

10.0     Liability........................................................................43
         10.1     Limitation of Liability.................................................43
         10.2     Connetics Indemnification...............................................43
         10.3     Genentech Indemnification...............................................43

11.0     Term and Termination.............................................................44
         11.1     Term....................................................................44
         11.2     Termination for Default.................................................45
         11.3     Genentech's Rights on Termination.......................................46
         11.4     Connetics' Rights on Termination........................................47
         11.5     Bankruptcy..............................................................48
         11.6     Unilateral Termination. ................................................49
         11.7     Survival of Certain Provisions..........................................49

12.0     General Provisions...............................................................50
         12.1     Notices.................................................................50
         12.2     Governing Law...........................................................50
         12.3     Entire Agreement........................................................50
         12.4     Binding Effect and Assignment...........................................51
         12.5     Waiver..................................................................51
         12.6     Severability............................................................51
         12.7     Publicity...............................................................52
         12.8     Counterparts............................................................52
         12.9     Force Majeure...........................................................53
         12.10    Headings................................................................53
         12.11    No Partnership..........................................................53

Exhibit A Patent Applications and Patents Included in Genentech Patent Rights.............55
Exhibit B Interferon Gamma................................................................56
Exhibit C Interferon Gamma-1B.............................................................57

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       vii
<PAGE>

Exhibit D Third Party Sponsored Studies...................................................58
Exhibit E Clinical Development Milestones.................................................59
Exhibit F Clinical Reports................................................................60
Exhibit G Third Party Royalties...........................................................61
Exhibit H Transfer Date Activities for Commercial Sales of Actimmune for CGD .............62
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      viii
<PAGE>

                              LICENSE AGREEMENT FOR

                                INTERFERON GAMMA

         This Agreement is entered into effective as of May 5, 1998, ("Effective
Date") by and between Connetics Corporation, a Delaware corporation with its
principal office at 3400 West Bayshore Road, Palo Alto, California 94303
("Connetics"), and Genentech, Inc., a Delaware corporation with its principal
office at 1 DNA Way, South San Francisco, California 94080 ("Genentech").

         WHEREAS, Connetics wishes to obtain a non-exclusive license to
manufacture and an exclusive license to use, sell, offer for sale and import
Interferon Gamma (as defined herein) in the United States for the treatment of
certain medical disorders;

         WHEREAS, in consideration for the foregoing, Connetics will issue to
Genentech shares of Connetics Common Stock on the terms and conditions set forth
in that certain stock purchase agreement between Genentech and Connetics of even
date herewith (the "Stock Agreement");

         WHEREAS, Genentech will manufacture and supply Connetics with
Interferon Gamma-1B (as defined herein) under the terms and conditions set forth
in that certain supply agreement between Genentech and Connetics of even date
herewith (the "Supply Agreement");

         WHEREAS, Connetics and Genentech are parties to that certain Agreement
on Interferon Gamma-1B dated December 8, 1995 (the "Prior Agreement") and desire
to terminate the Prior Agreement effective as of the date hereof and to accept
the rights and obligations created

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        1
<PAGE>

pursuant hereto in lieu of the rights and obligations under the Prior Agreement;
and

         WHEREAS, Genentech and Connetics therefore agree to undertake the
foregoing, all under the terms and conditions set forth in this Agreement and
for the consideration set forth herein and in the Stock Agreement.

         NOW, THEREFORE, in consideration of the mutual promises contained
herein, the Parties agree as follows:

1.0      DEFINITIONS

         1.1     "Best Efforts" shall mean every necessary and prudent effort of
a Party applied in a prompt, commercially reasonable manner, to the maximum
extent reasonably allowed by such Party's available financial resources, taking
into account all of such Party's business commitments for such financial
resources.

         1.2     "Biogen License" shall mean that certain license agreement
between Genentech and Biogen, Inc. ("Biogen") dated January 5, 1990, as amended
on November 23, 1992.

         1.3     "Biogen License Rights" shall mean all sublicenseable rights
granted to Genentech by Biogen under the Biogen License.

         1.4     "BLA" shall mean Biologics License Application.

         1.5     "Bulk Product" shall mean Interferon Gamma-1B provided as bulk
protein manufactured in compliance with Good Manufacturing Practices, pursuant
to applicable FDA regulatory approvals and supplied to Connetics in such a form
and in such containers as shall be

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        2
<PAGE>

mutually determined by Genentech and Connetics and as described in the Supply
Agreement.

         1.6     "C.F.R." shall mean Code of Federal Regulations.

         1.7     "CGD" shall mean chronic granulomatous disease.

         1.8     "Connetics Knowhow" shall mean all proprietary information,
methods, processes, techniques and data that have not been publicly disclosed,
that relate to Interferon Gamma and that arise out of Connetics' and its
sublicensees' efforts in the development of Interferon Gamma (including
Interferon Gamma as part of a Licensed Product) hereunder and that on the
Effective Date and hereafter during the term of this Agreement are owned or
controlled by Connetics or its sublicensees or under which Connetics or its
sublicensees otherwise has the right to grant licenses or sublicenses.

         1.9     "Connetics Patent Rights" shall mean all patents, patent
applications and any patents issuing therefrom, together with any substitutions,
extensions, reexaminations, reissues, renewals, divisions, continuations and
continuations-in-part thereof, that (a) claim inventions constituting Interferon
Gamma or its manufacture or use that arise out of Connetics' or its
sublicensee's efforts in the development of Interferon Gamma (including
Interferon Gamma as part of a Licensed Product) hereunder during the term of
this Agreement, and (b) are owned by Connetics or its sublicensees or under
which Connetics or its sublicensees otherwise has the right to grant licenses or
sublicenses as provided herein.

         1.10    "ELA" shall mean Establishment License Application.

         1.11    "FDA" shall mean the United States Food and Drug
Administration.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        3
<PAGE>

         1.12    "Field of Use" shall mean the administration to humans of
Licensed Product for the treatment or prevention of: (a) any dermatological
disease or condition including, without limitation, atopic dermatitis,
keloids/hypertrophic scars, pustular psoriasis and scleroderma, but excluding
any cancer disease or condition, (b) any infectious disease or condition
including, without limitation, fungal, viral and bacterial infections, (c)
osteopetrosis, (d) chronic granulomatous disease, (e) pulmonary fibrosis, and
(f) asthma. Notwithstanding the foregoing, the Field of Use shall not include
the administration to humans of Licensed Product for the treatment or prevention
of any type of arthritis or cardiac or cardiovascular disease or condition, or
use of Licensed Product for any indication or use in the field of oncology or
endocrinology. Each of Subsections 1.12 (a) through (f) inclusive shall
hereinafter each be referred to individually as an "Area of the Field of Use"
and together as the "Areas of the Field of Use."

         1.13    "Finished Product" shall mean Interferon Gamma-1B supplied in
vialed form as 100 micrograms of Interferon Gamma-1B protein in a 0.5 ml fill
volume and as described in the Supply Agreement, manufactured in compliance with
Good Manufacturing Practices and intended for commercial sale to treat CGD and
osteopetrosis and for clinical studies.

         1.14    "Fully Burdened Non-human Interferon Gamma Manufacturing Cost"
shall mean the cost of Genentech's production and testing of Non-human
Interferon Gamma, which shall be comprised of the sum of: [ * ]

         1.15    "Gene Therapy" shall mean the therapeutic or prophylactic
treatment of a human being with: (a) one or more oligonucleotides or nucleotide
sequences, in native form or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        4
<PAGE>

chemically modified, which are introduced into the body in free form, bound to a
carrier molecule, contained in any molecular vesicle (e.g. a liposome),
incorporated into or attached to a vector of any type, contained in any cellular
construct and/or contained in any mechanical device or (b) cells which have been
manipulated ex vivo using one or more oligonucleotides or nucleotide sequences.

         1.16    "Genentech Knowhow" shall mean all proprietary information,
methods, processes, techniques and data that are in the possession or control of
Genentech on the Effective Date or thereafter during the term of this Agreement,
that Genentech is free to license or sublicense, that have not been publicly
disclosed, and that are specific and reasonably necessary for the use, sale,
offer for sale or importation of Interferon Gamma in the Field of Use in the
Territory, but shall not include information regarding the manufacture of
Interferon Gamma.

         1.17    "Genentech Manufacturing Knowhow" shall mean all proprietary
information, methods, processes, techniques and data that are in the possession
of Genentech at such time as Genentech determines or is required pursuant to the
terms of the Supply Agreement to make a manufacturing technology transfer to
Connetics, that are not generally known, and that are specific and reasonably
necessary for the manufacture of Interferon Gamma in the Field of Use in the
Territory.

         1.18    "Genentech Patent Rights" shall mean all patents and patent
applications and any patents issuing therefrom, together with any extensions,
reissues, reexaminations, substitutions, renewals, divisions, continuations and
continuations-in-part thereof (a) that are owned or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        5
<PAGE>

controlled by Genentech presently or hereafter, during the term of this
Agreement, and under which Genentech is free to license or sublicense, and (b)
to the extent they claim or directly relate to Interferon Gamma or its
manufacture or use in the Field of Use, including, without limitation, the
patent rights granted under that certain license agreement between Genentech and
Children's Medical Center Corporation, dated July 16, 1990 (the "CMCC License"),
but specifically excluding any rights granted to Genentech under the Biogen
License. Genentech Patent Rights shall include, without limitation, the patents
and patent applications listed in EXHIBIT A attached hereto. Notwithstanding the
foregoing, Genentech Patent Rights shall exclude any rights Genentech acquires
after the Effective Date of this Agreement under third-party license agreements,
with the exception of those acquired under the CMCC License, unless and until
the Parties mutually agree on terms and conditions for the sublicense of such
rights from Genentech to Connetics.

         1.19    "IND" shall mean Investigational New Drug Application.

         1.20    "Interferon Gamma" shall mean a polypeptide having the 126
amino acid sequence set forth on EXHIBIT B or a variant of such sequence having
at least 70% homology thereto, or such polypeptide with one or more additional
amino acid residue(s) extending from the N-terminus thereof AND/OR one or more
additional amino acid residue(s) extending from the C-terminus thereof, such
polypeptides including, without limitation, Interferon Gamma-1B.

         1.21    "Interferon Gamma-1B" shall mean a single chain polypeptide
containing the 140 amino acid sequence set forth on EXHIBIT C hereto, i.e., the
active ingredient in the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        6
<PAGE>

ACTIMMUNE7 (Interferon Gamma-1B) Injection product.

         1.22    "Licensed Product" shall mean any pharmaceutical formulation
containing Interferon Gamma whether alone or together with or incorporated into
any other substance or product or material or device, whether active or not, and
which (i) but for the licenses granted hereunder, the manufacture, use, sale,
offer for sale or importation of which in the Territory would infringe or
contribute to the infringement of Genentech Patent Rights in the Territory, or
(ii) is based upon or incorporates or utilizes Genentech Knowhow. For purposes
of clarification, it is understood that this definition shall not include any
pharmaceutical formulation which induces the presence or activity of Interferon
Gamma IN VIVO, or the DNA encoding Interferon Gamma for Gene Therapy, or other
biological techniques aimed at establishing or modulating endogenous Interferon
Gamma IN VIvo.

         1.23    "NDA" shall mean New Drug Application.

         1.24    "NDC" shall mean National Drug Code.

         1.25    "Net Sales" shall mean, as to each calendar quarter, the gross
invoiced sales prices charged for all Licensed Products sold by Connetics and
its sublicensees in arm's length transactions to independent third parties
during such quarter, after deduction of the following items paid by Connetics
and its sublicensees during such calendar quarter with respect to sales of
Licensed Products regardless of the calendar quarter in which such sales were
made, provided and to the extent that such items are incurred or allowed and do
not exceed reasonable and customary amounts in the market in which such sales
occurred:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        7
<PAGE>

                 [ * ]

                 Notwithstanding the foregoing, no deduction shall be made for
bad debt expense.

         1.26    "Party" shall mean Genentech or Connetics, and, when used in
the plural, shall mean both of them.

         1.27    "PLA" shall mean Product License Application.

         1.28    "Territory" shall mean the United States of America and its
territories and possessions.

         1.29    "Transfer Date" shall mean, unless otherwise mutually agreed to
by the Parties, the last day of the second full calendar month following the
first delivery by Connetics to Genentech of Connetics' labeling and packaging
materials for Genentech's use in labeling and packaging Finished Product,
pursuant to a purchase order submitted by Connetics and accepted by Genentech,
to be sold commercially by Connetics for treatment of CGD, provided that the
activities set forth on Exhibit H have been completed.

2.0      LICENSE GRANT

         2.1     Patent and Knowhow License Grant

                 (a)      Genentech grants to Connetics an exclusive license,
even as to Genentech, under Genentech Patent Rights and under Genentech Knowhow
to use, sell, offer for sale and import (but not to make or have made) Licensed
Products in the Field of Use in the Territory,

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        8
<PAGE>

(excluding, with respect to the fields of (i) scleroderma and (ii) infectious
disease or condition caused by human papillomavirus, Licensed Products
containing any form of Interferon Gamma other than Genentech Gamma Interferon
TRIANGLE3, as that term is defined in the Biogen License). Notwithstanding the
foregoing, Genentech reserves the right to use (but not to import, offer for
sale or sell) Licensed Products within the Field of Use for research purposes.

                 (b)      Genentech grants to Connetics a non-exclusive license
under Genentech Patent Rights and under Genentech Knowhow to use, sell, offer
for sale and import (but not to make or have made) Licensed Products containing
any form of Interferon Gamma other than Genentech Gamma Interferon TRIANGLE3 (as
that term is defined in the Biogen License) in the Territory in the fields of:
(i) scleroderma and (ii) infectious disease or condition caused by human
papillomavirus.

                 (c)      Genentech grants to Connetics a non-exclusive
sublicense under the Biogen License Rights to use, sell, offer for sale and
import Licensed Products (excluding Licensed Products containing Biogen Gamma
Interferon TRIANGLE0 as that term is defined in the Biogen License) in the
Territory in the fields of scleroderma and infectious disease or condition
caused by human papillomavirus.

                 (d)      Genentech grants to Connetics a non-exclusive license
under Genentech Patent Rights to make or have made Licensed Products in the
Field of Use for use and sale in the Territory.

                 (e)      Genentech grants to Connetics a non-exclusive license
under Genentech

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        9
<PAGE>

Patent Rights and Genentech Knowhow to use non-human animal species derived
homologues of Interferon Gamma (Non-human Interferon Gamma) for non-commercial
research purposes to support the Field of Use in the Territory.

         Except as expressly granted herein, there are no implied licenses under
the Genentech Patent Rights or any other intellectual property rights owned or
controlled by Genentech.

         2.2      Trademark License Grant

                  (a)      Genentech hereby grants to Connetics a non-exclusive,
royalty-free license to use the trademark, ACTIMMUNE, for the advertising,
promotion, marketing, distribution and sale of Licensed Products in the
Territory. Connetics shall have the right to grant sublicenses to such
non-exclusive license, subject, however, to the prior written consent of
Genentech, which consent shall not be unreasonably withheld. Genentech agrees
not to grant any other licenses to use the ACTIMMUNE trademark without the
consent of Connetics, which consent shall not be unreasonably withheld.

                  (b)      Use of the Mark. In using the ACTIMMUNE mark,
Connetics shall display said mark in upper case letters or otherwise display
it in a style or size of print distinguishing the mark from any accompanying
wording or text. Where feasible, Connetics shall display the registration
symbol -Registered Trademark- to the right of and slightly above or below
the last letter of the word, ACTIMMUNE. Prior to any new use by Connetics of
the ACTIMMUNE mark on product packaging or package inserts for the Licensed
Products, Connetics shall notify and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       10
<PAGE>

provide Genentech with an example of the proposed use for approval by
Genentech, which approval shall not be unreasonably withheld or delayed. Such
additional use, with respect to the ACTIMMUNE mark, shall automatically become
a part of the license grant under Section 2.2(a) above.

                  (c)      Quality Control. If Connetics uses the ACTIMMUNE mark
for Licensed Products, such products shall be of at least the quality described
in the Specifications therefor as defined in the Supply Agreement.

                  (d)      Ownership. Connetics hereby acknowledges Genentech's
exclusive right, title and interest in and to the ACTIMMUNE mark and agrees that
it will not at any time do, or cause to be done, any act or thing contesting or
in any way impairing or intending to impair the validity of and/or Genentech's
exclusive right, title and interest in and to the ACTIMMUNE mark. Connetics will
not in any manner represent that it owns the ACTIMMUNE mark and hereby
acknowledges that its use of the ACTIMMUNE mark as set forth in Section 2.2(b)
above shall not create any rights, title or interest in or to the ACTIMMUNE mark
in its favor, but that all use of the ACTIMMUNE mark by Connetics shall inure to
the benefit of Genentech.

         2.3      Sublicenses.

                  (a)      Connetics may grant sublicenses under the rights
granted in Section 2.1(d) on thirty (30) days prior written notice to Genentech,
subject to Genentech's prior written approval, which approval shall be at
Genentech's sole discretion. Genentech agrees that Boehringer Ingelheim
International GmbH is acceptable to Genentech as a Connetics'

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       11
<PAGE>

sublicensee under the rights granted in Section 2.1(d) for the purpose of
manufacturing and supplying Bulk Product and/or Finished Product to Connetics,
and/or to its sublicensees under Sections 2.1(a), (b) and (c). In the event that
Genentech approves the grant of a sublicense under Section 2.1(d), Genentech may
in its sole discretion, or as agreed by the Parties in the Supply Agreement,
agree to grant to Connetics and such approved sublicensee a non-exclusive
license under Genentech Manufacturing Knowhow solely to make or have made
Licensed Products for use and sale by Connetics and its sublicensees in the
Field of Use in the Territory, and Genentech shall thereafter disclose to
Connetics and such sublicensee such Genentech Manufacturing Knowhow as soon as
reasonably possible.

                  (b)      Connetics may grant one or more sublicenses under the
rights granted in Sections 2.1(a), (b), (c) and (e) in any applicable Area of
the Field of Use, on thirty (30) days prior written notice to Genentech, subject
to Genentech's prior written approval, which approval shall not be unreasonably
withheld.

                  (c)      Notwithstanding the above, Connetics may grant one
sublicense to InterMune (as defined in Section 3.1) under any or all of the
rights granted in Sections 2.1 and 2.2(a) above without Genentech's prior
written approval. InterMune (but no other sublicensee of Connetics) may grant
further sublicenses under Sections 2.1 and 2.2(a) to the extent that Connetics
has the right to do so pursuant to the provisions of this Section 2.3 and
Section 2.2(a). Connetics and InterMune shall give Genentech a copy of any
sublicense agreement entered into by either of them with a third party pursuant
to this Agreement as soon as reasonably possible

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       12
<PAGE>

after execution, provided that Connetics and InterMune may each redact from such
copies text of information or provisions that are not relevant to this Agreement
and the rights and obligations of the Parties hereunder. Genentech agrees to
permit InterMune to perform Connetics' rights and obligations under Section
2.2(b), (c) and (d), Section 2.5, Sections 3.1 through 3.8 and Article 4.0 of
this Agreement (excluding matters related to any alleged breach of the
Agreement, or dispute between the Parties concerning the performance of this
Agreement, under such enumerated Sections and Article), to the extent such
rights and obligations are sublicensed to InterMune by Connetics, and Genentech
agrees to deal with InterMune in lieu of Connetics as if it were Connetics
hereunder for purposes of performance under such enumerated Sections and
Article, provided that Connetics shall remain liable and responsible for
performance of all of the obligations of Connetics and InterMune under this
Agreement. In the event that Connetics sublicenses all of its rights under
Section 2.1 and 2.2(a) to InterMune pursuant to a written sublicense which
provides that InterMune (and not Connetics) shall make, have made, use, sell,
offer for sale, import and develop Licensed Products in all Areas of the Field
of Use in the Territory, then Genentech agrees to permit InterMune to also
perform Connetics' rights and obligations under Articles 5.0 and 6.0 and
Sections 8.2 through 8.8 of this Agreement (excluding matters related to any
alleged breach of the Agreement, or dispute between the Parties concerning the
performance of this Agreement, under such enumerated Sections and Articles), and
Genentech also agrees to deal with InterMune in lieu of Connetics as if it were
Connetics hereunder for purposes of performance under such enumerated Sections
and Articles, provided

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       13
<PAGE>

that Connetics shall remain liable and responsible for performance of all of the
obligations of Connetics and InterMune under this Agreement. In the event that
InterMune sublicenses any of its rights to a third party pursuant to this
Agreement, such sublicensee shall not have the right to perform the rights and
obligations of Connetics or InterMune under the Sections and Articles enumerated
above, and Genentech shall not have any obligation to deal directly with such
sublicensee. Notwithstanding the above provisions of this Section 2.3(c), with
respect to any dispute concerning InterMune's performance, or alleged breach by
InterMune, of any applicable term of this Agreement, Genentech shall have the
right to deal directly with Connetics, and to proceed either against InterMune
or directly against Connetics, in Genentech's sole discretion, to enforce this
Agreement.

                  (d)      In the event of the grant of any sublicense by
Connetics (including such grant to InterMune) or by InterMune, the sublicensee
shall be subject to all of the applicable obligations of Connetics hereunder.
Connetics guarantees to Genentech the performance of Connetics' applicable
obligations hereunder by Connetics' sublicensees and by InterMune's
sublicensees.

         2.4      Grant Back License. Connetics hereby grants to Genentech under
any Connetics Patent Rights and Connetics Knowhow, a nonexclusive,
sublicenseable license in the Territory to make, have made, use, sell, offer for
sale and import Interferon Gamma for any use outside of the Field of Use, with a
royalty rate of one-half of a percent (0.5%) payable to Connetics on net sales
of Interferon Gamma by Genentech, its affiliates and its sublicensees covered by
such Connetics

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       14
<PAGE>

Patent Rights or incorporating such Connetics Knowhow. Genentech shall have the
right to grant sublicenses under such license, subject to the prior written
approval of Connetics, which approval shall not be unreasonably withheld. The
license granted to Genentech under this Section 2.4 shall expire on the later
of: (a) the expiration of the last to expire of any Connetics Patent Rights or
(b) if Connetics Knowhow was used, twenty (20) years from the first commercial
sale of Interferon Gamma outside the Field of Use by Genentech, its affiliates
or its sublicensees hereunder. As used herein, "net sales" shall have the
equivalent definition given to Net Sales in Section 1.25 above.

         2.5      Data Transfer and Cooperation

                  (a)      Genentech shall provide Connetics with reasonable
access to all such relevant information and materials in its possession (subject
to Genentech's own internal reasonable needs for the information and materials)
that Connetics reasonably needs to develop and commercialize Licensed Products
in the Field of Use under the license granted to Connetics under Section 2.1
above. Connetics shall submit requests for such information to Genentech's
Clinical Collaborations Operations Department - Medical Affairs at the address
set forth at the beginning of this Agreement. Access to such information and
materials shall be made in a timely and orderly fashion and in a manner such
that the value of the accessed information is preserved in all material
respects.

                  (b)      Connetics shall provide Genentech with reasonable
access to such relevant information and materials in its possession as is
reasonably necessary for Genentech to exercise

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       15
<PAGE>

the license rights granted by Connetics under Section 2.4 and Genentech shall
submit requests for such information to Connetics' Vice President - Intellectual
Property at the address set forth at the beginning of this Agreement. Access to
such information and materials shall be made in a timely and orderly fashion and
in a manner such that the value of the accessed information is preserved in all
material respects.

                  (c)      Commencing on May 1, 1998 Connetics or its
sublicensees shall be responsible for any costs associated with maintaining the
Genentech breeding colony of interferon gamma gene knock-out mice at Charles
River Labs (the "Knock-Out Mice"). In consideration for Connetics paying these
costs, Genentech hereby transfers all ownership of such particular Knock-Out
Mice to Connetics, subject to Genentech's right to use such Knock-Out Mice and
the progeny thereof for Genentech's own research purposes to the extent such
Knock-Out Mice are not being used (or planned to be used) by Connetics or its
sublicensees. If Connetics and its sublicensees wish to discontinue the
maintenance of such Knock-Out Mice colony, Connetics shall give Genentech sixty
(60) days prior notice and the right to take over such maintenance, at
Genentech's sole discretion, before Connetics discontinues such maintenance.
Connetics acknowledges that Genentech has, prior to the Effective Date hereof,
transferred interferon gamma gene knock-out mice to other third parties.

                  (d)      Connetics shall use its Best Efforts to obtain a
license from the FDA, which shall include obtaining a U.S. license number and an
NDC number, to enable the effective transfer from Genentech to Connetics of the
PLA for CGD on file with the FDA (the "CGD

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       16
<PAGE>

PLA"). Genentech shall use its Best Efforts to assist such transfer, to the
extent reasonably requested by Connetics. Genentech also shall, before the
Transfer Date, reasonably assist Connetics in initiating Connetics' sales of
Licensed Product in the Area of the Field of Use of CGD by transferring to
Connetics information reasonably requested by Connetics that relates to such
sales efforts for CGD. Connetics shall reimburse Genentech for all reasonable
costs associated with Genentech's providing of such information within ninety
(90) days of Connetics' receipt of an invoice of such cost from Genentech.

                  (e)      Genentech shall transfer the CGD PLA, IND and copies
of all material correspondence with the FDA regarding such PLA and IND to
Connetics as soon as reasonably possible after the Effective Date of this
Agreement and Connetics shall be responsible for all activities, at its own
cost, necessary to maintain the CGD PLA and IND and keep them active with the
FDA after such date. Connetics shall reimburse Genentech for 50% of all
reasonable costs associated with Genentech's transfer of the CGD PLA, IND and
such FDA correspondence within ninety (90) days of Connetics' receipt of an
invoice of such cost from Genentech.

                  (f)      Connetics shall not commence marketing and sales of
Finished Product prior to the Transfer Date. On the Transfer Date, Genentech
shall transfer to Connetics the responsibility for all marketing and sales of
Finished Product in the Field of Use in the Territory, provided that all the
activities listed on Exhibit H attached hereto are completed. The Parties shall
use Best Efforts to complete the tasks set forth on Exhibit H as expeditiously
as possible.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       17
<PAGE>

                  (g)      Genentech shall provide Connetics with reasonable
access to relevant data and regulatory information in its possession in the form
existing as of the Effective Date, whether written or electronic, including all
clinical safety data and clinical efficacy data that are related to the
manufacture, use and sale of Interferon Gamma within the Field of Use and the
right to cross-reference Genentech's IND, ELA, and PLA information for
Interferon Gamma in any Genentech regulatory filings related to Interferon Gamma
within the Field of Use. Other than as expressly set forth herein, Genentech
shall have no further obligation with respect to Connetics' efforts to obtain
the FDA license referred to in Section 2.5(d) above. At Genentech's sole
discretion, Genentech may participate in regulatory filings in the Field of Use
in the Territory if the Parties agree that Genentech's participation in such
regulatory filings would expedite the approval and commercialization of a
Licensed Product. Connetics shall reimburse Genentech for all reasonable costs
associated with Genentech's providing of data and regulatory information and
referencing within ninety (90) days of Connetics' receipt of an invoice of such
cost from Genentech. Connetics shall submit requests for such information to
Genentech's Clinical Collaborations Operations Dept. - Medical Affairs at the
address set forth in the beginning of this Agreement. Such requests shall not be
submitted more than two (2) times in any twelve (12) month period, unless such
requests concern information that is critical to product registration
activities. Access to such information shall be made in a timely and orderly
fashion and in a manner such that the value of the accessed information is
preserved in all material respects.

                  (h)      To the extent reasonably requested by Genentech,
Connetics shall provide

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       18
<PAGE>

Genentech with access to all data and regulatory information in its possession,
whether written or electronic, in the form existing as of the date of
Genentech's request, including all clinical safety data and clinical efficacy
data, that directly relates to the use of Interferon Gamma outside the Field of
Use and shall give Genentech the right to cross-reference Connetics' IND, ELA,
BLA and PLA information, if applicable, in any Genentech regulatory filings that
are related to the use or sale of Interferon Gamma outside the Field of Use.
Genentech shall reimburse Connetics for all reasonable actual costs associated
with Connetics' providing of data and regulatory information and referencing
within ninety (90) days of the receipt of an invoice of such cost by Genentech
from Connetics. Such requests shall not be submitted more than two (2) times in
any twelve (12) month period, unless such requests concern information that is
critical to product registration activities. Access to such information shall be
made in a timely and orderly fashion and in a manner such that the value of the
accessed information is preserved in all material respects.

                  (i)      Commencing from Genentech's first delivery to
Connetics or Intermune of Finished Product for clinical studies in accordance
with the Supply Agreement, Connetics shall thereafter be responsible for
supplying ACTIMUNE free of charge to, and funding (if any) of, the third party
sponsors of the clinical studies listed in Exhibit D attached hereto and
incorporated herein. Connetics shall enter into clinical research agreements
with such third party sponsors governing such studies that commence after the
Effective Date hereof. With respect to clinical research agreements between
Genentech and such sponsors in effect prior to the Effective Date,

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       19
<PAGE>

Connetics shall replace Genentech, pursuant to an assignment, as a party.
ACTIMMUNE (and funding, if any) for all such studies shall be supplied by
Connetics to such sponsors as described in such clinical research agreements.

                  (j)      As of the Transfer Date, Connetics shall conduct an
indigent patient program for Licensed Products sold for use in the field of CGD.
As soon as reasonably possible after Genentech transfers information regarding
patients who have participated in Genentech's indigent patient program,
Connetics will inform Genentech whether or not such patients will be eligible
and participating in Connetics' indigent patient program.

3.0      PRODUCT DEVELOPMENT AND MILESTONES

         3.1      Commercialization Milestones.

                  (a)      Connetics shall use its Best Efforts to develop, seek
FDA clearance for marketing of, commercialize and sell Licensed Products in the
Territory in all Areas of the Field of Use. The Parties acknowledge that a new
company, named InterMune Pharmaceuticals, Inc. ("InterMune"), has been
incorporated to conduct development and commercialization of Licensed Products
in the Field of Use pursuant to an appropriate sublicense from Connetics to
Intermune. Connetics agrees to perform the following Commercialization
Milestones no later than the date set forth below opposite the appropriate
Commercialization Milestone description:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       20
<PAGE>

<TABLE>
<CAPTION>
COMMERCIALIZATION MILESTONE                                               DATE OF COMPLETION
----------------------------------------                                  -----------
<S>                                                                     <C>
(a) Completion of the formation of InterMune                              May 1, 1998

(b) Execution of a sublicense agreement granting to
InterMune rights, as permitted in this Agreement, necessary
to perform development of Licensed Products in the Field                  June 1, 1998

(c)  Closing of at least [ * ] in equity
financing of InterMune by third parties and/or Connetics                  July 15, 1998

(d) Closing of at least another additional [ * ] in
equity financing of InterMune by third parties and/or Connetics           September 1, 1998

(e)  Enrollment and active participation

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       21
<PAGE>

of the first patient in the first new clinical trial
for a Licensed Product in the Field of Use in the Territory               October 1, 1998
</TABLE>

                  (b)      If Connetics fails to perform any of the
Commercialization Milestones described in 3.1 (a) through (e) inclusive by the
applicable Date of Completion for any reason within Connetics' control, then,
notwithstanding the termination provisions in Section 11.2 below, Genentech
shall have the right to terminate this Agreement and the licenses granted to
Connetics hereunder, upon written notice to Connetics, which termination shall
become effective thirty (30) days after Genentech's sending written notice of
such termination, unless such Commercialization Milestone has been completed
prior to the expiration of such thirty day period. If Connetics fails to perform
any of the Commercialization Milestones for causes beyond Connetics' control,
Genentech shall not have the termination rights above, provided that Connetics
has mitigated such causes to the extent it can reasonably do so. If Connetics
fails to reasonably mitigate such causes, Genentech will have the termination
rights described above. In addition, if Genentech exercises such termination
rights above, Genentech shall be automatically granted a co-exclusive (with
Connetics and Connetics' sublicensees), sublicenseable, royalty-free, worldwide
license: (i) to the result of efforts made by Connetics and its sublicensees in
the development of Licensed Products hereunder, (ii) to use all regulatory
submissions made by Connetics and its sublicensees hereunder, and (iii) under
all Connetics Patent Rights and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       22
<PAGE>

Connetics Knowhow, arising from the efforts made by Connetics and its
sublicensees hereunder in the research and development of Licensed Products, to
make, have made, use, sell, offer for sale or import Licensed Products. Upon
Genentech's exercise of such termination right described above, Connetics shall
promptly provide Genentech with copies of all related documentation, whether
written or electronic, and materials, including biological materials, in the
form existing as of the effective date of such termination, reasonably necessary
for Genentech to exercise its license rights under this Section 3.1(b). Such
transfer shall be made in an orderly fashion and in a manner such that the value
in what is being transferred is preserved in all material respects. The
foregoing shall constitute Genentech's exclusive remedies for Connetics failure
to complete one or more of the Commercialization Milestones above, provided,
however, that Genentech's rights and remedies for breach of other provisions of
this Agreement, and under the Supply Agreement and the Stock Agreement, shall
remain in full force and effect.

         3.2      Diligence

                  (a)      Attached hereto as EXHIBIT E are Connetics' Clinical
Development Milestones (the "Clinical Development Milestones") for Licensed
Products in the Field of Use and the Dates of Completion for each such
milestone. Connetics shall use its Best Efforts to adhere to the Dates of
Completion as set forth in Exhibit E. Connetics shall notify Genentech in
writing when it achieves a Clinical Development Milestone.

                  (b)      From time to time, Connetics may suggest
modifications to the Clinical Development Milestones based on new information.
Such modifications shall be effective only

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       23
<PAGE>

as mutually agreed upon, in writing, by the Parties. Genentech shall consider
such requested modifications in good faith and shall agree to any modifications
that are reasonably necessary to achieve the overall objectives of the
development of Licensed Product hereunder.

                  (c)      In the event that Connetics determines that it will
be unable to meet any Date of Completion for a Clinical Development Milestone
due to an event within Genentech's control, including without limitation, delay
in the performance by Genentech of any of its obligations hereunder (e.g. the
transfer of technology or materials, including the supply of Interferon
Gamma-1B), Connetics shall give prompt notice to Genentech of such inability and
shall specify the amount of delay Connetics believes resulted from such event
within Genentech's control. Unless Genentech disagrees in writing on reasonable
grounds with the amount of such delay specified by Connetics, such Date of
Completion will automatically be extended by the length of time of the delay. In
the event Genentech disagrees in writing on reasonable grounds with the amount
of delay specified by Connetics, the Parties shall negotiate a new Date of
Completion in good faith.

                  (d)      In the event that Connetics determines that it will
be unable to meet any Date of Completion for a Clinical Development Milestone
due to an event which would be considered a force majeure (as described in
Section 12.9), Connetics shall give prompt written notice to Genentech of such
inability and the length of the delay Connetics believes resulted from such
force majeure. Unless Genentech disagrees in writing on reasonable grounds with
the length of such delay specified by Connetics, such Date of Completion will be
automatically

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       24
<PAGE>

extended by such specified length of time of the delay. In the event Genentech
disagrees in writing on reasonable grounds with the length of delay specified by
Connetics, the Parties shall negotiate a new Date of Completion in good faith.

                  (e)      In the event that Connetics determines that it will
be unable to meet any Date of Completion for a Clinical Development Milestone
for reasons other than (i) force majeure and/or (ii) an event within Genentech's
control, Connetics shall notify Genentech of such inability, identifying the
nature of the inability with reasonable specificity and may ask Genentech for a
reasonable extension of time in which to complete such Clinical Development
Milestone. In Genentech's sole discretion, Genentech may grant Connetics such an
extension to complete such Clinical Development Milestone.

                  (f)      Except as set forth in Sections 3.2(c) or 3.2(d) or
in the event that Genentech shall have agreed to an extension of the time to
complete a Clinical Development Milestone as set forth in Section 3.2(e), if
Connetics fails to complete a Clinical Development Milestone by the
corresponding Date of Completion with respect to one or more of the Areas of the
Field of Use (other than in the dermatological Area of the Field of Use as
described in Section 1.12(a) above) Genentech shall have the right to terminate
this Agreement with respect to such Area(s) of the Field of Use, by providing
Connetics written notice thereof, and the termination of the Agreement with
respect to such Area(s) of the Field of Use shall be effective thirty (30) days
after Connetics' receipt of such notice unless such Clinical Development
Milestone shall have been met prior to the expiration of such thirty (30) day
period, and such

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       25
<PAGE>

termination shall be Genentech's exclusive remedy for such failure of Connetics
to complete such Clinical Development Milestone. Upon such termination of the
Agreement with respect to such Area(s) of the Field of Use: (i) Genentech shall
automatically have all the rights set forth in Sections 11.3(a) and (b) solely
with respect to such Area(s) of the Field of Use; and (ii) any sublicense(s)
granted by Connetics with respect to such Area(s) of the Field of Use shall not
automatically terminate, but instead, Genentech shall have the option to either
terminate or continue this Agreement with respect to such Area(s) of the Field
of Use with such sublicensee(s).

         3.3      Review of Clinical Development Plan and Marketing Programs. On
or about each August 1 during the term of this Agreement, Connetics shall supply
Genentech with a report on Connetics' development and marketing programs for
Licensed Products in the Field of Use in the Territory. The report shall include
the following: (i) a description of Connetics' progress in such programs during
the twelve (12) months prior to the date of each such report, (ii) a description
of Connetics' planned development and marketing programs for the twelve (12)
months after the date of each such report, (iii) a copy of the most recent
version of the Clinical Development Milestones (if not previously provided to
Genentech), (iv) a copy of all previous versions of the Clinical Development
Milestones (if not previously provided to Genentech), (v) an explanation of any
discrepancies between Connetics' progress during the prior twelve (12) months
and the Clinical Development Milestones and (vi) a proposal to address such
discrepancies, as contemplated under Section 3.2. Genentech shall have the right
to comment on the Clinical

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       26
<PAGE>

Development Milestones and the development and marketing programs, and at
Genentech's discretion, the Parties shall meet to discuss and agree upon changes
to the Clinical Development Milestones.

         3.4      New Delivery Forms. Connetics shall have the right to develop
and obtain regulatory approval for the marketing of new delivery forms of
Interferon Gamma for use in Licensed Products in the Field of Use in the
Territory.

         3.5      Costs of Development. Connetics shall be responsible for all
aspects and costs of development, regulatory approval and registration of
Licensed Products.

         3.6      Joint Development and Marketing Activities. Upon written
notice to Genentech, Connetics and InterMune shall be permitted to discuss and
enter into agreements and participate in joint development and marketing
activities for Licensed Products in the Field of Use outside the Territory with
other Genentech Interferon Gamma licensees.

         3.7      Compliance with Law and Safety and Adverse Event Reporting.

                  (a)      Connetics shall conduct clinical trials hereunder,
and shall make, use, sell and distribute Licensed Products in accordance with
all applicable laws and regulations. Genentech and Connetics shall make
available to each other during the term of this Agreement all safety data
obtained which relates to the use of Licensed Products in the Field of Use.
Connetics will provide to Genentech's Medical Information and Drug Experience
department at the time of filing a copy of each adverse event report or any
report, including summary reports, it is required to file under Title 21 or any
other applicable provision of the C.F.R. regarding

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       27
<PAGE>

Interferon Gamma. Genentech will provide Connetics at the time of filing with a
copy of each adverse event report or any report, including summary reports, it
is required to file regarding Interferon Gamma under Title 21 or any other
applicable provision of the C.F.R..

                  (b)      Connetics shall maintain a safety database for all
Licensed Products and clinical trials conducted hereunder and shall submit to
regulatory agencies all adverse event and safety reports required to be filed
pursuant to Title 21 or any other applicable provision of the C.F.R. Connetics
shall also be responsible for providing product, medical and clinical
information regarding Licensed Product to its customers.

         3.8      Clinical Development Reports. During the course of clinical
development of Licensed Products and clinical studies conducted by Connetics
hereunder, Connetics shall submit to Genentech the reports listed on Exhibit F
attached hereto and incorporated herein. Connetics shall submit such reports to
Genentech as promptly as reasonably practicable after such reports are completed
or such applicable information is available.

         3.9      Technology Outside the Field of Use

                  (a)      Upon mutual written amendment to this Agreement, the
Parties may expand the Field of Use, subject to the terms and conditions for
supply of Interferon Gamma 1-B set forth in the Supply Agreement, the payments
set forth in Sections 8.2 through 8.8 below inclusive and all other applicable
obligations of Connetics under this Agreement.

                  (b)      Connetics may request an expansion of the Field of
Use in the Territory, by providing Genentech with a written letter of intent
which incorporates the terms and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       28
<PAGE>

conditions specified in the Supply Agreement and Sections 8.2 through 8.8 of
this Agreement and sets forth a detailed clinical development plan and
reasonable proposed timeline (through FDA clearance) for developing the
additional medical indication(s) sought. Such letter of intent shall be deemed
Confidential Information of Connetics. Upon receipt of such letter of intent,
unless Genentech is conducting research in, or developing, Interferon Gamma for
such specified use, is already engaged in negotiations with a third party for
such specified use, or is prevented by prior written agreements to grant rights
to such additional indications to Connetics, Genentech shall negotiate
exclusively in good faith with Connetics, for a period of sixty (60) days on a
one time basis only for each such new indication outside the Field of Use, to
expand the Field of Use as proposed in the letter of intent on terms
substantially similar to those contained in this Agreement. If the Parties do
not reach mutual written agreement with respect to such proposed expansion of
the Field of Use within sixty (60) days, Genentech shall continue to have the
right to license its rights to such proposed additional indications for
Interferon Gamma outside the Field of Use to third parties other than Connetics,
provided that, for a period of six (6) months after the 60 day exclusive
negotiation period with Connetics, the milestone fee and royalty terms offered
by Genentech to third parties for such indications are not more favorable to
such third parties than those in the final offer made by Connetics.

                  (c)      Prior to offering any third party an opportunity to
obtain any right or license under Genentech Patent Rights, Genentech Knowhow, or
Biogen License Rights to use, sell, offer for sale or import Licensed Products
for any indication outside the Field of Use in the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       29
<PAGE>

Territory, Genentech shall first offer to Connetics to expand the Field of Use
to include such indication, in accordance with Section 3.8(d) below. Such
obligation to first offer to Connetics such indication outside the Field of Use
shall apply only to the first time Genentech wishes to offer rights to another
party to such indication outside the Field of Use.

                  (d)      Genentech may offer to expand the Field of Use by
written notice to Connetics ("Offer Notice"). Upon receipt of such Offer Notice,
Connetics shall have thirty (30) days to provide Genentech with a written letter
of intent which incorporates the terms and conditions specified in the Supply
Agreement and Sections 8.2 through 8.8 of this Agreement. Upon receipt of such
letter of intent, Genentech shall negotiate exclusively in good faith with
Connetics, for a period of thirty (30) days on a one time basis only for each
such new indication outside the Field of Use, to expand the Field of Use as
proposed in the letter of intent on terms substantially similar to those
contained in this Agreement. If the Parties do not reach mutual written
agreement with respect to such proposed expansion of the Field of Use within 30
days, Genentech shall continue to have the right to license its rights to such
proposed additional indications for Interferon Gamma outside the Field of Use to
third parties other than Connetics. To remain under consideration as a potential
licensee for such rights to Interferon Gamma outside the Field of Use, within
ninety (90) days of receipt of Genentech's Offer Notice, Connetics shall provide
Genentech with a detailed written clinical development plan and reasonable
proposed timeline for developing (through FDA clearance) the additional medical
indication(s) sought, which development plan shall be deemed the Confidential
Information of

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        30
<PAGE>

Connetics.

4.0      Supply of Interferon Gamma-1B

         4.1      Bulk Product and Finished Product. Genentech shall supply
Connetics with, and Connetics shall purchase, Bulk Product for clinical studies
and for sales of Licensed Product and Finished Product for commercial sale of
Licensed Product to treat CGD and osteopetrosis and for clinical studies,
pursuant to the terms and conditions of the Supply Agreement.

         4.2      Supply of Non-human Interferon Gamma. Upon Connetics'
reasonable request and in Genentech's sole discretion, Genentech may choose to
sell to Connetics Non-human Interferon Gamma at a price equal to [ * ].
Notwithstanding the foregoing, Genentech shall have no obligation to (a) provide
any minimum amount of Non-human Interferon Gamma to Connetics or (b) produce
additional amounts of Non-human Gamma Interferon in the event its current
inventory is depleted.

5.0      Intellectual Property Rights

         5.1      Ownership. Genentech shall retain title to Genentech Patent
Rights, Genentech Knowhow, Genentech Manufacturing Knowhow, the ACTIMMUNE mark,
and to any patent rights and knowhow related to Interferon Gamma or Licensed
Products developed solely by Genentech. Connetics shall retain title to
Connetics Patent Rights and Connetics Knowhow and to any patent rights and
knowhow related to Interferon Gamma and Licensed Products developed

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        31
<PAGE>

solely by Connetics. Except as expressly provided herein, each Party shall own
and shall have the exclusive right to exploit all intellectual property rights
owned or acquired by such Party.

         5.2      Patent Prosecution and License Fees

                  (a)      With the exception of Genentech Patent Rights under
the CMCC License, Genentech shall be responsible for the prosecution and
maintenance of the Genentech Patent Rights in the Territory at Genentech's
expense, in consultation with Connetics. Genentech shall be responsible for the
prosecution and maintenance and outside counsel fees associated therewith of the
Genentech Patent Rights under the CMCC License in the Field of Use in the
Territory at Connetics' expense, upon prior consultation with and approval from
Connetics, which approval shall not be unreasonably withheld or delayed.
Genentech shall keep Connetics promptly informed of the status of prosecution of
Genentech Patent Rights in the Territory, including providing copies of all
material correspondence with the U.S. Patent and Trademark Office. Connetics
shall have the right to comment upon such prosecution and Genentech agrees to
take such comments into consideration reasonably in advance of any action taken
by Genentech in such prosecution.

                  (b)      Connetics shall assist Genentech in prosecuting and
maintaining the Genentech Patent Rights as contemplated by Section 5.2(a) above.

                  (c)      At least thirty (30) days prior to the time each
benchmark payment of [ * ] under the [ * ] License becomes due during the term
of this Agreement, Genentech shall notify Connetics of such payment due and
Connetics shall have the option of paying such benchmark

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        32
<PAGE>

payment, on Genentech's behalf, when due to [ * ]. In the event that
Connetics chooses not to pay the benchmark payment when due, Connetics shall
so notify Genentech and Genentech shall have the option of paying such
benchmark payment. If Genentech pays such benchmark payment, Connetics shall
reimburse Genentech for such payment within thirty (30) days of receipt of
Genentech's request for reimbursement.

         5.3      Patent Infringement

                  (a)      If either Party learns that a third party is
infringing Genentech Patent Rights or Connetics Patent Rights, it shall promptly
notify the other in writing. The Parties shall use reasonable efforts in
cooperation with each other to stop such patent infringement without litigation.

                  (b)      Genentech and Connetics each shall have the first
opportunity to take the appropriate steps to remove the infringement of its own
Patent Rights which claim Interferon Gamma and/or its manufacture or use in the
Field of Use including, without limitation, initiating suit. In either case, if
such Party decides not to take such steps with respect to its own Patent Rights
within one hundred twenty (120) days of discovering or being notified of the
infringement, the other Party may do so. Each of the Parties agrees to provide
reasonable assistance to the other in taking such steps. Any legal action taken
under this section will be at the expense of the Party by whom suit is filed and
will be controlled by the Party bringing suit. The Party not bringing suit may
choose to be represented in any such action by counsel of its own choice at its
own expense. The Party bringing suit shall be reimbursed for its costs
associated

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        33
<PAGE>

with bringing suit with the proceeds of any damages or costs recovered. Any
monies remaining shall be split between the Parties on an equitable basis
proportional to their respective damage from the infringement. If both Parties
bring suit, equitable apportionment of the costs and damages to be recovered
shall be agreed upon before the filing of the suit.

         5.4      Third Party Rights. If a notice of infringement is received
by, or a suit is initiated against, either of Connetics or Genentech with
respect to Licensed Products or the ACTIMMUNE mark, the Parties will in good
faith discuss the best way to respond.

         5.5      Trademark Infringement

                  (a)      If either Party learns that a third party is
infringing the ACTIMMUNE mark, it shall promptly notify the other in writing.
The Parties shall use reasonable efforts in cooperation with each other to stop
such trademark infringement without litigation.

                  (b)      Genentech shall have the first opportunity to take
the appropriate steps to remove the infringement of the ACTIMMUNE mark,
including, without limitation, initiating suit. If Genentech decides not to take
such steps within one hundred twenty (120) days of discovering or being notified
of the infringement, Connetics may do so. Each of the Parties agrees to provide
reasonable assistance to the other in taking such steps. Any legal action taken
under this section will be at the expense of the Party by whom suit is filed and
will be controlled by the Party bringing suit. The Party not bringing suit may
choose to be represented in any such action by counsel of its own choice at its
own expense. The Party bringing suit shall be reimbursed for its costs
associated with bringing suit with the proceeds of any damages or costs

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        34
<PAGE>

recovered. Any monies remaining shall be split between the Parties on an
equitable basis proportional to their respective damage from the infringement.
If both Parties bring suit, equitable apportionment of the costs and damages to
be recovered shall be agreed upon before the filing of the suit.

         5.6      [ * ] License. If Genentech receives notice that it has
acquired any Genentech Patent Rights under the [ * ] License after the Effective
Date of this Agreement, Genentech shall notify Connetics in writing of such
additional rights as soon as reasonable after Genentech receives such notice.

6.0      Product Promotion

         6.1      Promotion. Genentech agrees, and shall require its
sublicensees, if any, to agree, not to promote Interferon Gamma or a Licensed
Product in the Field of Use in the Territory. Connetics agrees, and shall
require its sublicensees to agree, not to promote Interferon Gamma or a Licensed
Product outside the Field of Use or outside the Territory.

         6.2      Encroachment. In the event that either Party becomes aware of
spillover sales of Interferon Gamma by Genentech that is used within the Field
of Use or of Licensed Product by Connetics that is used outside the Field of
Use, the Parties shall meet and agree in good faith on reasonably appropriate
steps (a) to abate such encroachment and (b) to compensate the Party which has
suffered encroachment in its field of use by such spillover sales.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        35
<PAGE>

7.0      Confidentiality

         In the course of performance of this Agreement, one Party may disclose
to the other or receive information from the other relating to the subject
matter of this Agreement which information shall be considered to be the
disclosing Party's confidential information, if in the case of a written
disclosure, it is designated as confidential at the time of disclosure, or if in
the case of oral disclosure, the specific nature of the oral disclosure and its
confidentiality is confirmed in writing to the other Party within thirty (30)
days of the oral disclosure (the "Confidential Information"). Each Party shall
protect and keep confidential and shall not use, publish or otherwise disclose
to any third party, except as permitted by this Agreement or with the other
Party's written consent, the other Party's Confidential Information for a period
of five (5) years from the date of termination of this Agreement if it is
terminated at any time within five (5) years after the Effective Date of this
Agreement, otherwise for a period of three (3) years from date of termination or
expiration of this Agreement. A Party may disclose the other Party's
Confidential Information to its sublicensees hereunder, provided that such
sublicensees are subject to obligations of confidentiality at least equivalent
to those set forth in this Article 7. The Parties shall consult prior to the
submission of any manuscript for publication to determine if the publication
will contain any Confidential Information of the other Party. Such consultation
shall include providing a copy of the proposed manuscript to the other Party at
least forty-five (45) days prior to the proposed date of submission to a
publisher, incorporating appropriate changes proposed by the other Party into
the manuscript submission and deleting all of the other Party's

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        36
<PAGE>

Confidential Information which such Party does not agree to the publication
thereof. The foregoing notwithstanding, Confidential Information may be
disclosed: (a) during any official proceeding before a court or governmental
agency if reasonably related to that proceeding; (b) as a part of a patent
application filed on inventions made under this Agreement, provided that the
Party whose Confidential Information is included in such application shall have
the opportunity to review such disclosure at least fifteen (15) business days
prior to the date of such filing and such Party does not object to such
disclosure; and (c) as may be reasonably required to comply with applicable
governmental laws or regulations. For the purposes of this Agreement,
Confidential Information shall not include such information that:

                  (i)      was known to the receiving Party at the time of
                           disclosure;

                  (ii)     was generally available to the public or was
                           otherwise part of the public domain at the time of
                           disclosure or became generally available to the
                           public or otherwise part of the public domain after
                           disclosure other than through any act or omission of
                           the receiving Party in breach of this Agreement;

                  (iii)    became known to the receiving Party after disclosure
                           from a source that had a lawful right to disclose
                           such information to others; or

                  (iv)     was independently developed by the receiving Party
                           without the use of Confidential Information of the
                           other Party, as evidenced by written records.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        37
<PAGE>

If Connetics sublicenses any of its rights hereunder to InterMune pursuant to
this Agreement, Genentech and InterMune shall enter into a mutual
confidentiality agreement, substantially in the form of this Article 7.0, to
protect confidential information that may be disclosed by InterMune to
Genentech.

8.0      Up-front Payment, Milestone Payments and Royalties

         In consideration for the licenses granted to Connetics by Genentech
pursuant to Section 2.0 above, Connetics shall make the following payments to
Genentech:

         8.1      Up-front Payment. Connetics shall issue to Genentech upon the
Original Closing Date (as defined in the Stock Agreement) shares of Connetics
Common Stock ("Original Issuance Shares" as defined in the Stock Agreement) with
a fair market value equal to two million dollars ($2,000,000), on the terms and
conditions set forth in the Stock Agreement. If, on the Second Closing Date (as
defined in the Stock Agreement), the aggregate market value of the Original
Issuance Shares (based on the Second Issuance Price (as defined in the Stock
Agreement)) is less than four million dollars ($4,000,000), Connetics shall
issue to Genentech upon the Second Closing Date the number of additional shares
of Connetics Common Stock (the ASecond Issuance Shares," as defined in the Stock
Agreement) equal to the lesser of: (i) the number of shares necessary to
increase the aggregate market value of the Original Issuance Shares (based on
the Second Issuance Price) plus the Second Issuance Shares (based on the Second
Issuance Price) to four million dollars ($4,000,000) or (ii) the number of
shares necessary to increase the aggregate number of the Company's shares of
Common Stock held by Genentech

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        38
<PAGE>

(exclusive of any shares that Genentech has purchased from parties other than
the Company) to 9.9% of the Company's total outstanding shares of Common Stock
as of the close of business on the third trading day before the Second Closing
Date, on the terms and conditions set forth in the Stock Agreement. In lieu of
all or any portion of the Second Issuance Shares that the Company is obligated
to issue to Genentech on the Second Closing Date, the Company may elect to pay
Genentech the cash value of such Second Issuance Shares (based on the Second
Issuance Price). The Original Closing and the Second Closing of the stock
issuances shall take place as described in the Stock Agreement. In the event
that Connetics does not issue to Genentech all of the Second Issuance Shares or
the cash value of the Second Issuance Shares, Genentech may, in addition to
other remedies available to it by law or in equity, immediately terminate this
Agreement and the licenses granted to Connetics hereunder. Such termination by
Genentech of the Agreement and the licenses hereunder does not discharge
Connetics' obligation to issue all of the Second Issuance Shares or to pay to
Genentech the cash value of the Second Issuance Shares. The up-front payment
shall not be creditable against any royalty payments owed by Connetics under
Sections 8.3 and 8.4 below.

         8.2      Milestone Payments for Licensed Products. Connetics shall make
the following cash milestone payments to Genentech:

                  (a)      [ * ] within thirty (30) days following the dates on
which each of the first three (3) NDA's or BLA's for a Licensed Product is filed
with the FDA by Connetics for a new indication in the Field of Use; provided
however, that such milestone payments shall not be paid

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        39
<PAGE>

upon the filing of a NDA or BLA for an osteopetrosis or atypical mycobacterial
infection indication.

                  (b)      [ * ] within thirty (30) days following the date
Connetics receives FDA clearance of each new indication for a Licensed Product
for commercial sale in the United States; provided however, that such milestone
payment shall not be paid upon receipt of FDA clearance for an osteopetrosis or
atypical mycobacterial infection indication.

                  (c)      [ * ] within thirty (30) days following the first
date Connetics' aggregate Net Sales of all Licensed Products in the Territory
exceed [ * ] in any calendar year.

                  (d)      [ * ] within thirty (30) days following the first
date Connetics' aggregate Net Sales of all Licensed Products in the Territory
exceed [ * ] in any calendar year.

         Notwithstanding the foregoing, upon the expiration or revocation of the
last remaining issued patent within the Genentech Patent Rights during the term
of this Agreement, each of the milestones payments set forth in (a)-(d) above
thereafter shall be reduced by fifty percent (50%). Milestone payments shall not
be creditable against any royalty payments owed under Sections 8.3 and 8.4
below.

         8.3      Royalties. Connetics shall pay Genentech the following
royalties on Net Sales of Licensed Products by Connetics and its sublicensees:

                  (a)      For annual aggregate Net Sales of all Licensed
Products in the Territory of up to three million seven hundred thousand dollars
($3,700,000), a royalty rate equal to [ * ] of such Net Sales.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        40
<PAGE>

                  (b)      In addition to the payment of the royalty rate
specified in (a) above, for annual aggregate Net Sales of all Licensed Products
in the Territory exceeding three million seven hundred thousand dollars
($3,700,000), a royalty rate equal to [ * ] of such Net Sales exceeding
$3,700,000.

                  (c)      The above royalties shall be payable until the later
of: (i) the expiration or revocation of the last remaining issued patent within
the Genentech Patent Rights or (ii) twenty (20) years from the Effective Date of
this Agreement. Notwithstanding the foregoing, upon the expiration of the last
to expire issued patent within the Genentech Patent Rights during the term of
this Agreement, thereafter each of the royalty rates set forth in (a) and (b)
above shall be reduced by fifty percent (50%).

         8.4      Third-Party Royalties. If Genentech or Connetics is required
to pay any third party a royalty due to the manufacture, use, sale, offer for
sale or importation of a Licensed Product in the Territory for or by Connetics
or its sublicensees, Connetics shall be responsible for the payment of [ * ] of
such third-party royalty, provided however, that Connetics may deduct from the
royalties payable to Genentech under Section 8.3 above [ * ] of such third party
royalties incurred only due to use patents in the Field of Use in the Territory,
up to a maximum total deduction of [ * ] percentage points from the royalties
payable by Connetics to Genentech under Section 8.3. For purposes of
clarification, such deductions shall not apply to any benchmark payment under
the [ * ] License made by Connetics pursuant to Section 5.2(c) above. Attached
hereto as Exhibit G is a list of all such royalty obligations to third parties
known to Genentech as

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        41
<PAGE>

of the Effective Date without diligent search. No later than thirty (30) days
from the Effective Date, Genentech shall complete a reasonable internal
investigation of its records and update Exhibit G, as necessary, to accurately
reflect all such royalty obligations to third parties to the best of Genentech's
knowledge; provided however, Connetics acknowledges that Genentech has no
obligation to conduct due diligence or any investigation with respect to third
party patent rights related to Licensed Products. Genentech shall notify
Connetics in writing during the term of this Agreement if it becomes aware of
any additional Genentech third party royalty obligations.

         8.5      Royalty Payments. Royalty payments shall be made to Genentech
quarterly within ninety (90) days following the end of each calendar quarter for
which royalties are due. Each royalty payment shall be accompanied by a report
summarizing the total Net Sales during the relevant three-month period, and the
calculation of royalties, if any, due thereon pursuant to Section 8.3.

         8.6      Taxes. Genentech shall pay any and all taxes levied on account
of, or measured by, any payment, including, without limitation, royalties, it
receives under this Agreement.

         8.7      Termination. If the license granted to Connetics herein is
terminated by the Parties, Connetics shall have no obligation to make any
milestone or royalty payments to Genentech that has not accrued prior to the
effective date of such termination, but shall remain liable for all such
payments accruing prior to termination.

         8.8      Records and Reporting

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        42
<PAGE>

                  (a)      Records. Connetics and any sublicensee of Connetics
shall keep full, true and accurate books of account containing all particulars
which may be necessary for the purpose of showing Net Sales. Said books of
account shall be kept at the principal place of business of Connetics or its
sublicensee, as the case may be. Said books and the supporting data shall be
open at all reasonable times, for three (3) years following the end of the
calendar year to which they pertain (and access shall not be denied thereafter,
if reasonably available), to the inspection of an independent public accountant
retained by Genentech and reasonably acceptable to Connetics (or its
sublicensee) for the purpose of verifying Net Sales under this Agreement;
subject to the provisions of Section 8.8(c) below

                  (b)      Reports. Connetics shall within ninety (90) days
after the end of each calendar quarter beginning with the quarter of the first
commercial sale of Licensed Product in the Field of Use in the Territory by
Connetics or its sublicensee, deliver to Genentech a true and accurate report,
setting forth such particulars of the business conducted by Connetics and its
sublicensees during the preceding quarter as are pertinent to an accounting for
Net Sales and deductible expenses under this Agreement. Such reports shall
include at least the following: (i) the total gross sales of Licensed Products
occurring during that calendar quarter, (ii) the allowable deductions therefrom,
(iii) the total Net Sales of Licensed Products occurring during that calendar
quarter and (iv) the calculation of royalties, if any, due thereon pursuant to
the above Section 8.3.

                  (c)      Auditing. At Genentech's request and expense,
Connetics shall permit a

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        43
<PAGE>

certified public accountant selected by Genentech and acceptable to Connetics to
examine, not more than once in any four consecutive calendar quarters during the
term of this Agreement, but including one (1) post-termination audit, Connetics'
books of account and records of all sales of Licensed Products by Connetics for
the sole purpose of determining the correctness of the reports provided by
Connetics under the above Section 8.8(b). If such accountant reasonably
determines that the royalties owed by Connetics to Genentech under the above
Section 8.3 have been, for any calendar year in total, understated by Connetics,
Connetics shall immediately pay all understated royalties, together with
interest on such royalties from the date accrued at a rate of [ * ] and shall
pay the reasonable costs of the examination if Connetics has understated such
royalties by more than [ * ].

9.0      Representations and Warranties

         9.1      Disclaimer. Except as expressly provided herein, the Parties
disclaim all other representations and warranties, express or implied, including
without limitation, WARRANTIES OF COMMERCIAL UTILITY, MERCHANTABILITY, FITNESS
FOR A PARTICULAR PURPOSE, VALIDITY OR SCOPE OF GENENTECH PATENT RIGHTS or
NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS.

         9.2      Representations and Warranties.

                  (a) Each party represents and warrants to the other that: (a)
it is free to enter into this Agreement; (b) in so doing it will not violate any
other agreement to which it is a party;

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        44
<PAGE>

(c) it is currently capable of making the grant of rights described in Sections
2.1(a), (b), (c), (d), 2.2 and 2.4; and (d) it will not enter into any agreement
in the future which conflicts with or violates any term or provision of this
Agreement. Genentech makes no representation or warranty that all intellectual
property rights necessary for Connetics to make, have made, use, sell, offer for
sale and import Licensed Products in the Field of Use in the Territory have been
granted to Connetics under Section 2.0 of this Agreement.

                  (b)      Connetics further represents and warrants that, prior
to the Effective Date of this Agreement, Connetics' officers (acting under
delegated authority of its Board of Directors) have determined that the fair
market value of the exclusive license granted to Connetics hereunder is less
than $15,000,000 and therefore that the execution and delivery of this exclusive
license Agreement, or the performance of the obligations by Genentech or
Connetics hereunder, do not require that filings be made under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or under the
rules or regulations promulgated thereunder, by Connetics, Genentech, or their
respective affiliates or ultimate parent entities, if any.

                  (c)      Genentech represents and warrants to Connetics that
as of the Effective Date: (i) to Genentech's knowledge, it has not received any
notice of a claim by a third party for infringement of such third party's
intellectual property relating to the use and practice of the Genentech Knowhow,
the Genentech Manufacturing Knowhow, the Genentech Patent Rights or the Biogen
License Rights; and (ii) to the knowledge of Genentech's patent counsel, there
is no

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        45
<PAGE>

issued patent that would be infringed by the practice of the Genentech Knowhow,
the Genentech Manufacturing Knowhow or the Genentech Patent Rights as permitted
under the license rights granted under Section 2.1; and (iii) it has no
knowledge of any actual infringement by any third party in the Field of Use in
the Territory of the Genentech Patent Rights.

10.0     Liability

         10.1     Limitation of Liability. Neither Party shall be liable to the
other for indirect, incidental, special or consequential damages arising out of
any of the terms or conditions of this Agreement or with respect to their
performance or lack thereof.

         10.2     Connetics Indemnification. Connetics shall indemnify, defend
and hold harmless Genentech and its affiliates from and against all third party
costs, claims, suits, expenses (including reasonable attorneys' fees) and
damages arising out of or resulting from: (a) any willful or negligent act or
omission by Connetics relating to the subject matter of this Agreement or (b)
the use by or administration to any person of a Licensed Product, Bulk Product
or Finished Product that was sold, distributed or otherwise provided to a third
party by Connetics or its sublicensees under this Agreement; except where such
costs, claims, suits, expenses or damages arose or resulted from any negligent
act or omission by Genentech or any defect in the manufacture of Bulk Product or
Finished Product by Genentech that was not discovered by Connetics, provided
that Genentech gives reasonable notice to Connetics of any such claim or action,
tenders the defense of such claim or action to Connetics and assists Connetics
at

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        46
<PAGE>

Connetics' expense in defending such claim or action and does not compromise or
settle such claim or action without Connetics' prior written consent.

         10.3     Genentech Indemnification. Genentech shall indemnify, defend
and hold harmless Connetics, its affiliates and sublicensees from and against
all third party costs, claims, suits, expenses (including reasonable attorney's
fees) and damages arising out of or resulting from: (a) any willful or negligent
act or omission by Genentech relating to the subject matter of this Agreement;
(b) any defect in the manufacture of Bulk Product or Finished Product by
Genentech that was not discovered by Connetics; or (c) the use by or
administration to any person of a product containing Interferon Gamma sold,
distributed or otherwise provided to a third party by Genentech or its
sublicensees; except where the foregoing costs, claims, suits, expenses or
damages arose or resulted from (i) any negligent act or omission by Connetics or
(ii) the use by or administration to any person of a Licensed Product sold,
distributed or otherwise provided by Connetics or its sublicensees other than
resulting from a defect in the manufacture of such Licensed Product by
Genentech, provided that Connetics gives reasonable notice to Genentech of any
such claims or action, tenders the defense of such claim or action to Genentech
and assists Genentech at Genentech's expense in defending such claim or action
and does not compromise or settle such claim or action without Genentech's prior
written consent.

11.0     Term and Termination

         11.1     Term. This Agreement shall commence on the Effective Date of
this Agreement

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                        47
<PAGE>

and, unless terminated earlier, shall expire at the later to occur of (a) the
expiration of the last to expire of any Genentech Patent Rights or (b) twenty
(20) years from the Effective Date of this Agreement; provided, however, that in
the event that either the [ * ] License or the [ * ] License is terminated, the
licenses granted by Genentech to Connetics under the [ * ] License or the [ * ]
License shall also terminate. Genentech shall use its Best Efforts to keep the
[ * ] License and the [ * ] License in effect during the term of this Agreement,
provided, however, that if Connetics declines to pay a [ * ] benchmark payment
as outlined in Section 5.2(c) or pay any royalty owed to [ * ] under the [ * ]
License for the sales of Licensed Products, then Genentech shall not be
obligated to make such payment and Genentech shall have the option, in its sole
discretion, to terminate the [ * ] License. One year before the expiration of
this Agreement under this Section 11.1, the Parties agree to meet and to discuss
in good faith extending the term of this Agreement on terms mutually agreeable
to the Parties.

         11.2 Termination for Default. If either Party shall default in a
material manner with respect to any material provision of this Agreement and the
other Party shall have given the defaulting Party written notice of such
default, the defaulting Party shall have thirty (30) days to cure such default.
If such default is not cured within such thirty (30) day period, the
non-defaulting Party shall have the right, upon notice to the defaulting Party
and without prejudice to any other rights the non-defaulting Party may have, to
terminate this Agreement unless the defaulting Party is in the process of
attempting in good faith to remedy such default, in which case, the thirty (30)
day cure period shall be extended by an additional thirty (30) days. If

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       48

<PAGE>

Genentech terminates this Agreement pursuant to this Section 11.2, Genentech
shall automatically have all of the rights set forth in Sections 11.3(a) and (b)
of this Agreement. Upon such termination, any sublicenses granted under this
Agreement shall not automatically terminate, but instead, Genentech shall have
the option to either terminate or continue this Agreement with each sublicensee.
If Connetics terminates this agreement pursuant to this Section 11.2, Connetics
shall automatically have all of the rights set forth in Section 11.4 of this
Agreement. Connetics shall have no right to terminate this Agreement pursuant to
this Section 11.2 in the event of Genentech's failure to supply Bulk Product or
Finished Product. In the event of Genentech's failure to supply Bulk Product or
Finished Product, Connetics shall have the rights set forth in the Supply
Agreement.

         11.3 Genentech's Rights on Termination

              (a) If Genentech terminates this Agreement pursuant to Section
11.2 above, Genentech shall be automatically granted a nonexclusive,
sublicenseable, license in the Territory under Connetics Patent Rights and
Connetics Knowhow arising from the efforts made by Connetics and its
sublicensees hereunder in the research and development of Licensed Products, to
make, have made, use, sell, offer for sale or import Licensed Products and shall
be automatically granted a right to use all of Connetics' regulatory submissions
made by or on behalf of Connetics for Interferon Gamma and Licensed Products. If
Genentech sells a commercial product under the license granted in this Section
11.3 that would, but for the license granted herein, infringe a claim of such
Connetics Patent Rights or that is based upon, incorporates or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       49

<PAGE>

utilizes such Connetics Knowhow, Genentech shall pay Connetics a royalty, under
terms and conditions to be mutually agreed upon by the Parties, such royalty to
be commensurate with the value contributed by such Connetics Patent Rights and
Connetics Knowhow to such commercial product, but in no event shall such royalty
exceed two percent (2%) of Genentech's net sales of such commercial product. As
used herein, "net sales" shall have the equivalent definition given to Net Sales
in Section 1.25 above.

              (b) Upon the effective date of termination by Genentech pursuant
to Section 11.2 above, Connetics shall promptly provide Genentech with copies of
all related documentation regarding Connetics Patent Rights and Connetics
Knowhow arising from the efforts made by Connetics and its sublicensees
hereunder in the research, development and manufacture of Licensed Products,
whether written or electronic, and materials, including biological materials, in
the form existing as of the effective date of such termination, reasonably
necessary for Genentech to exercise its license rights under Section 11.3(a)
above. Such transfer shall be made in a timely and orderly fashion and in a
manner such that the value of what is being transferred is preserved in all
material respects. Connetics shall promptly take all appropriate and necessary
actions, including action before the involved regulatory agency, to effect
transfer to Genentech of, and shall also permit Genentech to reference, any FDA
submissions, including, without limitation, any PLA or BLA filed with the FDA
with respect to Licensed Products. Within ninety (90) days of such assignment
and completion of all such appropriate and necessary actions, Genentech will
reimburse Connetics for its actual expenses incurred in preparing

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       50

<PAGE>

documentation for filing or referencing the submission and in taking such
appropriate and necessary action related to such transfer or referencing.

         11.4 Connetics' Rights on Termination. Should Connetics terminate this
Agreement pursuant to Section 11.2 above, Genentech shall grant to Connetics (a)
an exclusive, sublicenseable, royalty-bearing license, according to royalty
terms described in Sections 8.3 and 8.4 within the Field of Use in the
Territory, under terms and conditions agreed upon by the Parties, under the
Genentech Patent Rights and Genentech Knowhow in order to permit Connetics to
continue using, selling, offering for sale and importing Licensed Products in
the Field of Use in the Territory (excluding, with respect to the fields of
scleroderma and infectious disease or condition caused by human papillomavirus,
Licensed Products containing any form of Interferon Gamma other than Genentech
Gamma Interferon TRIANGLE3, as that term is defined in the Biogen License), (b)
a non-exclusive, sublicenseable, royalty-bearing license, (conforming to the
license grant in Section 2.1 (b) above) according to royalty terms described in
Sections 8.3 and 8.4 in the Territory , under terms and conditions agreed upon
by the Parties, under the Genentech Patent Rights and Genentech Knowhow in order
to permit Connetics to continue using, selling, offering for sale and importing
Licensed Products containing any form of Interferon Gamma other than Genentech
Gamma Interferon TRIANGLE3 (as that term is defined in the Biogen License) in
the Territory in the fields of scleroderma and infectious desease or condition
caused by human papillomavirus, (c) a non-exclusive, sublicenseable license (the
royalty for which is already included in clause (a) above) in the Territory in
the fields of scleroderma and infectious disease

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       51

<PAGE>

or condition caused by human papillomavirus, under terms and conditions agreed
upon by the Parties, under the Biogen License Rights in order to permit
Connetics to continue using, selling, offering for sale and importing Licensed
Products (except those Licensed Products containing Biogen Gamma Interferon
TRIANGLE0) in the field of scleroderma and infectious disease or condition
caused by human papillomavirus in the Territory and (d) a non-exclusive
sublicenseable license (the royalty for which is already included in clause (a)
above) under Genentech Patent Rights and Genentech Manufacturing Knowhow in
order to permit Connetics to continue making and having made Licensed Products
in the Field of Use in the Territory.

         11.5 Bankruptcy. Either Party may, in addition to any other remedies
available to it by law or in equity, terminate this Agreement, in whole or in
part as the terminating Party may determine, by written notice to the other
Party in the event the other Party shall have become bankrupt, or shall have
made an assignment for the benefit of its creditors or there shall have been
appointed a trustee or receiver of the other Party or for all or a substantial
part of its property or any case or proceeding shall have been commenced or
other action taken by or against the other Party in bankruptcy or seeking
reorganization, liquidation, dissolution, winding-up, arrangement, composition
or readjustment of its debts or any other relief under any bankruptcy,
insolvency, reorganization or other similar act or law of any jurisdiction now
or hereafter in effect and any such event shall have continued for sixty (60)
days undismissed, unbonded and undischarged. All rights and licenses granted
under to this Agreement by one Party to the other Party are, and shall otherwise
be deemed to be, for purposes of Section 365 (n)

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       52

<PAGE>

of the Bankruptcy Code, licenses of rights to "intellectual property" as defined
under Section 101 (56) of the Bankruptcy Code. The Parties agree that the
licensing Party under this Agreement shall retain and may fully exercise all of
its rights and elections under the Bankruptcy Code in the event of a bankruptcy
by the other Party. The Parties further agree that in the event of the
commencement of a bankruptcy proceeding by or against one Party under the
Bankruptcy Code, the other Party shall be entitled to complete access to any
such intellectual property pertaining to the rights granted in the licenses
hereunder of the Party by or against whom a bankruptcy proceeding has been
commenced and all embodiments of such intellectual property.

         11.6 Unilateral Termination. In addition to any other right of
termination provided herein, Connetics shall have the right to terminate this
Agreement for any reason, with or without cause upon six (6) months' prior
written notice to Genentech. If Connetics terminates this Agreement pursuant to
this Section 11.6, Connetics agrees that for the following three (3) years it
will not use, sell or acquire from any third party (whether by license or
otherwise) any Licensed Product in the Field of Use. If Connetics terminates
this Agreement pursuant to this Section 11.6, the licenses granted hereunder
shall terminate and Genentech shall automatically have all of the rights set
forth in Sections 11.3(a) and (b) of this Agreement.

         11.7 Survival of Certain Provisions. Termination of this Agreement for
any reason shall not release either Party from any obligation arising prior to
the date of termination. The provisions of Sections 1.0, 2.4 (except in the
event of termination of this Agreement by Connetics pursuant to Section 11.2),
11.3(a) and (b) (except in the event of termination of this

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       53

<PAGE>

Agreement by Connetics pursuant to Section 11.2), 11.4 (except in the event of
termination of this  Agreement by Genentech pursuant to Section 11.2), and
Articles 5.0, 7.0, 9.0, 10.0, 11.0 (except as provided in this paragraph) and
12.0 shall survive any termination of this Agreement.

12.0     General Provisions

         12.1 Notices. All notices which may be required pursuant to this
Agreement: (i) shall be in writing, (ii) shall be addressed, in the case of
Genentech (except as otherwise specified herein), to the Corporate Secretary at
the address set forth at the beginning of this Agreement, and in the case of
Connetics, to the Vice President - Intellectual Property at the address set
forth at the beginning of this Agreement, (or to such other person or address as
either Party may so designate from time to time), (iii) shall be mailed,
postage-prepaid, by registered mail or certified mail, return receipt requested,
or transmitted by courier for hand delivery or transmitted by facsimile and (iv)
shall be deemed to have been given on the date of receipt if sent by mail or on
the date of delivery if transmitted by courier or facsimile. Notices by
facsimile may be sent to the following numbers: for Connetics, to (650)
843-2899; for Genentech, to (650) 952-9881.

         12.2 Governing Law. This Agreement shall be governed by and construed
in accordance with the laws of the state of California (other than its choice of
law principles).

         12.3 Entire Agreement. This Agreement is the entire agreement between
the Parties, and there are no prior written or oral promises or representations
not incorporated herein or therein, except that certain Confidentiality
Agreement between the Parties dated January 9, 1997

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       54

<PAGE>

which shall remain in full force and effect. This Agreement shall supersede and
replace the Prior Agreement in its entirety, and the Prior Agreement shall be
terminated automatically as of the Effective Date. No amendment or modification
of the terms of this Agreement shall be binding on either Party unless reduced
to writing and signed by an authorized officer of the Party to be bound.

         12.4 Binding Effect and Assignment. This Agreement shall be binding
upon and inure to the benefit of the Parties hereto and their respective
permitted successors and assigns. This Agreement shall not be assignable by
either Party without the other's prior written consent, provided however, that
either Party may assign this Agreement, without the other Party's written
consent but after providing thirty (30) days prior written notice to the other
Party, to any successor pursuant to a consolidation or merger of such Party with
or into any other corporation or corporations that results in a change of
greater than 50% of the voting control of such Party, or a sale, conveyance or
disposition of all or substantially all of the assets of such Party or the
effectuation by such Party of a transaction or series of related transactions in
which more than 50% of the voting power of such Party is disposed of.

         12.5 Waiver. The waiver by a Party hereto of any breach of or default
under any of the provisions of this Agreement or the failure of a Party to
enforce any of the provisions of this Agreement or to exercise any right
thereunder shall not be construed as a waiver of any other breach or default or
as a waiver of any such rights or provisions hereunder.

         12.6 Severability. If any part of this Agreement shall be invalid or
unenforceable under

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       55
<PAGE>

applicable law, such part shall be ineffective only to the extent of such
invalidity or unenforceability, without in any way affecting the remaining parts
of this Agreement. In addition, the part that is ineffective shall be reformed
in a mutually agreeable manner so as to as nearly approximate the intent of the
Parties as possible.

         12.7 Publicity. Connetics and Genentech agree that, except as may
otherwise be required by applicable laws, regulations, rules, or orders,
including the disclosure requirements of the Securities and Exchange Commission
("SEC"), no information concerning this Agreement and the transactions
contemplated herein (except information which is already in the public domain)
shall be made public by either Party without the prior written consent of the
other Party. Notwithstanding the foregoing, with respect to complying with the
disclosure requirements of the SEC, in connection with any required SEC filing
of this Agreement by Connetics, Connetics shall seek confidential treatment of
portions of this Agreement from the SEC and Genentech shall have the right to
review and comment on such an application for confidential treatment prior to
its being filed with the SEC. Genentech shall provide its comments, if any, on
such application as soon as practicable and in no event later than seven (7)
days after such application is provided to Genentech. To assist Connetics in its
compliance with SEC disclosure obligations, Genentech shall provide to
Connetics, within fourteen (14) days of the Effective Date, electronic copies of
this Agreement (and all exhibits hereto) and the Supply Agreement. In addition,
notwithstanding the foregoing, Connetics shall have the right to disclose
information concerning this Agreement and the transactions contemplated herein
to its legal representatives, advisors,

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       56

<PAGE>

prospective investors, investors, third party auditors, sublicensees and
prospective sublicensees hereunder to the extent reasonably necessary and under
obligations of confidentiality no less stringent than those provided for in
Article 7.0.

         12.8 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original for all purposes, but
all of which together shall constitute one and the same instrument.

         12.9 Force Majeure. Neither Party shall be liable to the other for its
delay or failure to perform under this Agreement or shall have any right to
terminate this Agreement for any such delay or failure in performance
attributable to any act of God, flood, fire, explosion, strike, lockout, labor
dispute, casualty or accident, war, revolution, civil commotion, act of public
enemies, blockage or embargo, injunction, law, order, proclamation, regulation,
ordinance, demand or requirement of any government or subdivision, authority or
representative of any such government, or any other cause beyond the reasonable
control of such Party, if the Party affected shall give prompt notice of any
such cause to the other Party. The Party giving such notice shall thereupon be
excused from such of its obligations, hereunder for the period of time that it
is so disabled.

         12.10 Headings. Headings are for the convenience of reference only and
shall not control the construction or interpretation of any of the provisions of
this Agreement.

         12.11 No Partnership. Nothing in this Agreement is intended or shall be
deemed to constitute a partnership, agency, employer-employee, or joint venture
relationship between the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       57

<PAGE>

Parties.

                           [SIGNATURE PAGE TO FOLLOW]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       58

<PAGE>

         IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly
executed by its duly authorized representatives as of the date set forth above.

GENENTECH, INC.                                    CONNETICS CORPORATION

By:    /s/ Nick Simon                              By:  /s/ Thomas G. Wiggans
   ---------------------------------

Name:    Nick Simon                                Name:   Thomas G. Wiggans
     -------------------------------                       -----------------

Title:  V.P., Business and Corporate Development   Title:   President and CEO
       -----------------------------------------           ------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       59

<PAGE>

                                    EXHIBIT A

       PATENT APPLICATIONS AND PATENTS INCLUDED IN GENENTECH PATENT RIGHTS

<TABLE>
<CAPTION>

--------------------------------------------------------------------------------
      U.S. SERIAL NUMBER                               U.S. PATENT NUMBER
--------------------------------------------------------------------------------
<S>                                                    <C>
           08/460,524                                       Pending
--------------------------------------------------------------------------------
           08/460,539                                       Pending
--------------------------------------------------------------------------------
                                                           5,690,925
--------------------------------------------------------------------------------
                                                           5,582,824
--------------------------------------------------------------------------------
                                                           5,151,265
--------------------------------------------------------------------------------
                                                           5,200,177
--------------------------------------------------------------------------------
                                                           5,112,605
--------------------------------------------------------------------------------
                                                           5,196,191
--------------------------------------------------------------------------------
                                                           5,096,705
--------------------------------------------------------------------------------
                                                           5,574,137
--------------------------------------------------------------------------------
                                                           5,248,499
--------------------------------------------------------------------------------
</TABLE>

                                                                              55

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                                    EXHIBIT B

                                INTERFERON GAMMA

                                      [ * ]

                                                                              56

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                                    EXHIBIT C

                               INTERFERON GAMMA-1B

                                      [ * ]

                                                                              57

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                                    EXHIBIT D

                          THIRD PARTY SPONSORED STUDIES

                                      [ * ]

                                                                              58

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                                    EXHIBIT E
                                      [ * ]

                                                                              59

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                                    EXHIBIT F

                                CLINICAL REPORTS

The following information/reports will be provided to Genentech in a timely
manner:

-    FDA Meeting Minutes

-    IND(s)
-    Initial
-    Updates (if applicable)

-    Annual Report(s)

-    Investigator Brochure(s)

-    Clinical Studies:
-    Protocol(s)
-    Prior to FDA submission
-    First Patient-In (FPI)
-    First Patient-Out (FPO)
-    Last Patient-In (LPI)
-    Last Patient-Out (LPO)

-    Serious Adverse Event (SAE) Summary

-    Clinical Study Interim Analysis and Update(s) (if applicable)

-    Go/No-Go Decision Minutes

-    Clinical Study Final Report(s)

                                                                              60

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
<PAGE>

-    Draft
-    Final Copy

                                                                              61

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                                    EXHIBIT G

                              THIRD PARTY ROYALTIES

Royalties are payable under the [ * ] License, as follows (capitalized terms
shall have the meanings defined in the [ * ] License): a [ * ] royalty is
payable on Net Sales of gamma interferon in Approved Countries in the Territory
for the prophylaxis or treatment of atopic dermatitis and/or steroid-dependent
asthma, where there is substantial protection from an issued Licensed Patent for
the approved indication and where the Licensee has enjoyed Market Exclusivity.
The royalty rate is [ * ] on Net Sales in the Licensed Field in Approved
Countries where the Licensee enjoyed Market Exclusivity but where there is no
substantial patent protection, or while the Licensed Patent applications
covering the indication are still pending, provided that such applications have
been diligently prepared, filed and maintained. The royalty rates described
above are reduced by [ * ] for Approved Countries where the Licensee has not
enjoyed Market Exclusivity.

                                                                             62

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                                    EXHIBIT H

                     TRANSFER DATE ACTIVITIES FOR COMMERCIAL
                           SALES OF ACTIMMUNE FOR CGD

         Prior to the Transfer Date, as defined in Section 1.29 of this
Agreement, the following activities must be completed by the appropriate Party
as described below:

         I.       Regulatory Requirements

                  1.  FDA License - Connetics must obtain all licenses,
                      including license numbers, required for the sale of
                      Actimmune for CGD by Connetics. Connetics shall also
                      obtain a NDC number.

                  2.  PLA/IND Transfer - Genentech shall transfer to Connetics
                      the PLA and IND for CGD on file with the FDA.

                  3.  Connetics must obtain FDA review and approval, as required
                      by law or regulation, for Connetics' labels, product
                      insert and packaging for sale of Actimmune for CGD.

                  4.  Genentech shall transfer its safety information to
                      Connetics for Actimmune, as provided in Section 2.5(g) of
                      this Agreement. Connetics shall establish a safety
                      database system for Actimmune, such that as of the
                      Transfer Date, Connetics shall be responsible for all
                      safety-related requirements under FDA regulations,
                      including the reporting of adverse events.

                  5.  Prior to the Transfer Date, Connetics shall establish all
                      procedures, controls and other methods and capabilities
                      needed in order to comply with all requirements, laws and
                      regulations applicable to the use, distribution and sale
                      of Actimmune for CGD.

         II.      Quality Control, Product Testing

                  1.  To the extent that Connetics is required by law or
                      regulation to conduct any quality control, quality
                      assurance and/or stability testing of Actimmune sold for
                      CGD, in addition to any such testing to be conducted by
                      Genentech pursuant to the Supply Agreement, Connetics
                      shall establish procedures and obtain regulatory approval
                      to do so prior to the Transfer Date.

                                                                              63

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

         III.     Uninsured Patient Program

                  Connetics shall have established an uninsured patient program,
                  including procedures for determining patient eligibility.
                  Genentech shall transfer to Connetics its existing information
                  regarding such patients prior to the Transfer Date, to the
                  extent it has received consent from such patients to do so.
                  Connetics shall notify Gennetech prior to the Transfer Date
                  which of the patients participating in Genentech's uninsured
                  patient program, and for which Genentech has transferred
                  information, shall receive drug under Connetics' uninsured
                  patient program.

         IV.      Product Distribution and Sale

                  1.  Connetics shall establish product distribution and
                      inventory systems for Actimmune. Genentech will provide to
                      Connetics the name of its current distributor.

                  2.  Connetics shall establish systems and personnel required
                      to address customer inquiries, medical information
                      requrests and product returns.

                                                                              64

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                                AMENDMENT NO. ONE
                                       TO
                                LICENSE AGREEMENT

         THIS AMENDMENT NUMBER ONE TO LICENSE AGREEMENT FOR INTERFERON GAMMA
("Amendment") is entered into effective December 28, 1998, between Genentech,
Inc. ("Genentech") and Connetics Corporation ("Connetics"). Terms not otherwise
defined in this Amendment shall have the meanings as defined in the License
Agreement.

                                 R E C I T A L S

A.       The parties have previously entered into a License Agreement effective
         May 5, 1998, relating to interferon gamma (the "License Agreement"),
         together with a Stock Purchase Agreement of even date (the "Stock
         Agreement").

B.       Pursuant to Section 2.3(c) of the License Agreement, Connetics had the
         right to sublicense the Agreement to InterMune, and has in fact entered
         into a sublicense to that effect dated August 21, 1998.

C.       Pursuant to Section 8.1 of the License Agreement, and the terms of the
         Stock Agreement, Connetics agreed to issue additional stock to
         Genentech if certain conditions were not met by December 28, 1998, and
         the parties anticipate that those conditions will not be met by that
         date.

D.       The parties desire to amend the License Agreement effective as of the
         date first written above, on the terms forth in this Amendment, and
         simultaneously with a corresponding Amendment Number One to the Stock
         Purchase Agreement ("Stock Agreement Amendment").

NOW THEREFORE, the parties agree as follows:

                                    AGREEMENT

1.       Section 8.1 of the License Agreement is hereby amended to read in its
         entirety as follows:

                                                                              60

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

         8.1      Up-front Payment. Connetics shall issue to Genentech upon the
         Original Closing Date (as defined in the Stock Agreement) shares of
         Connetics Common Stock ("Original Issuance Shares" as defined in the
         Stock Agreement) with a fair market value equal to two million dollars
         ($2,000,000), on the terms and conditions set forth in the Stock
         Agreement. If on the Notification Date or, if later, the Second Closing
         Date (each as defined in the Stock Agreement Amendment), the aggregate
         market value of the Original Issuance Shares (based on the Second
         Issuance Price, as defined in the Stock Agreement Amendment) is less
         than $4,000,000, then Connetics shall issue to Genentech on the Second
         Closing Date that number of additional shares of its Common Stock (the
         "Second Issuance Shares") equal to the lesser of: (i) the number of
         shares necessary to increase the aggregate market value of the Original
         Issuance Shares (based on the Second Issuance Price) and the Second
         Issuance Shares (based on the Second Issuance Price) to $4,000,000; or
         (ii) the number of shares (rounded to the nearest whole number )
         necessary to increase the aggregate number of shares of Connetics
         Common Stock held by Genentech (exclusive of any shares that Genentech
         has purchased from parties other than Connetics) to 9.9% of Connetics'
         total outstanding shares of Common Stock as of the close of business on
         the Notification Date or the Second Closing Date, if later. In lieu of
         all or any portion of the Second Issuance Shares that Connetics is
         obligated to issue to Genentech on the Second Closing Date, Connetics
         may elect to pay Genentech the cash value of such Second Issuance
         Shares (based on the Second Issuance Price). The Original Closing of
         the stock issuances shall take place as described in the Stock
         Agreement and the Second Closing of the stock issuances shall take
         place as described in the Stock Agreement Amendment. In the event that
         Connetics does not issue to Genentech all of the Second Issuance Shares
         or the cash value of the Second Issuance Shares, Genentech may, in
         addition to other remedies available to it by law or in equity,
         immediately terminate this Agreement and the licenses granted to
         Connetics under this Agreement. Such termination by Genentech of the
         Agreement and the licenses hereunder does not discharge Connetics'
         obligation to issue all of the Second Issuance Shares or to pay to
         Genentech the case value of the Second Issuance Shares. The up-front
         payment shall not be creditable against any royalty payments owed by
         Connetics under Section 8.3 and 8.4 of this Agreement.

2.       To the extent necessary, the remaining provisions of the License
         Agreement are amended to reflect the revised definitions of Second
         Closing Date and Second Issuance Shares, as modified by the Stock
         Agreement Amendment.

                                                                              61

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

3.       The remainder of the License Agreement, including the exhibits to that
         Agreement (except the Stock Agreement, to the extent modified by the
         Stock Agreement Amendment), will continue in full force and effect as
         though fully set forth in this Amendment.

IN WITNESS WHEREOF, the parties have executed this Amendment Number One to
License Agreement as of the date first written above.

Genentech, Inc.                            Connetics Corporation

By:      /s/ William D. Young              By:      /s/ Thomas G. Wiggans
   ------------------------------------       ----------------------------------
         William D. Young                  Thomas G. Wiggans
         Chief Operating Officer           President & Chief Executive Officer

                                                                              62

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                                AMENDMENT NO. TWO
                                       TO
                                LICENSE AGREEMENT

THIS AMENDMENT NUMBER TWO TO LICENSE AGREEMENT FOR INTERFERON GAMMA
("AMENDMENT") is entered into effective January 15, 1999, by and between
Genentech, Inc. ("Genentech") and Connetics Corporation ("Connetics").

                                 R E C I T A L S

A.    The Parties have previously entered into that certain License Agreement
         for Interferon Gamma, dated May 5, 1999, as amended on December 23,
         1998 (the "License Agreement").

B.    Pursuant to Section 2.3(c) of the License Agreement, Connetics has the
         right to sublicense certain of its rights under the Agreement to
         InterMune Pharmaceutical, Inc. ("InterMune"), and has in fact entered
         into a sublicense to that effect dated August 21, 1998.

C.    On December 3, 1998, the Parties entered into a Letter Agreement to
         document the intent and agreement of Connetics and Genentech with
         respect to additional terms governing the transfer and distribution of
         Interferon Gamma-1B, pending the preparation of an amendment to the
         License Agreement.

D.    The Parties now desire to enter into a definitive amendment to the
         License Agreement, effective as of the date first written above, to
         permit a limited distribution of Interferon Gamma-1B by Connetics or
         its sublicensee under Genentech labels and to add other additional
         terms governing the transfer and distribution of Interferon Gamma-1B.

NOW THEREFORE, the Parties hereby agree as follows:

                                    AGREEMENT

1. Terms not otherwise defined in the Amendment shall have the meanings defined
in the License Agreement.

                                                                              60

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

2. Section 1.29 of the License Agreement is hereby deleted and replaced in its
entirety as follows:

         1.29 "Transfer Date" shall mean January 15, 1999, unless otherwise
         mutually agreed to in writing by the Parties

                                                                              61

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

3. A new Section 1.30 is added to the License Agreement to read in its entirety
as follows:

         1.30 "Connetics Product" shall mean Finished Product under the
         ACTIMMUNE-Registered Trademark- and labeled under the name of
         Connetics or its sublicensee. For clarification, all terms and
         conditions of this Agreement that apply to Finished Product shall
         also apply to Connetics Product.

4. A new Section 1.31 is added to the License Agreement to read in its entirety
as follows:

         1.31 "Distribution Period" shall mean the period of time beginning
         January 15, 1999 and ending on the earlier of: (a) the first date on
         which Genentech supplies InterMune with Connetics Product or (b) sixty
         (60) days after InterMune's receipt of a license from the FDA to sell
         interferon Gamma-1B for CGD.

5. A new Section 1.32 is added to the License Agreement to read in its entirety
as follows:

         1.32 "Genentech Finished Product" shall mean Genentech's inventory
         of Interferon Gamma-1B under the ACTIMMUNE-Registered Trademark- and
         labeled under Genentech's name. For clarification, Genentech
         Finished Product is a Licensed Product under this Agreement.

6. A new Section 1.33 is added to the License Agreement to read in its entirety
as follows:

         1.33 "Genentech Bulk Product" shall mean Genentech's inventory of
         Interferon Gamma-1B bulk protein existing as of the Transfer Date.

7. A new Section 1.34 is added to the License Agreement to read in its entirety
as follows:

         1.34 "Genentech Product" shall mean, together, Genentech Finished
         Product and Genentech Bulk Product.

8. A new Section 1.35 is added to the License Agreement to read in its entirety
as follows:

         1.35 "Fully Burdened Manufacturing Cost" shall mean [ * ], which shall
         be comprised of the sum of: [ * ].

                                                                              62

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

9. A new Section 1.36 is added to the License Agreement to read in its entirety
as follows:

         1.36 "Third Party Manufacturing Royalties" shall mean all royalties
         paid or incurred by Genentech to third parties under licenses taken by
         Genentech with respect to patents or patent applications that, but for
         such license(s), would be infringed by the manufacture, use, sale,
         offer for sale or importation of Genentech Finished Product or
         Genentech Bulk Product, which royalties are based on the manufacture
         and sale of Genentech Finished Product or Genentech Bulk Product by
         Genentech (or its contract manufacturer) or by Connetics or its
         sublicensees (or a contract manufacturer on their behalf). Genentech
         shall notify Connetics in writing during the term of this Agreement if
         it becomes aware of any Third Party Manufacturing Royalties.

10. A new Subsection 2.5(k) is added to the License Agreement to read in its
entirety as follows:

         2.5(k) Provided that all the activities listed on Exhibit H attached
         hereto are completed, Genentech also shall transfer to Connetics or its
         sublicensee on the Transfer Date all responsibility for the
         distribution, sales and product support of Genentech Finished Product,
         in the Territory, for the treatment of infections associated with CGD,
         subject to the provisions of Section 4.3 below and the following terms
         and conditions:

                  (i) Product support of Genentech Finished Product shall
                  include, without limitation, all financial services, all
                  reporting required by federal and state law or regulation,
                  professional services, customer inquiries, product returns,
                  government chargebacks, product refunds, and patient
                  assistance programs except for the processing of state
                  Medicaid invoices and certain product returns as provided in
                  Subsections 2.5(k)(iii) and (iv) below.

                  (ii) Connetics or its sublicensee shall sell and distribute
                  Genentech Finished Product only during the Distribution
                  Period, after which time Connetics or its sublicensee shall
                  market, sell and distribute Connetics Product, or other
                  Finished Product, for CGD. Notwithstanding the foregoing, for
                  a period of ten (10) business days after the last day of the
                  Distribution Period, Connetics or its sublicensee may continue
                  to sell and

                                                                              63

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                  distribute its existing inventory of Genentech Finished
                  Product in order to reduce or exhaust such existing inventory.
                  Under no circumstances, however, will Genentech be required to
                  manufacture, fill, label, package, or otherwise supply
                  Genentech Finished Product to Connetics or its sublicensees
                  after the end of the Distribution Period. After the
                  Distribution Period Connetics or its sublicensees shall retain
                  full responsibility, and provide all product support, for all
                  Genentech Product sold or distributed by Genentech, Connetics
                  or its sublicensees, prior to, during and after the
                  Distribution Period, including without limitation, Genentech
                  Product in distribution channels.

                  (iii) Notwithstanding the above, Genentech shall remain
                  responsible for processing state Medicaid invoices for
                  Genentech Finished Product, in accordance with this
                  subsection, during the Distribution Period and for that period
                  of time after the Distribution Period during which states
                  continue to send Medicaid rebate invoices for Genentech
                  Finished Production sold under the Genentech NDC label number
                  50242. Within fifteen (15) days after the end of each calendar
                  quarter, Connetics or its sublicensee shall supply Genentech
                  with a report of its Average Manufacturer Price ("AMP") and
                  Best Price ("BP"), as defined in the U.S. Omnibus Budget
                  Reconciliation Act of 1990 ("OBRA 90"), for Genentech Finished
                  Product for such quarter, and detailed calculations
                  determining such AMP and BP. The AMP, BP and supporting
                  calculations shall be based on the carton price for Genentech
                  Finished Product. Genentech shall report such quarterly AMP
                  and BP to the Health Care Finance Administration as required
                  by law and regulation, and will also process state Medicaid
                  rebate invoices received for Genentech Finished Product.
                  Genentech will pay, adjust or dispute the state Medicaid
                  rebate invoices as permitted under OBRA 90. Within sixty (60)
                  days of receipt of an invoice from Genentech, Connetics or its
                  sublicensee will reimburse Genentech the full amounts of
                  Medicaid rebates paid by Genentech. Genentech will have the
                  right to examine, but not more than once every calendar year,
                  the books of account and records of Connetics and its
                  sublicensees for the purpose of determining the correctness of
                  the quarterly reports provided by Connetics or its
                  sublicensees under this subsection. If Genentech reasonably
                  determines that any such reports(s) were incorrect, Connetics

                                                                              64

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                  shall pay Genentech's costs of correcting its reports to
                  federal agencies and will also pay any penalties or fees
                  associated with such incorrect reporting.

                  (iv) As of the Transfer Date, Connetics or its sublicensees
                  will be responsible for processing returns and related credits
                  for all Finished Product, except that Genentech will process
                  credits for returns of Genentech Finished Product if Genentech
                  receives a returned Genentech Finished Product from a third
                  party. Within sixty (60) days of receipt of an invoice from
                  Genentech, Connetics or its sublicensees will reimburse
                  Genentech for such return credits processed by Genentech.

                  (v) Connetics or its sublicensees shall be responsible for all
                  government chargebacks for Genentech Finished Product sold by
                  wholesalers to customers on and after the Transfer Date, and
                  for all government chargebacks for all Connetics Product and
                  other Finished Product sold by Connetics and its sublicensees.

                  (vi) Connetics and its sublicensees shall not actively market
                  or promote Interferon Gamma-1B during the Distribution Period
                  and while selling or distributing Genentech Finished Product.
                  During the Distribution Period, Connetics and its sublicensees
                  shall not distribute any notice, publication or make any
                  presentation to any third party regarding Interferon Gamma-1B
                  without Genentech's prior review of such notice, publication
                  or presentation, and receipt of Genentech's prior written
                  consent. Connetics and its sublicensees shall not sell
                  Genentech Finished Product at a price higher than that charged
                  by Genentech on January 14, 1999.

11. A new Section 2.5(l) is added to the License Agreement to read in its
entirety as follows:

         2.5(l) Connetics agrees that, as of the Transfer Date and under the
     terms and conditions below, it or its sublicensee will supply Genentech
     Finished Product to those certain patients in the U.S. to whom Genentech
     has an existing contractual or regulatory obligation to supply Interferon
     Gamma-1B, including prior clinical study patients. In addition, Connetics
     or its sublicensee will supply Genentech Finished

                                                                              65

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

     Product to Hoffman-LaRoche Canada Limited ("Roche Canada") for distribution
     to patients to whom there is a contractural or regulatory obligation to
     supply Interferon Gamma-1B. Connetics also agrees that it or its
     sublicensee will supply Genentech Finished Product free of charge to those
     [ * ] oncology study patients (including [ * ] National Cancer Institute
     oncology clinical trial patients) who are continuing to receive Interferon
     Gamma-1B. Genentech shall supply a list of all such patients, and
     information regarding the amount and destination of such Interferon
     Gamma-1B, as soon as reasonably possible. After the end of the Distribution
     Period, Connetics or its sublicensee shall supply Connetics Product, or
     other Finished Product, to such patients and to Roche Canada in the same
     quantities. No other right or license is implied or granted to Connetics or
     its sublicensees to distribute Genentech Finished Product, or any other
     Licensed Product, outside the Field of Use or outside the Territory.

                  (i) To supply the patients and Roche Canada as described
                  above, Connetics or its sublicensee shall pay a price for such
                  Genentech Finished Product, and such Connetics Product and
                  other Finished Product supplied by Genentech, equal to [ * ]
                  percent [ * ] of Genentech's Fully Burdened Manufacturing
                  Cost, plus [ * ] of Third Party Manufacturing Royalties
                  attributable to the manufacture or distribution of such
                  Genentech Finished Product or other Finished Product.

                  (ii) For U.S. CGD clinical study patients that do not qualify
                  for Connetics' (or its sublicensee's) indigent patient
                  program, Connetics (or its sublicensee) shall supply, at its
                  own cost, Genentech Finished Product and Finished Product to
                  such patients free of charge for a period of time ending not
                  later than December 31, 1999. Connetics (or its sublicensee)
                  shall notify such patients that such drug shall not continue
                  to be supplied free of charge by Genentech, Connetics or its
                  sublicensee, and Connetics or its sublicensee shall use its
                  best efforts to terminate such supply of drug before December
                  31, 1999, after reasonable prior notice to such patients. If [
                  * ] reasonably determines that [ * ].

                  (iii) Roche Canada will reimburse Connetics, or its
                  sublicensee, for its cost of supplying such Genentech Finished
                  Product and Connetics Product

                                                                              66

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                  to the patients in Canada under a separate agreement to be
                  negotiated and executed by Roche Canada and Connetics.

                  (iv) Connetics, or its sublicensee, will supply Genentech
                  Finished Product and Finished Product to the [ * ] oncology
                  patients without charge to Genentech or to such patients. If,
                  however, Genentech has not extended the Field of Use of this
                  Agreement to the field of oncology within six (6) months of
                  the Effective Date of this Amendment No. 2, then Genentech
                  will reimburse Connetics, or its sublicensee, for the cost of
                  such Genentech Finished Product and Finished Product during
                  such six month period. If Genentech thereafter extends the
                  Field of Use to oncology, then as of the effective date of
                  such extension Connetics or its sublicensee will provide
                  Finished Product to such patients without charge to Genentech
                  or to such patients. If Genentech does not extend the Field of
                  Use to oncology, Connetics or its sublicensee will continue to
                  supply such oncology patients, but Genentech will reimburse
                  Connetics, or its sublicensee, for such drug in an amount
                  equal to one hundred percent (100%) of the price paid to
                  Genentech for such Genentech Finished Product and Finished
                  Product and the direct administrative and distribution costs
                  of providing such drug to such patient.

12. A new Section 4.3 is added to the License Agreement to read in its entirety
as follows:

         4.3 (a) Genentech shall sell to Connetics, or its sublicensee,
     Genentech's existing inventory of Genentech Product for commercial sale
     solely for the treatment of infections associated with CGD. Connetics shall
     pay a price for such Genentech Product equal to [ * ] percent [ * ] of
     Genentech's Fully Burdened Manufacturing Cost, plus [ * ] of Third Party
     Manufacturing Royalties attributable to the manufacture or sale of such
     Genentech Product.

             (b) Genentech shall deliver Genentech Finished Product to
     Connetics to a single destination in the United States chosen by Connetics,
     by carrier identified by Connetics. Title and risk of loss as to all
     Genentech Finished Product shall pass to Connetics at point of origin (FOB
     Genentech). Connetics shall be responsible for all freight, freight
     brokerage, insurance and other costs associated with shipping

                                                                             67

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

     Genentech Finished Product hereunder. As soon as reasonably possible after
     each shipment of Genentech Finished Product, Genentech shall forward to
     Connetics all customary documents concerning the shipment, including
     Genentech's invoice relating to such shipment. To the extent possible, a
     certificate of analysis will be included in each shipment. Where it is not
     possible to include a certificate of analysis with a shipment, Genentech
     shall furnish the same to Connetics as soon as reasonably possible.

                  (c) Payment by Connetics shall be made within sixty (60) days
         after Connetics' receipt of Genentech's invoice for the supply of
         Genentech Finished Product. All payments to Genentech by Connetics
         under this Agreement shall be made in United States dollars by wire
         transfer (or such other reasonable means as Genentech may direct) to
         such United States bank account as Genentech may direct. If a wire
         transfer is to be made, Connetics shall provide notice at least five
         (5) days prior to the date of transfer of the amount of payment and the
         date good funds will be received. Such notice shall be given to the
         Treasurer of Genentech at the address set forth at the beginning of
         this Agreement or such other address as Genentech may subsequently
         direct.

                  (d) Genentech shall use its best efforts to maintain its Fully
         Burdened Manufacturing Cost for Genentech Finished Product at or below
         the benchmark costs of [ * ] dollars [ * ] per vial of Genentech
         Finished Product (the "Benchmark Costs"). All the provisions of Section
         2.6(e) of that certain Supply Agreement, dated May 5, 1998, between
         Genentech and Connetics, shall apply to such Benchmark Costs herein.

                  (e) All transfer of Genentech Finished Product to Connetics or
         its sublicensee hereunder shall be subject to the provisions hereof and
         shall not be subject to the terms and conditions contained on any
         purchase order or confirmation by Genentech, except insofar as any such
         purchase order or confirmation establishes: (i) the quantity and form
         of Genentech Product, (ii) the shipment date; (iii) the shipment routes
         and destinations; or (iv) the carrier.

13. This Amendment supersedes in its entirety the Letter Agreement dated
December 3, 1998.

                                                                              68

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

14. All other terms and provisions of the License Agreement, including all
exhibits to that Agreement, will continue in full force and effect as though
fully set forth in this Amendment. Nothing in this Amendment shall be construed
as affecting Connetics' obligations to be liable and responsible for the
performance of all of the obligations of Connetics and its sublicensees under
the License Agreement.

IN WITNESS WHEREOF, the parties have executed this Amendment Number Two to
License Agreement as of the date first written above.

Genentech, Inc.                          Connetics Corporation

By:   /s/ Nicholas J. Simon              By:  /s/ Thomas G. Wiggans
   ------------------------------------     ------------------------------------

Name:  Nicholas J. Simon                 Thomas G. Wiggans
     ----------------------------------  President and Chief Executive Officer

Title:   Vice President, Business and
      ---------------------------------
         Corporate Development

Acknowledged and agreed as to InterMune's rights and obligations hereunder as
Connetics' sublicensee under the License Agreement:

InterMune Pharmaceuticals, Inc.

By:      /s/ Scott Harkonen
   ------------------------------------
         Scott Harkonen, M.D.
         President

                                                                              69

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                               AMENDMENT NO. THREE
                                       TO
                                LICENSE AGREEMENT

         THIS AMENDMENT NUMBER THREE TO LICENSE AGREEMENT FOR INTERFERON GAMMA
("Amendment") is entered into effective April 27, 1999 (the "Amendment Effective
Date"), by and between Genentech, Inc. ("Genentech") and Connetics Corporation
("Connetics"). Genentech and Connetics may each be referred to herein as a
"Party" and jointly as the "Parties."

                                    RECITALS

A.       The Parties have previously entered into that certain License Agreement
         for Interferon Gamma, dated May 5, 1998, as amended on December 23,
         1998 and on January 15, 1999 (the "License Agreement").

B.       Pursuant to Section 2.3(c) of the License Agreement, Connetics has the
         right to sublicense certain of its rights under the Agreement to
         InterMune Pharmaceuticals, Inc. ("InterMune"), and has in fact entered
         into such sublicense to that effect dated August 21, 1998.

C.       The Parties have entered into that certain letter agreement dated
         January 5, 1999 and revised on March 1, 1999 (the "Letter Agreement"),
         documenting the intent and agreement of Connetics and Genentech with
         respect to certain additional rights to be granted to Connetics and its
         sublicensees under the Genentech License, pending the preparation of an
         amendment to the License Agreement.

D.       In consideration of such additional rights, InterMune will issue to
         Genentech shares of Genentech Series A-1 Preferred InterMune stock on
         the terms and conditions set forth in that certain stock purchase
         agreement between Genentech and InterMune of even date herewith.

                                                                              60

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

E.       The Parties now desire to enter into a definitive amendment to the
         License Agreement, as of the Amendment Effective Date, through which
         Genentech shall grant, and Connetics and InterMune shall accept, such
         certain additional rights under the License Agreement.

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants
and conditions herein contained, and intending to be legally bound hereby, the
Parties mutually agree as follows:

1.       Terms not otherwise defined in this Amendment shall have the meanings
defined in the License Agreement.

2.       A new Section 1.7.1 is hereby added to read in its entirety as follows:

                  1.7.1 "Combination Product Adjustment" shall mean the
         following: in the event that a Licensed Product is sold in the form of
         a combination product containing one or more active ingredients or
         components in addition to such Licensed Product, Net Sales for such
         combination product will be adjusted by multiplying actual Net Sales of
         such combination product by the fraction A/(A + B) where A is the
         invoice price of the Licensed Product, if sold separately, and B is the
         invoice price of any other active ingredient(s) or component(s) in the
         combination, if sold separately. If, on a country-by-country basis, the
         other active ingredient(s) or component(s) in the combination are not
         sold separately in said country, Net Sales shall be calculated by
         multiplying actual Net Sales of such combination product by the
         fraction A/C where A is the invoice price of the Licensed Product if
         sold separately, and C is the invoice price of the combination product.
         If, on a country-by-country basis, neither the Licensed Product nor the
         other active ingredient(s) or component(s) of the combination product
         is sold separately in said country, Net Sales allocable to the Licensed
         Product shall be determined by mutual agreement reached in good faith
         by the Parties based on an equitable method of determining such Net
         Sales that, among other considerations, takes into account, on a
         country-by-country basis, variations in potency, the relative
         contribution of each active ingredient or component in the combination
         product and the relative value to the end-user of each active
         ingredient or component.

3.       Section 1.12 of the License Agreement is hereby deleted and replaced in
its entirety as follows:

                  1.12 "Field of Use" shall mean the administration to humans of
         Licensed Protein Product for the treatment or prevention of any human
         disease or condition, provided

                                                                              61

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

         however, that "Field of Use" shall not include: (i) the administration
         to humans of Licensed Protein Product for the treatment or prevention
         of any type of arthritis or cardiac or cardiovascular disease or
         condition or (ii) use of Licensed Protein Product for Gene Therapy.
         Each "indication" listed on Exhibit E attached hereto shall be referred
         to herein individually as an "Area of the Field of Use" and
         collectively as "Areas of the Field of Use."

4.       A new Section 1.15.1 is hereby added to the Agreement to read in its
entirety as follows:

                  1.15.1 "Gene Therapy Field of Use" shall mean the
         administration to humans of Licensed Gene Product for Gene Therapy for
         the treatment or prevention of any human disease or condition, provided
         however, that "Gene Therapy Field of Use" shall not include any
         treatment or prevention of any type of cardiac or cardiovascular
         disease or condition.

                                                                             62

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

5.       Section 1.18 of the License Agreement is hereby deleted and replaced in
its entirety as follows:

                  1.18 "Genentech Patent Rights" shall mean all patents and
         patent applications and any patents issuing therefrom, together with
         any extensions, reissues, reexaminations, substitutions, renewals,
         divisions, continuations and continuations-in-part thereof:

                           (a) that are owned or controlled by Genentech
                  presently or hereafter, during the term of this Agreement, and
                  under which Genentech is free to license or sublicense; and

                            (b) to the extent they claim or directly relate to:
                  (i) Interferon Gamma or the manufacture or use of Interferon
                  Gamma in the Field of Use, or (ii) IG Nucleotide Sequence or
                  the manufacture or use of IG Nucleotide Sequence in the Gene
                  Therapy Field of Use;

                  including, without limitation, the patent rights granted under
                  that certain license agreement between Genentech and
                  Children's Medical Center Corporation, dated July 16, 1990
                  (the "CMCC License"), but specifically excluding any rights
                  granted to Genentech under the Biogen License. Genentech
                  Patent Rights shall include, without limitation, the patents
                  and patent applications listed in Exhibit A attached hereto.
                  Notwithstanding the foregoing, Genentech Patent Rights shall
                  exclude any rights Genentech acquires after the Effective Date
                  under third-party license agreements, with the exception of
                  those rights acquired under the CMCC License, unless and until
                  the Parties mutually agree on terms and conditions for the
                  sublicense of such rights from Genentech to Connetics.

6.       A new Section 1.20.1 of the License Agreement is hereby added to read
in its entirety as follows:

                  1.20.1 "IG Nucleotide Sequence" shall mean any DNA or RNA
         sequence encoding Interferon Gamma.

7.       Section 1.22 of the License Agreement is hereby deleted and replaced in
its entirety as follows:

                                                                              63

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                       1.22 "Licensed Product" shall mean, collectively:

                            (a) Any pharmaceutical formulation containing
                            Interferon Gamma, whether alone or together with or
                            incorporated into any other substance or product or
                            material or device, whether active or not, and which
                            (i) but for the licenses granted hereunder, the
                            manufacture, use, sale, offer for sale or
                            importation of which in the Territory would infringe
                            or contribute to the infringement of the Genentech
                            Patent Rights in the Territory, or (ii) is based
                            upon or incorporates or utilizes Genentech Knowhow
                            (a "Licensed Protein Product"); and

                            (b) Any pharmaceutical formulation containing the IG
                            Nucleotide Sequence, whether alone or together with
                            or incorporated into any other substance or product
                            or material or device, whether active or not, and
                            which but for the licenses granted hereunder, the
                            manufacture, use, sale, offer for sale or
                            importation of which in the Territory would infringe
                            or contribute to the infringement of the Genentech
                            Patent Rights in the Territory (a "Licensed Gene
                            Product").

8.       The following two sentences are hereby added to the end of
Section 1.25:

                  [ * ], shall also be deducted from the gross invoiced sales
         prices charged for such Licensed Products in determining Net Sales for
         such Licensed Products. In the event that a Licensed Product is sold in
         the form of a combination product containing one or more active
         ingredients or components in addition to such Licensed Product, Net
         Sales for such combination product will be calculated in accordance
         with the Combination Product Adjustment."

9.       Section 1.28 of the License Agreement is hereby deleted and replaced in
its entirely as follows:

                  1.28 "Territory" shall mean the United States of America, and
         its territories and possessions, and Japan.

10.      A new Section 1.37 is hereby added to the License Agreement to read in
its entirety as follows:

                                                                              64

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                  1.37 "Third Party Product Rights" shall mean any rights
         licensed or sublicensed to any third party by Genentech as of the
         Effective Date to use, manufacture or sell (a) Interferon Gamma, (b)
         the IG Nucleotide Sequence or (c) any pharmaceutical formulation
         containing either or both of Interferon Gamma and the IG Nucleotide
         Sequence, whether alone or together with or incorporated into any other
         substance or product or material or device, whether active or not;
         PROVIDED, HOWEVER, that Third Party Product Rights shall not include
         any right regarding use of the foregoing in any treatment or prevention
         of any type of cardiac or cardiovascular disease or condition.

11.      Section 2.1 of the License Agreement is hereby deleted and replaced in
         its entirety as follows:

                  2.1 Patent and Knowhow License Grants.

                  (a) Genentech hereby grants to Connetics an exclusive license,
         even as to Genentech, under Genentech Patent Rights and under Genentech
         Knowhow to use, sell, offer for sale and import (but not to make or
         have made) Licensed Protein Products in the Field of Use in the
         Territory (excluding Japan), (excluding, with respect to the fields of
         (i) scleroderma and (ii) infectious disease or condition caused by
         human papillomavirus, Licensed Protein Products containing any form of
         Interferon Gamma other than Genentech Gamma Interferon TRIANGLE 3 (as
         that term is defined in the Biogen License)). Notwithstanding the
         foregoing, Genentech reserves the right to use (but not to import,
         offer for sale or sell) Licensed Protein Products within the Field of
         Use solely for non-commercial research purposes.

                  (b) Genentech hereby grants to Connetics a non-exclusive
         license under Genentech Patent Rights and under Genentech Knowhow to
         use, sell, offer for sale and import (but not to make or have made)
         Licensed Protein Products containing any form of Interferon Gamma other
         than Genentech Gamma Interferon TRIANGLE 3 (as that term is defined in
         the Biogen License) in the Territory (excluding Japan) in the fields
         of: (i) scleroderma and (ii) infectious disease or condition caused by
         human papillomavirus.

                  (c) Genentech hereby grants to Connetics a non-exclusive
         sublicense under the Biogen License Rights to use, sell, offer for sale
         and import Licensed Protein Products (excluding Licensed Protein
         Products containing Biogen Gamma Interferon TRIANGLE 0 (as that

                                                                              65

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

         term is defined in the Biogen License)) in the Territory (excluding
         Japan) in the fields of scleroderma and infectious disease or condition
         caused by human papillomavirus.

                  (d) Genentech hereby grants to Connetics a non-exclusive
         license under Genentech Patent Rights to make or have made in the
         Territory (excluding Japan) Licensed Protein Products for use or sale
         in the Field of Use in the Territory (excluding Japan).

                  (e) Genentech hereby grants to Connetics a non-exclusive
          license under Genentech Patent Rights and Genentech Knowhow to use
          non-human animal species derived homologues of Interferon Gamma
          ("Non-human Interferon Gamma") solely for non-commercial research
          purposes to support the Field of Use in the Territory (excluding
          Japan). Genentech hereby grants to Connetics a non-exclusive license
          under Genentech Patent Rights to use non-human animal species derived
          homologues of IG Nucleotide Sequence ("Non-human Interferon
          Gamma-encoding IG Nucleotide Sequence") solely for non-commercial
          research purposes to support the Gene Therapy Field of Use in the
          Territory (excluding Japan).

                  (f) Genentech hereby grants to Connetics a co-exclusive
         license under Genentech Patent Rights to use, make, have made, import,
         offer for sale and sell Licensed Gene Products in the Gene Therapy
         Field of Use in the Territory (excluding Japan). Notwithstanding the
         foregoing, Genentech reserves the right to use (but not to import,
         offer for sale or sell) Licensed Gene Products within the Gene Therapy
         Field of Use solely for non-commercial research purposes. As used in
         this subsection (f), "co-exclusive" shall mean that (i) Genentech shall
         not grant a license to any party other than Connetics to use, make,
         have made, import, offer for sale or sell Licensed Gene Products in the
         Gene Therapy Field in the Territory (excluding Japan) other than to the
         extent that such rights (including certain rights to sublicense) [ * ],
         and (ii) Genentech shall not authorize or approve any grant or
         assignment [ * ].

                   (g) (i) Genentech hereby grants to Connetics an exclusive
         license, even as to Genentech, under Genentech Patent Rights and under
         Genentech Knowhow, in Japan to make, have made, use, sell, offer for
         sale and import Licensed Protein Product that is [ * ] (as that term is
         defined in [ * ] solely for the treatment of atopic dermatitis and
         infectious tuberculosis, subject to subsection (ii) below.

                                                                              66

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                           (ii) Connetics, its Affiliates and sublicensees
         hereunder shall [ * ] acting on behalf and in place of [ * ], and shall
         [ * ], to the extent based, in whole or in part, upon [ * ] Genentech
         Patent Rights as the result of the [ * ] to the extent such [ * ]
         (including, without limitation, the [ * ] other than the [ * ] shall
         not extend to: (A) the [ * ]; or (B) the [ * ] for the [ * ] (except
         for [ * ] or as an [ * ]) or [ * ]. Connetics' and its Affiliates' and
         sublicensees' obligation to [ * ] described in this subsection (ii)
         shall terminate with respect to each of [ * ] simultaneously with [ *
         ].

                           (iii) In the event that any Third Party Product
         Rights held by a third party in Japan that [ * ] revert to Genentech,
         then Genentech shall notify Connetics or its designated sublicensee in
         Japan of such reversion, and upon such notice Genentech shall be deemed
         to have automatically granted to Connetics the license under Genentech
         Patent Rights and under Genentech Knowhow to all such reverted rights,
         which license shall be exclusive to the extent that such reverted
         rights were exclusive. All rights granted to Connetics pursuant to this
         subsection (iii) shall be subject to the terms of this Agreement,
         including without limitation subsection (ii) above, Section 3.2(g) and
         Section 8.3.

                  (h) In the event that any Third Party Product Rights (other
         than those described in subsection (g) above) shall revert to
         Genentech, then Genentech shall notify Connetics of such reversion. For
         the ninety (90) day period following its receipt of such notice,
         Genentech and Connetics shall negotiate exclusively in good faith the
         reasonable commercial terms upon which Genentech would be willing to
         grant to Connetics the license to such reverted rights. If the Parties
         fail to enter a written agreement for a license to such rights by the
         end of such ninety (90) day period, then Genentech shall have no
         further obligation to Connetics with respect to such rights; provided
         that for six (6) months following such ninety (90) day period,
         Genentech shall not enter into an agreement to grant a license to such
         rights with a third party on terms that, taken as a whole, are less
         favorable to Genentech than those last offered by Connetics for such
         rights. With respect to the foregoing sentence, [ * ] shall be [ * ] in
         light of all [ * ], including without limitation the [ * ] with such [
         * ] of such [ * ] under such [ * ] commercially reasonable [ * ] of the
         [ * ] of such [ * ] that may be [ * ]. Nothing in the preceding
         sentence shall imply any [ * ]. Connetics may not transfer its rights
         under this Section 2.1(h) to any party other than InterMune without
         Genentech's prior written consent.

                                                                              67

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

         Except as expressly granted herein, there are no implied licenses under
the Genentech Patent Rights or any other intellectual property rights owned or
controlled by Genentech.

12.      Section 2.3(b) of the License Agreement is hereby deleted and replaced
in its entirety as follows:

                  (b) Connetics may grant one or more sublicenses under the
         rights granted in Sections 2.1(a), (b), (c), (e), (f) and (g) in the
         Field of Use and the Gene Therapy Field of Use, on thirty (30) days
         prior written notice to Genentech, and subject to Genentech's prior
         written approval, which approval shall not be unreasonably withheld.

13.      A new Section 3.2(g) is hereby added to read in its entirely as
follows:

                  (g) In addition to the Clinical Development Milestones (as set
         forth in Exhibit E hereto), Connetics shall use its Best Efforts to
         develop and commercialize Licensed Products: (i) in the Field of Use
         with respect to indications and diseases that, under the provisions of
         this Amendment, have been added to the "Field of Use" as defined in the
         original License Agreement executed as of May 5, 1998, and (ii) in the
         Gene Therapy Field of Use. Such additional indications and diseases in
         the Field of Use, and the Gene Therapy Field of Use, collectively are
         referred to in this subsection (g) as the "Additional Indications." In
         the event that Connetics is not conducting such development efforts
         with respect to any Additional Indication(s) in a country or countries
         in the Territory as of the [ * ] (or if rights to such Additional
         Indication were granted to Connetics pursuant to Section 2.1(g)(iii),
         then as of the [ * ] that Genentech notifies Connetics or its
         designated sublicensee regarding such rights as set forth in that
         Section) or at any time thereafter, Genentech shall have the right to
         terminate this Agreement, and the licenses granted hereunder, with
         respect to Licensed Products for such Additional Indication(s) in such
         country or countries, upon [ * ] days prior written notice to
         Connetics, unless Connetics can reasonably demonstrate, during such
         notice period, by its written records that as of the date of such
         notice it is conducting such development efforts with respect to such
         Additional Indication(s) in such country or countries.

14.      Sections 8.2(a) and (b) of the License Agreement are hereby deleted and
replaced in their entirety as follows:

                                                                              68

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                  (a) [ * ] within thirty (30) days following the dates on which
          the first NDA or BLA, as applicable, for a Licensed Protein Product is
          filed with the FDA by Connetics for [ * ]; provided however, that such
          milestone payments shall only be paid once for each of the foregoing
          indications, and shall not be paid upon the filing of a NDA or BLA for
          an osteopetrosis or any mycobacterial infection indication.

                  (b) [ * ] within thirty (30) days following the date Connetics
          receives the first FDA approval of [ * ]; provided however, that such
          milestone payment shall only be paid once for each of the foregoing
          indications, and shall not be paid upon receipt of FDA approval for
          commercial sale for an osteopetrosis or any mycobacterial infection
          indication.

15.      Section 8.3 of the License Agreement is hereby deleted and replaced in
its entirety as follows:

         8.3      Royalties. Connetics shall pay Genentech the following
         royalties on Net Sales of Licensed Products by Connetics and its
         sublicensees:

                  (a) For annual aggregate Net Sales of all Licensed Protein
         Products in the Territory (excluding Japan) [ * ], a royalty rate equal
         to [ * ] of such Net Sales.

                  (b) [ * ], for annual aggregate Net Sales of all Licensed
         Protein Products in the Territory (excluding Japan) [ * ], a royalty
         rate equal to [ * ] of such Net Sales [ * ].

                  (c) For Net Sales of all Licensed Protein Products in Japan, a
         royalty rate equal to [ * ] of such Net Sales; PROVIDED, HOWEVER, that
         in the event that [ * ] in Japan for an indication for which InterMune
         has exclusive rights under Section 2.1(g), the foregoing royalty rate
         shall be reduced to [ * ] for Net Sales of [ * ] in Japan for such
         indication [ * ]. For the sake of clarity, Net Sales of Licensed
         Protein Products to which Connetics acquires rights pursuant to Section
         2.1(g)(iii) shall be subject to this subsection (c).

                      (d) (i) For Net Sales of Licensed Gene Product in the
         Territory, where such Licensed Gene Product is used in conjunction with
         a Licensed Protein Product for the treatment or prevention of a given
         indication in a given patient population, a royalty rate equal to [ * ]
         of such Net Sales. As used in this subsection (d), "indication" shall
         mean any particular medical condition within the Field of Use and

                                                                              69

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

         Gene Therapy Field of Use, including but not limited to labeling claims
         approved by a regulatory agency.

                                    (ii) For Net Sales of Licensed Gene Product
         in a country in the Territory, where such Licensed Gene Product is used
         in a given patient population for the treatment or prevention of the
         same indication for which a given Licensed Protein Product is used in
         such patient population, a royalty rate equal to (A) [ * ] of such Net
         Sales during the [ * ] period following the first commercial sale of
         such Licensed Gene Product in such country for the treatment or
         prevention of such indication in such patient population by Connetics,
         or its Affiliates and sublicensees (the "First Commercial Sale"); (B) [
         * ] of such Net Sales during the [ * ] period following the First
         Commercial Sale; and (C) [ * ] of such Net Sales beginning on the [ * ]
         anniversary of the First Commercial Sale and thereafter.

                           (iii) Notwithstanding the provisions of subsections
         (i) and (ii) above, in the event that annual Net Sales of a Licensed
         Gene Product for the treatment or prevention of an indication in a
         patient population in a country in the Territory [ * ] for the
         treatment or prevention of such indication in such patient population
         in such country, the royalty rate thereafter applicable to Net Sales of
         such Licensed Gene Product for the treatment or prevention of such
         indication in such patient population in such country shall be [ * ] of
         such Net Sales.

                           (iv) In the event that Connetics or InterMune
         determines at any point following [ * ] that the above royalty rates
         are having or are likely to have an adverse impact on Connetics' or
         InterMune's ability to compete effectively in its sales of such
         Licensed Gene Product, Connetics or InterMune shall so notify
         Genentech, and the Parties shall in good faith discuss and attempt to
         reach a reasonable and mutually agreeable resolution to the situation.

                  (e) (i) The royalties set forth in subsections (a), (b) and
         (c) above shall be payable, on a country-by-country basis, until the
         later of: (A) the expiration or revocation of the last remaining issued
         patent in such country within the Genentech Patent Rights that covers
         Licensed Protein Products, or (B) [ * ] years from the Effective Date
         of this Agreement. Notwithstanding the foregoing, upon the expiration
         of the last to expire issued patent in each country within the
         Genentech Patent Rights during the term of this

                                                                              70

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

         Agreement, thereafter each of the royalty rates set forth in (a), (b)
         and (c) above shall be reduced by [ * ] with respect to such country.

                           (ii) The royalties set forth in subsection (d) above
         shall be payable, on a country-by-country basis, until the expiration
         or revocation of the last remaining issued patent in such country
         within the Genentech Patent Rights that covers Licensed Gene Products.

16.      Section 8.4 of the License Agreement is hereby deleted and replaced in
its entirety as follows:

                  8.4 Third-Party Royalties. If Genentech or Connetics is
         required to pay any third party a royalty due to the manufacture, use,
         sale, offer for sale or importation of a Licensed Product in the
         Territory for or by Connetics or its sublicensees, Connetics shall be
         responsible for the payment of [ * ] of such third-party royalty,
         PROVIDED HOWEVER, that Connetics may deduct from the royalties
         otherwise payable to Genentech under Section 8.3 above, an amount equal
         to [ * ] of such third party royalties incurred only due to use patents
         in the Field of Use or in the Gene Therapy Field of Use in the
         Territory, provided that the amount deducted shall not exceed [ * ] of
         the royalties otherwise payable by Connetics to Genentech under Section
         8.3. For purposes of clarification, such deductions shall not apply to
         [ * ]. Attached hereto as Exhibit G is a list of all such royalty
         obligations to third parties known to Genentech as of the Effective
         Date without diligent search. No later than thirty (30) days from the
         Effective Date, Genentech shall complete a reasonable internal
         investigation of its records and update Exhibit G, as necessary, to
         accurately reflect all such royalty obligations to third parties to the
         best of Genentech's knowledge; provided however, Connetics acknowledges
         that Genentech has no obligation to conduct due diligence or any
         investigation with respect to third party patent rights related to
         Licensed Products. Genentech shall notify Connetics in writing during
         the term of this Agreement if it becomes aware of any additional
         Genentech third party royalty obligations.

17.      Section 8.5 of the License Agreement is hereby deleted and replaced in
its entirety as follows:

                  8.5 Royalty Payments.

                                                                              71

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                  (a) Royalty payments shall be made to Genentech quarterly
         within ninety (90) days following the end of each calendar quarter for
         which royalties are due. Each royalty payment shall be accompanied by a
         report summarizing the total Net Sales during the relevant three-month
         period, and the calculation of royalties, if any, due thereon pursuant
         to Section 8.3.

                  (b) Notwithstanding subsection (a) above, any royalty payments
         which accrue during 1999 on Net Sales of Licensed Protein Product sold
         by Connetics' sublicensee InterMune shall be paid to Genentech in the
         form of promissory note, in the form attached hereto as Exhibit I. For
         each calendar quarter in 1999 for which royalty payments are due,
         InterMune shall execute and deliver to Genentech, within ninety (90)
         days following the end of each such calendar quarter, a promissory note
         in the form of Exhibit I, and in the amount of such royalties due to
         Genentech for such quarter. Each such promissory note shall be
         accompanied by the report described in Section 8.5(a) above for such
         quarter. In the event that any such note is delivered by InterMune
         after such 90 day period, nevertheless interest shall accrue on the
         date that such note was due.

18.      The following provision is hereby inserted as Section 10.4 to the
License Agreement:

                  10.4 Insurance. At all times during the term of this
         Agreement, Connetics and its sublicensees shall provide the following
         insurance at its sole cost and expense:

                      (a) Commercial General Liability, including coverage
         for products and completed operations (maintained for a period of at
         least [ * ] after the expiration or termination of this Agreement) [ *
         ]. The policy shall have a limit of no less than [ * ] dollars.

                      (b) Foreign Local Coverages: Where required by law,
         Connetics and its sublicensees will purchase foreign local coverages in
         an amount that, at a minimum, satisfies the legal requirements of that
         jurisdiction.

                      (c) Policy Conditions: All policies under (a) and (b)
         above shall:

                          (i) be written by insurance companies with an A.M.
         Best's rating of A:VIII or higher (or if Connetics' or its sublicensees
         policies are not subject to the Best rating, then by carriers who are
         acceptable to Genentech); and

                                                                              72

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                          (ii) add Genentech as an additional insured.

                      (d) Additionally, Connetics shall use its Best Efforts to
         obtain from its insurance carrier for the policies described in
         subsections (a) and (b) covenants:

                          (i) [ * ]; and

                          (ii) [ * ].

                  Connetics and its sublicensees shall provide Genentech a
         certificate of insurance which shall reflect the above coverages and
         provisions, with annual renewals as long as the contract continues.

19.      Section 11.1 of the License Agreement is hereby deleted and replaced in
its entirety as follows:

         11.1 Term. This Agreement shall commence on the Effective Date of this
         Agreement and, unless terminated earlier, shall expire:

                  (a) With respect to Licensed Protein Products, at the later to
         occur of (i) the expiration of the last to expire of any Genentech
         Patent Rights covering a Licensed Protein Product, or (ii) twenty (20)
         years from the Effective Date of this Agreement; and

                  (b) With respect to Licensed Gene Products, at the expiration
         of the last to expire of any Genentech Patent Rights covering a
         Licensed Gene Product;

                  PROVIDED, HOWEVER, that in the event that either the CMCC
         License or the Biogen License is terminated, the licenses granted by
         Genentech to Connetics under the CMCC License or the Biogen License
         shall also terminate. Genentech shall use its Best Efforts to keep the
         CMCC License and the Biogen License in effect during the term of this
         Agreement, provided, however, that if [ * ] as outlined in Section
         [ * ] under the [ * ] shall not be [ * ] shall have the [ * ]. One (1)
         year before the expiration of this Agreement under Section 11.1(a), the
         Parties agree to meet and to discuss in good faith extending the term
         of this Agreement with respect to Licensed Protein Products on terms
         mutually agreeable to the Parties.

                                                                              73

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

20.      Exhibit E of the License Agreement is hereby deleted and replaced in
its entirety with new Exhibit E attached hereto and incorporated herein.

21.      In consideration for the rights granted to Connetics and its
sublicensees under this Amendment, InterMune shall issue to Genentech eight
hundred seventy five thousand (875,000) shares of Series A-1 Preferred Stock
simultaneously herewith.

22.      This Amendment supersedes the Letter Agreement in its entirety. All
other terms and provisions of the License Agreement, including all exhibits to
that Agreement, will continue in full force and effect as though fully set forth
in this Amendment. Nothing in this Amendment shall be construed as affecting
Connetics' obligations to be liable and responsible for the performance of all
of the obligations of Connetics and its sublicensees under the License
Agreement.

                       THIS SPACE INTENTIONALLY LEFT BLANK

                                                                              74

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by the
respective duly authorized officers as of the date first written above.

GENENTECH, INC.                           CONNETICS CORPORATION

By: /s/ Nicholas J. Simon                 By:  /s/ T. G. Wiggans
   ---------------------------------         -----------------------------------

Printed Name: Nicholas J. Simon           Printed Name: T. G. Wiggans

Title: Vice President, Business and       Title: President and Chief Executive
Corporate Development                     Officer

Acknowledged and agreed as to InterMune's rights and obligations hereunder as
Connetics' sublicensee under the License Agreement:

INTERMUNE PHARMACEUTICALS, INC.

By: /s/ W. Scott Harkonen
   ---------------------------------

Printed Name: W. Scott Harkonen

Title: President

                                                                              75

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                                    EXHIBIT E

                           CLINICAL DEVELOPMENT MILESTONES

                                      [ * ]

                                                                              76

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                           CONVERTIBLE PROMISSORY NOTE

$                                                                        , 2000
 ----------                                                    ----------
                                                          Palo Alto, California

FOR VALUE RECEIVED, InterMune Pharmaceuticals, Inc., a California corporation
("COMPANY") promises to pay to Genentech, Inc., a Delaware corporation, or its
registered assigns ("HOLDER"), the principal sum of _______________ Dollars and
__________ Cents ($__________ ), or such lesser amount as shall equal the
outstanding principal amount hereof, together with interest from the date of
this Note on the unpaid principal balance at a rate equal to prime rate plus two
percent (2%) per annum, computed on the basis of the actual number of days
elapsed and a year of 365 days. All unpaid principal, together with any then
unpaid and accrued interest and other amounts payable hereunder, shall be due
and payable on the earlier of (i) December 31, 2002, (ii) the closing of the
initial public offering of the Company's Common Stock pursuant to a registration
statement declared effective by the Securities Exchange Commission, and (iii)
the merger or consolidation of the Company with or into any other corporation or
corporations (except where a majority of the outstanding equity securities of
the surviving corporation immediately after the merger or consolidation is held
by persons who were shareholders of the Company immediately prior to the merger
or consolidation), or a sale or other transfer of all or substantially all of
the assets of the Company (or any series of related transactions resulting in
the same).

The following is a statement of the rights of Holder and the conditions to which
this Note is subject, and to which Holder, by the acceptance of this Note,
agrees:

         1.       DEFINITIONS. As used in this Note, the following capitalized
terms have the following meanings:

         (a)      "COMPANY" includes the corporation initially executing this
                  Note and any Person which shall succeed to or assume the
                  obligations of Company under this Note in accordance with and
                  subject to the terms of this Note.

                                                                              77

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

         (b)      "HOLDER" shall mean the Person specified in the introductory
                  paragraph of this Note or any other Person(s) who shall at the
                  time be the registered holder of this Note.

         (c)      "LIEN" shall mean, with respect to any property, any security
                  interest, mortgage, pledge, lien, claim, charge or other
                  encumbrance in, of, or on such property or the income
                  therefrom, including, without limitation, the interest of a
                  vendor or lessor under a conditional sale agreement, capital
                  lease or other title retention agreement, or any agreement to
                  provide any of the foregoing, and the filing of any financing
                  statement or similar instrument under the Uniform Commercial
                  Code or comparable law of any jurisdiction.

         (d)      "LICENSE AGREEMENT" means the License Agreement for Interferon
                  Gamma between Genentech, Inc. and Connectics Corporation dated
                  May 5, 1998, as amended on December 23, 1999, January 15, 1999
                  and April ___, 1999, and as further amended from time to time.

         (e)      "PERSON" shall mean and include an individual, a partnership,
                  a corporation (including a business trust), a joint stock
                  company, a limited liability company, an unincorporated
                  association, a joint venture or other entity or a governmental
                  authority.

         2.       PREPAYMENT. Upon five (5) days prior written notice to Holder,
Company may prepay this Note in whole or in part; provided, however, that any
such prepayment will be applied first to the payment of expenses due under this
Note, second to interest accrued on this Note and third, if the amount of
prepayment exceeds the amount of all such expenses and accrued interest, to the
payment of principal of this Note.

         3.       CERTAIN COVENANTS. While any amount is outstanding under the
Note:

         (a)      LIENS. Without the prior written consent of Holder, Company
                  shall not create, incur, assume or permit to exist any Lien on
                  or with respect to the License Agreement or any intellectual
                  property or other assets of Holder licensed by the Company
                  thereunder.

                                                                              78

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

         (b)      ASSET DISPOSITIONS. Without the prior written consent of
                  Holder, Company shall not sell, lease, transfer, license or
                  otherwise dispose of the License Agreement or any intellectual
                  property or other assets of Holder licensed or sublicensed by
                  the Company thereunder, other than as permitted under the
                  License Agreement.

         (c)      DIVIDENDS, REDEMPTIONS, ETC. Without the prior written consent
                  of Holder, Company shall not (i) pay any dividends or make any
                  distributions on its equity securities; (ii) purchase, redeem,
                  retire, defease or otherwise acquire for value any of its
                  equity securities, other than in respect to stock purchases
                  from departing employees; (iii) return any capital to any
                  holder of its equity securities; (iv) make any distribution of
                  assets, equity securities, obligations or other securities to
                  any holder of its equity securities; or (v) set apart any sum
                  for any such purpose.

         4.       EVENTS OF DEFAULT. The occurrence of any of the following
shall constitute an "Event of Default" under this Note and the other Transaction
Documents:

         (a)      FAILURE TO PAY. Company shall fail to pay (i) when due any
                  principal payment under this Note or the License Agreement or
                  (ii) any interest or other payment required under the terms of
                  this Note or the License Agreement and such payment shall not
                  have been made within five (5) days of Company's receipt of
                  Holder's written notice to Company of such failure to pay; or

         (b)      BREACHES OF CERTAIN COVENANTS. Company shall fall to observe
                  or perform any covenant, obligation, condition or agreement
                  set forth in Section 3 of this Note; or

         (c)      BREACHES OF OTHER COVENANTS. Company shall fall to observe or
                  perform any other covenant, obligation, condition or agreement
                  contained in this Note (other than those specified in Sections
                  4(a) and 4(b)) or fail to observe or perform any material
                  covenant, obligation, condition or agreement contained in the
                  License Agreement and such failure shall continue for fifteen
                  (15) days; or

                                                                              79

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

         (d)      REPRESENTATIONS AND WARRANTIES. Any representation, warranty,
                  certificate, or other statement (financial or otherwise) made
                  or furnished by or on behalf of Company to Holder in writing
                  in connection with this Note or the License Agreement, or as
                  an inducement to Holder to enter into this Note or the License
                  Agreement, shall be false, incorrect, incomplete or misleading
                  in any material respect when made or furnished; or

         (e)      VOLUNTARY BANKRUPTCY OR INSOLVENCY PROCEEDINGS. Company shall
                  (i) apply for or consent to the appointment of a receiver,
                  trustee, liquidator or custodian of itself or of all or a
                  substantial part of its property, (ii) be unable, or admit in
                  writing its inability, to pay its debts generally as they
                  mature, (iii) make a general assignment for the benefit of its
                  or any of its creditors, (iv) be dissolved or liquidated, (v)
                  become insolvent (as such term may be defined or interpreted
                  under applicable statute), (vi) commence a voluntary case or
                  other proceeding seeking liquidation, reorganization' or other
                  relief with respect to itself or its debts under any
                  bankruptcy, insolvency or other similar law now or hereafter
                  in effect or consent to any such relief or to the appointment
                  of or taking possession of its property by any official in an
                  involuntary case or other proceeding commenced against it, or
                  (vi) take any action for the purpose of effecting any of the
                  foregoing; or

         (f)      INVOLUNTARY BANKRUPTCY OR INSOLVENCY PROCEEDINGS. Proceedings
                  for the appointment of a receiver, trustee, liquidator or
                  custodian of Company or of all or a substantial part of the
                  property thereof, or an involuntary case or other proceedings
                  seeking liquidation, reorganization or other relief with
                  respect to Company or the debts thereof under any bankruptcy,
                  insolvency or other similar law now or hereafter in effect
                  shall be commenced and an order for relief entered or such
                  proceeding shall not be dismissed or discharged within thirty
                  (30) days of commencement; or

         (g)      LICENSE AGREEMENT. The License Agreement terminates or is
                  declared void.

         5.       RIGHTS OF HOLDER UPON DEFAULT. Upon the occurrence or
existence of arty Event of Default (other than an Event of Default, referred to
in Sections 4(e) and 4(f)) and at any time thereafter during the continuance of
such Event of Default, Holder may, by written notice to Company, declare all
outstanding obligations payable by Company under this Note to be

                                                                              80

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

immediately due and payable without presentment, demand, protest or any other
notice of any kind, all of which are hereby expressly waived, anything contained
herein or in the License Agreement to the contrary notwithstanding. Upon the
occurrence or existence of any Event of Default described in Sections 4(e) and
4(f), immediately and without notice, all outstanding Obligations payable by
Company under this Note shall automatically become immediately due and payable,
without presentment, demand, protest or any other notice of any kind, all of
which are hereby expressly waived, anything contained herein or in the License
Agreement to the contrary notwithstanding. In addition to the foregoing
remedies, upon the occurrence or existence of any Event of Default, Holder may
exercise any other right, power or remedy granted to it by this Note or the
License Agreement or otherwise permitted to it by law, either by suit in equity
or by action at law, or both.

         6.       CONVERSION RIGHTS.

         (a)      OPTIONAL CONVERSION. At the sole election of Holder, this Note
                  may be converted into equity securities of the Company, as set
                  forth in Section 6(b) below, at any time.

         (b)      SECURITIES ISSUED UPON CONVERSION. In the event that Holder
                  elects to convert all or a part of this Note into equity
                  securities of the Company, Holder shall provide the Company
                  with written notice of its election. Upon receipt of such
                  notice by the Company, the sum of the aggregate principal and
                  accrued interest designated in such notice shall be
                  automatically converted into that number of shares of the
                  Company's equity securities (the "SHARES") that are sold in
                  the last financing precedent to the date of such conversion
                  involving the sale by the Company of equity securities (other
                  than those issued to employees of the Company) in which the
                  Company receives an aggregate of at least $1,000,000 in cash
                  (excluding any financing incident to a corporate or strategic
                  partnering transaction) (an "EQUITY FINANCING") as is equal to
                  such unpaid principal and interest to be converted divided by
                  the per share purchase price of the Shares issued in such
                  Equity Financing (the "PER SHARE PRICE"), with any fraction of
                  a Share rounded to the next whole Share. The Company covenants
                  to cause the Shares, when issued pursuant to this Section 6,
                  to be fully paid and nonassessable, and free from all taxes,
                  liens and charges with respect to

                                                                              81

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                  the issuance thereof and such Shares shall be issued on the
                  same contractual terms as those issued in the Equity
                  Financing.

         7.       SURRENDER AND CANCELLATION OF NOTE. Upon payment in full of
all principal, expenses and interest payable under this Note, Holder agrees to
surrender this Note to Company for cancellation.

         8.       SUCCESSORS AND ASSIGNS. Subject to the restrictions on
transfer described in Section 10 below, the rights and obligations of Company
and Holder shall be binding upon and benefit the successors, assigns, heirs,
administrators and transferees of the parties.

         9.       WAIVER AND AMENDMENT. Any provision of this Note may be
amended, waived or modified upon the written consent of Company and Holder.

         10.      ASSIGNMENT BY COMPANY. Neither this Note nor any of the
rights, interests or obligations hereunder may be assigned, by operation of law
or otherwise, in whole or in part, by Company without the prior written consent
of Holder.

         11.      NOTICES. Any notice, request or other communication required
or permitted hereunder shall be in writing and shall be deemed to have been duly
given if personally delivered or mailed by registered or certified mail, postage
prepaid, or by recognized overnight courier or personal delivery (a) if to
Company, at 3294 West Bayshore Road, Palo Alto, CA 94303, and (b) if to Holder,
to Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080-4990, attention
Legal Department. Any party hereto may by notice so given change its address for
future notice hereunder. Notice shall conclusively be deemed to have been given
when received.

         12.      PAYMENT. Payment shall be made in lawful tender of the United
States.

         13.      DEFAULT RATE; USURY. In the event that any payment of
principal or interest provided for herein is not paid by Company when due
(including the entire unpaid balance of this Note in the event such amount is
made immediately due and payable pursuant to the terms hereof), then Company
shall pay interest on the such amounts not paid when due at a rate per annum
equal to the rate otherwise applicable hereunder plus two percent (2%). In the
event any interest is paid on this Note which is deemed to be in excess of the
then legal maximum rate, then that portion of the interest payment representing
an amount in excess of the then legal

                                                                              82

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

maximum rate shall be deemed a payment of principal and applied against the
principal of this Note.

         14.      ENTIRE AGREEMENT. This Note and the License Agreement, taken
together, constitute and contain the entire agreement of Company and Holder, and
supersede any and all prior agreements, negotiations, correspondence,
understandings and communications among the parties, whether written or oral,
respecting the subject matter hereof.

         15.      EXPENSES; WAIVERS. If action is instituted to collect this
Note, Company promises to pay all costs and expenses, including, without
limitation, reasonable attorneys' fees and costs, incurred in connection with
such action. Company hereby waives notice of default, presentment or demand for
payment, protest or notice of nonpayment or dishonor and all other notices or
demands relative to this instrument.

         16.      GOVERNING LAW. This Note and all actions arising out of or in
connection with this Note shall be governed by and construed in accordance with
the laws of the State of California, without regard to the conflicts of law
provisions of the State of California. or of any other state.

IN WITNESS WHEREOF, Company has caused this Note to be issued as of the date
first written above.

                                      INTERMUNE PHARMACEUTICALS, INC.
                                      a California corporation

                                      By:
                                         ---------------------------------------

                                      Name:
                                           -------------------------------------

                                      Title:
                                            ------------------------------------

                                                                              83

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

<PAGE>

                                  EXHIBIT 1.16

                           GENENTECH SUPPLY AGREEMENT

The Genentech Supply Agreement was filed as Exhibit 10.16 to the Company's
Registration Statement on Form S-1/A, dated March 22, 2000, and is herein
incorporated by reference.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00004-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00004-of-00352.parquet"}]]